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AdoCbl 5-deoxyadenosylcobalamin
AdoHcy S-adenosylhomocysteine
AdoMet S-adenosylmethionine
AMN amnionless
ApoTC apo-transcobalamin
BAD betaine aldehyde dehydrogenase
BHMT betaine homocysteine methyltransferase
BW birth weight
Cbl cobalamin
CBS cystathionine ß-synthetase
CGL cystathionine y-lyase
CUBN cubilin
CVA cerebrovascular accident
DIS diffuus intravasale stolling
DMG dimethylglycine
ECMO extra corporeal membrane oxygenation
ELBW extremely low birth weight (<1000 g)
GA gestational age
HC haptocorrin
Hey homocysteine
holoHC holo-haptocorrin
ICH intracranial hemorrhage
IF intrinsic factor
IUGR intrauterine growth retardation
IVH intraventricular hemorrhage
LBW low birth weight (<2500 g)
MAT methionine adenosyltransferase
MCM L-methylmalonyl-CoA mutase
MeCbl methylcobalamin
MMA methylmalonic acid
5MTHF 5-methyltetrahydrofolate
MTHFR 5,10-methylenetetrahydrofolate reductase
MTRR Methionine synthase reductase
MTR methionine synthase
MUT methylmalonyl-CoA mutase
NICU neonatal intensive care unit
NTDs neural tube defects
OR Odds ratio
PEMT phosphatidylethanolamine-N-methyltransferase
REPL recurrent early pregnancy loss
SAHH S-adenosylhomocysteine hydrolase
SD standard deviation
SGA small for gestational age
TCII transcobalamin II
tHcy total homocysteine
VLBW very low birth weight (<1500 g)
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Part I General introduction
Introduction
Pediatricians do their jobs with one strong internal motivation: to improve 
children’s health and well being. Threats to general health of infants and 
children worldwide are, amongst others: malnutrition and poverty, infectious 
diseases, congenital malformations, and accidents. For neonatologists, their 
job comes with an extra challenge: they have to take into account the prenatal 
period as a possible risk factor for disease or for problems occurring in the 
neonatal period. Collaborating with the obstetric gynecologist, in an attempt 
to find possible factors determining the fetal condition in utero, with the 
ultimate goal to influence those factors in such a way that a healthy newborn 
baby will be delivered with good future perspectives, is part of their daily 
routine. Unfortunately, such factors remain unknown for many problems, 
bringing along increased risk of morbidity and mortality for the neonate, but 
also increased risk of diseases for the adult he or she will become.
Three important clinical problems of the newborn will be addressed in this 
thesis: cerebrovascular accidents, low birth weight, and cobalamin disturbances. 
Cerebrovascular accidents (CVAs) in newborn infants, involving amongst 
others intracranial hemorrhage and arterial ischemic lesions, are associated 
with many factors such as perinatal trauma, perinatal infection, prematurity, 
acquired or inherited thrombophilic conditions and hypoxic-ischemic events. 
In approximately 30% of cases the cause remains unknown. CVAs in the 
newborn can lead to irreversible neurological sequelae or even death, the 
former leading to lifelong disabilities and possibly decreased quality of life. In 
newborns admitted at a Neonatal Intensive Care Unit, CVAs occur in 
approximately 10%.
Birth weight (BW), attained by many different paths of intrauterine growth, can 
be used as an outcome measure and basis for estimating the effects of 
intrauterine growth and nutrition on immediate neonatal morbidity and 
mortality. It can also be used for estimating effects on diseases in adulthood, 
such as hypertension, type 2 diabetes, coronary heart disease and stroke. 
Cobalamin (Cbl) disturbances, especially nutritional Cbl deficiency in infants, 
seem to be more common than previously recognized and can lead to severe 
and irreversible neurological sequelae. Cbl concentrations in plasma have 
limited value to establish the diagnosis of Cbl deficiency. Instead, to detect 
intracellular deficiency, one can determine concentrations of the metabolic 
markers methylmalonic acid (MMA) and homocysteine (Hey).
Aspects of one carbon metabolism have been linked to both adverse pregnancy 
outcome such as low birth weight (LBW), and cardiovascular risk in children
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GENERAL INTRODUCTION
and adults, such as CVAs. In this introduction we will provide further background 
on different aspects of one carbon metabolism, in particular homocysteine, 
cobalamin and choline metabolism. We will discuss what is already known 
about one carbon metabolism in relation to disease in infancy and childhood; 
we will explore possible relations between aspects of one carbon metabolism 
and cerebrovascular accidents, birth weight, and give background information 
on cobalamin deficiency.
Cerebrovascular disease in newborns
CVA in newborns is an important clinical problem due to its relatively high 
frequency of occurrence and the possible long term neurological sequelae or 
even death. A definition of CVA is the rapidly developing loss of brain function(s) 
due to disturbance in the blood supply to the brain. In this thesis, we use the 
term CVA for both perinatal stroke and perinatal hemorrhage. Perinatal stroke 
can be defined as a group of disorders with a focal disruption of blood supply 
due to arterial or venous thrombus or embolus from 20 weeks gestational age 
(GA) to 28 days after birth. Perinatal stroke can be divided into arterial ischemic 
stroke and sinovenous thrombosis. Perinatal hemorrhage is due to the leakage 
of blood. The overall incidence of CVA in childhood is low but in strong 
contrast, CVAs occurring in the perinatal period have a much higher incidence 
(1). It is estimated that the incidence of ischemic perinatal stroke is 1 in 2300 
to 5000 births and accounts for 30% of children affected with cerebral palsy 
(1). Of major importance is the fact that approximately 10% of newborns 
admitted to a Neonatal Intensive Care Unit (NICU) suffer from a form of CVA. 
Independent of the cause, CVA alone can result in significant morbidity, 
varying from mild hemiplegia to severe cerebral palsy, sensory impairments, 
mental retardation and even death. Known potential risk factors of perinatal 
CVA are amongst others, prematurity, polycythemia, catheter-related 
complications, infectious factors, intrauterine growth retardation (IUGR) and 
maternal factors such as diabetes or antiphospholipid syndrome (1,2). Aspects 
of the multifactorial pathophysiology leading to CVA in the newborn remain 
unclear and in about one third of cases no obvious cause or risk factors can 
be diagnosed (3). Identifying potentially treatable factors is of utmost 
importance.
15
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Figure 2 Cartoon depicting in brief main risk factors for CVA in newborns
Risk factors CVA in newborns:
In traventricular hemorrhage 
Prematurity 
Birth (trauma)
Perinatal infection 
Hypercarbia
Fluctuations in cerebral blood flow and 
pressure :rapid volume expansion, tracheal 
suctioning, convulsions, open duct o f Botalli 
Metabolic disturbances
Intracranial hemorrhage 
(Subdural, subarachnoidal, 
intracerebellar, Intraparenchymal)
Trauma 
Hypoxic events 
Pri mi parous 
Older maternal age 
Small birth canal 
Large baby 
Prematurity 
Prolonged labor 
Breech or foot extraction 
Difficult forcepsA/acuumextraction 
Disturbed coagulation 
ECMO
Birth weight
LBW and small for gestational age (SGA) are associated with increased 
perinatal mortality and morbidity, short- and long-term childhood morbidity 
and a range of cardiovascular and metabolic diseases later in life (4). Even 
after exclusion of newborns with established diagnoses explaining neurological 
disturbances, considerable concern remains regarding school performance, 
neurological and psychological deficits and reduced rates of postnatal growth. 
Associations between LBW and chronic disease in adulthood, such as 
hypertension, coronary heart disease, stroke or type 2 diabetes, have been 
extensively described (5, 6, 6, 7). The so-called “Barker hypothesis” or “fetal 
origins of adult disease” postulates that undernutrition in utero and during 
infancy can lead to a permanent “ reset” or “ reprogramming” of the body 
resulting in changes in gene expression and thereby altered body structure, 
metabolism, and responses to later environment. This reprogramming can be 
seen as a manifestation of developmental plasticity, i.e. “the phenomenon by 
which one genotype can give rise to a range of different physiological or 
morphological states in response to different environmental conditions during 
development” (8).
Regarding the discussion about the risks associated with BW, a few definitions 
should be noted. Many different terms are used to describe variations in fetal
Ischemic lesions 
Maternal diabetes 
Maternal drug abuse 
IUGR
Hypoxic-ischemic events
Perinatal infection
Acquired thrombophilic conditions
Inherited thrombophilic conditions
Cardiac abnoormalities
Birth trauma
DIS
ECMO
Indwelling catheters 
Polycyth e mi a/an em i a 
Vascular abnormalities
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growth. LBW refers to BW <2500 g, very low birth weight (VLBW) to BW<1500 
g, extremely low birth weight (ELBW) to BW <1000 g. These terms do not 
incorporate GA. SGA however, refers to a baby with a BW below the 10th 
percentile adjusted for gestational age and ideally also for newborn sex. IUGR 
is often used synonymously with SGA but sometimes refers to a pathophysi­
ological process resulting in restriction of fetal growth. By definition, 10% of 
newborns are below the 10th percentile regardless of their clinical condition or 
the necessity of therapeutic intervention. This group may reflect either biologic 
diversity o rthe  result of IUGR. On the other hand, a newborn with IUGR can be 
delivered with a BW above the 10th percentile depending on duration of growth 
retardation. Such a baby may still be considered growth restricted.
Maternal prepregnancy weight, prepregnancy height, weight gain during 
gestation, GA and male newborn sex are positively associated with BW in their 
offspring (9-11). Maternal height and weight are both positively related to BW; 
however, when corrected for weight, maternal height was no longer correlated 
(12). Also, increasing strength of the correlation between maternal weight gain 
and BW has been described in moderately overweight, normal weight and 
underweight pregnant women. In obese women maternal weight gain was not 
correlated to BW (13). In a study described by Catalano et al GA, maternal 
weight gain, and prepregnancy weight, newborn sex and parity together 
explained 29% of variation in BW (9). GA is strongly positively related to BW. 
Additionally, male newborns are on average 150 g heavier than female 
newborns (9). Parity has been shown to increase BW by 100-150 g in 
subsequent pregnancies but the risk of LBW increases again with the fourth 
and subsequent children (9, 11). Smoking is a well known and strong negative 
determinant of BW resulting on average in 200-300 g decreased weight (14, 
15). Ethnicity also influences BW with differences in fetal growth patterns 
remaining after controlling for risk factors or confounders (16). Placental 
vascular pathology is an important contributor to IUGR and/or LBW. In 
pre-eclamptic women, vascular changes leading to decreased uteroplacental 
blood flow can lead to IUGR or LBW.
To summarize, associations between (low) BW and risk of disease in adulthood 
have been extensively observed. These associations extend across the range 
of birth weights related to gestational age. They are believed to be the 
consequence of developmental plasticity. Prevention of LBW and IUGR is 
therefore of immense clinical and economic importance. Understanding the 
etiology is the first step towards prevention. Hence, revealing potentially 
treatable  factors associated with LBW and/or IUGR is very important to prevent 
morbidity in early and later life.
17
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Figure 3 Cartoon depicting in brief known determinants and consequences 
of (low) birth weight and metabolites of one carbon metabolism as 
possible determinants
Known determ inants of birth weight:
Gestational age f
Male newborn sex j*
Maternal weight \
Weight gain during pregnancy f
Parity >1 and <4 f
Parity S 4 I
Smoking I
Maternal malnutrition I
Possible determ inants studies in th is  thesis
Homocysteine
Cobalamin
Choline
Known consequences o f low birth weight:
Neonatal:
Increased morbidity 
Increased mortality
Infancy/childhood:
Schoolperformance I  
Reduced growth rate 
Neurological outcome J,
In adulthood increased risk on: 
Cardiovascular dieases 
Type 2 diabetes 
Hypertension 
Metabolic syndrome
One carbon metabolism
One carbon metabolism refers to a network of biochemical reactions 
characterized by transfer of one carbon groups, for example a methyl and/or 
formyl group. It is a so-called household metabolism, that is, one carbon 
metabolism reactions take place in every cell in the human body and are 
essential for cellular function. The transfer of one carbon groups plays a critical 
role in méthylation reactions such as méthylation of DNA using S-adenosyl- 
methionine (Adomet), and in the synthesis of thymidine and purines needed 
for DNA synthesis and repair. Adomet is a universal methyl donor and is 
involved in over 80 méthylation reactions. Given these important functions, it 
is not surprising that disturbances in one carbon metabolism are associated 
with a variety of pathologic conditions having their onset from early pregnancy 
to adulthood including such congenital abnormalities as neural tube defects, 
congenital heart defects and cleft palate and/or lip (17-22). Pregnancy 
complications such as recurrent early pregnancy loss, placental abruption, 
fetal loss, IUGR or LBW and pre-eclampsia have also been related to aspects 
of one carbon metabolism (23-26). Associations with cardiovascular disease,
18
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including stroke, venous and arterial thrombosis, with cancer, psychiatric 
disturbances and bone disease have been described in adults and in children 
(27-33). To summarize, one carbon metabolism plays an essential role in 
cellular metabolism including methylation and DNA synthesis and is related to 
multiple abnormalities and diseases.
Figure 4 One carbon metabolism
r ADMA Creatinine
Creatine *'
Gly ,  MTHF
B; ■SD)/
Sar
B2 DPI
DM G
THF
MTHF
THF
Bet
Cho
Braco b 2
MMA-CoA 
yil#' B,Ï> fcpc
■ Suc-CoA *■ Cys
10fTHF: 10-formylTHF; 5fTHF: 5-formylTHF; ADMA: asymmetric dimethylarginine;AdoHcy: S-ade- 
nosyl-L-homocysteine; AdoMet: S-adenosyl-L-methionine; apABG: acetamidobenzoylglutamate; 
B12: vitamin B12 (cobalamin); B2: vitaminB2 (riboflavin); B6: vitamin B6 (pyridoxal phosphate);BD: 
betaine aldehyde dehydrogenase; Bet: betaine; BT: BHMT, betaine-homocysteine methyltrans- 
ferase; Choi: choline;CHTHF: methenyl THF; CL: cystathionine gamma-lyase; CO: choline oxidase; 
Cre: creatinine; CS: cystathioninebeta-synthase; Cysta: cystathionine; DD: dimethylglycinedehy- 
drogenase; DHF: dihydrofolate; DMG: dimethylglycine; DR: DHF reductase; FA: folic acid; GAA: 
guanidinoacetic acid; Gly: glycine; GM: guanidinoacetatemethyl-transferase; GT: glycine N-methyl- 
transferase; hmDHF: 4-alfa-hydroxy-5-methyl-DHF; MA: methionine adenosyltransferase; Met: 
methionine; MM: methylmalonyl-CoA mutase; MMA: methylmalonic acid; MMA-CoA: methylmalo- 
nyl-CoA; MS: methionine synthase; MT: methyltransferase; mTHF: 5-methyltetrahydrofolate; MTHF: 
5,10-methylenetetrahydrofolate; MR: MTHFR, methylenetetrahydrofolate reductase; pABG: p-amin- 
obenzoyl-glutamate; Pr-L-Arg: arginine residue in proteins; Protein-L-Arg(CH3)2: dimethylated 
arginine residue in proteins; PT: PRMT, protein-arginine methyltransferase; Sar: sarcosine; SD: 
sarcosine dehydrogenase; SDMA: symmetric dimethylarginine; Ser: serine; SH: S-adenosyl- 
homocysteine hydrolase; ST: serine hydroxymethltransferase;Suc-CoA: succinyl-CoA; THF: tetra- 
hydrofolate.
Reproduced with permission from CCLM , de Gruyter. Copyright 2007. A ll rights reserved. Full text 
article available on www.reference-global.com (34).
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Part II Homocysteine 
Introduction
Homocysteine (Hey) is a sulfur-containing amino acid which is absent in the 
diet and is not used for protein synthesis. It plays an essential role in one 
carbon metabolism at the point where transsulfuration and remethylation 
intersect and folate metabolism is linked to cobalamin (figure 5). In 1964 Mudd 
and his colleagues showed that accumulation of Hey in blood and urine 
leading to severe homocystinuria was due to deficiency of the enzyme 
cystathionine (3-synthetase (CBS) (35). This is the so-called classic hyper- 
homocystinuria, referring to total homocysteine (tHcy) concentrations often 
exceeding 100 pmol/L. McCully postulated that the extremely high tHcy 
concentrations were responsible for premature arterial damage observed in 
patients with homocystinuria (36). These observations formed the basis for 
the research studying the association between elevated tHcy concentrations 
and vascular disease in the general population, eventually leading to the 
identification of mildly elevated tHcy concentrations as a riskfacto rfor vascular 
disease in adults and children.
Homocysteine metabolism
Intracellular Hey concentration is supposed to be precisely regulated and 
superfluous Hey is transported out of the cell. Hey is formed from methionine 
during S-adenosylmethionine dependent methylation reactions. Methionine 
and ATP lead to biosynthesis of S-adenosylmethionine (AdoMet) in a reaction 
catalyzed by methionine adenosyltransferase (MAT; EC 2.5.1.6) (figure 5). 
Donating a methyl group leads to formation of S-adenosylhomocysteine 
(AdoHcy), which is a potent inhibitor of AdoMet dependent methyltransferases. 
Subsequently, S-adenosylhomocysteine hydrolase (SAHH; EC 3.3.1.1) 
catalyses the reaction in which AdoHcy is hydrolyzed to Hey and adenosine. 
Excess Hey is directed into the transsulfuration pathway in which Hey is 
irreversibly converted to cysteine in two steps. This requires two sequential 
vitamin B6 dependent reactions catalyzed by cystathionine (3-synthetase 
(CBS; EC 4.2.1.22) and cystathionine y-lyase (CGL; EC 4.4.1.1). Hey and serine 
are condensated to cystathionine and
cystathionine is subsequently hydrolyzed to cysteine and a-ketobutyrate. Hey 
can also be remethylated to methionine in two ways. This remethylation 
pathway can be catalyzed by methionine synthase (MTR; EC 2.1.1.13) using 
5-methyltetrahydrofolate (5MTHF) and methylcobalamin (meCbl) as methyl 
donor and cofactor respectively. Methionine synthase reductase (MTRR) is 
able to regenerate active MTR. This is where homocysteine metabolism
2 0
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intersects with Cbl and the folate cycle in one carbon metabolism. Alternatively, 
betaine, derived from choline, can be used as methyl donor generating dime- 
thylglycine (DMG). This reaction is catalyzed by betaine homocysteine methyl 
transferase ( BHMT; EC 2.1.1.5) (37, 38).
Figure 5 Simplified scheme of Homocysteine metabolism
Methylated product
Adenosine
CBS
Cystathionine *  
CGL
1
B6
Cysteine 
Diet ------------ > Choline
M ethylacceptor 
—  AdoMet
PhCh *  PEMT x PE
5,10-m ethylene THF 
B2 
MTHFR
5-methyl THF MTRR B12 THF  
\  M TR /
Homocysteine Methionine *
ChD
/  BHMT
Betaine zinc Dimethylglycine
I  BAD  
Betaine aldehyde Sarcosine
ATP
Diet
Glycine
Main regulating enzymes are depicted and cofactors are encircled.
AdoHcy: S-adenosylhomocysteine; AdoMet: S-adenosylmethionine; BAD: betaine aldehyde 
dehydrogenase; BHMT: betaine-homocysteine methyltransferase; CBS: cystathionine B-synthase; 
CGL: cystathionine y-lyase; ChD: choline dehydrogenase; MTHFR: methylenetetrahydrofolate 
reductase; MTR:methionine synthase; MTRR: methionine synthase reductase. THF: tetrahydro- 
folate. PhCh: phosphatidylcholine. PE: phosphatidylethanolamine. PEMT: phosphatidyleth- 
anolamine-N-methyltransferase. MAT: methionine adenosyl transferase.
1: transsulfuration; 2: remethylation through methionine synthase; 3. remethylation through 
BHMT.
Adapted from Sandra Heil, PhD thesis.
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Inborn errors of Hey metabolism
Cystathionine B-synthetase deficiency
Homozygosity for CBS deficiency is the most common cause of classic 
homocystinuria. The classical clinical picture of severe homocystinuria 
includes premature vascular disease and thrombosis, mental retardation and 
psychiatric disturbances, ectopia lentis and myopia, and skeletal abnormalities 
(mainly osteoporosis). In most CBS deficient patients, vitamin B6 
responsiveness is probably dependent on residual activity of the CBS 
protein.
Dysfunction of Methionine synthase
MTR dysfunction can be caused by a defective MTR enzyme, by missing 
cofactor (meCbl) or by defective MTRR. Disorders causing isolated defects in 
MTR function, and disorders that cause defects in both MTR and methylmalo- 
nyl-CoA mutase (MUT) function, are historically named by complementation 
group (see Part III, Cobalamin, for detailed information). Complementation 
groups CblE and CbIG both result in isolated homocystinuria and are directly 
involved in MTR and MTRR activity, respectively. In the CbIG complementation 
group deficient MTR activities are found due to mutations in the MTR gene 
leading to absent MTR protein or changes in the Cbl-binding domain The 
CblE complementation group has defects in MTRR enzyme. The MTRR enzyme 
is a reductase required for the reductive reactivation of MTR when the Cbl 
cofactor has become oxidized to Cbl2+, rendering MTR inactive (38-40). Clinical 
pictures of both groups are nearly identical and encompass symptoms such 
as vomiting, poor feeding, hypotonia, seizures, developmental delay, ataxia, 
blindness, megaloblastic anemia and vascular disease. Biochemically 
increased tHcy concentrations and often hypomethioninemia are found.
5,10-Methylenetetrahydrofolate reductase deficiency
Lack of activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) (EC 
1.1.99.15) will lead to the inability to form 5MTHF which is the co-substrate in 
remethylation. As a consequence, plasma tHcy concentrations will be 
increased and homocystinuria will be present. Patients develop hyperhomo- 
cysteinemiawith low concentrations of methionine and neurologic dysfunction, 
psychomotor retardation, seizures and peripheral neuropathy. They probably 
also have higher incidence of vascular disease (39).
Concentrations and determinants of homocysteine
Plasmatotal homocysteine (tHcy) refers to the sum of all forms of homocysteine 
in plasma after quantitative reductive cleavage of all disulfide bonds. In plasma
2 2
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or serum, Hey exists in several interchangeable forms. About 80% is bound to 
albumin, approximately 20% forms low molecular weight disulphides and 
approximately 1% is reduced “free” Hey. In general, they are collectively 
measured as tHcy after quantitative reduction (41). Blood sampling requires 
special precautions. Release of different forms of Hey from red blood cells is 
dependent of time and temperature and causes 10%/h increase in tHcy 
concentrations in adults. Therefore, samples should be placed on ice 
immediately after drawing blood or centrifugation of plasma or serum should 
take place within 30 minutes (24, 42). After removal of the blood cells, tHcy in 
serum or plasma is stable for days at room temperature, for weeks at 0-2 C 
and for years when frozen at -20 C.
Concentrations and determinants in adults
In adults, tHcy is usually 5-15 jumol/L and hyperhomocysteinemia is defined as 
tHcy>15jUmol/L. However, reported reference ranges differ markedly, probably 
due to a skewed tHcy distribution, varying definitions of the upper threshold, 
sampling differences, variation in determinants and/or laboratory techniques. 
In children an age-dependent increase in tHcy concentrations has repeatedly 
been reported with tHcy concentrations varying from 4 to 8 jumol/L in 
prepubertal children (43).
Folate and Cbl intake influence tHcy concentrations in adults and older children 
(44).
THcy concentrations increase with age in children and adults (29, 44, 45). 
Males have higher tHcy concentrations than females. This difference might be 
due to sex hormones (there is no difference before onset of puberty), difference 
in muscle mass, or vitamin status. Decreased renal function leads to higher 
concentrations (44). Polymorphisms in the genes encoding for proteins 
involved in Hey metabolism can result in increased tHcy concentrations. The 
common C677T polymorphism in the MTHFR gene (alanine to valine 
substitution) causes reduced catalytic activity and thermolability of the enzyme 
and predisposes to approximately 20% increased tHcy concentrations, mainly 
in situations with impaired folate status. In the Netherlands the frequency of 
the 7T genotype is approximately 10% (46). Smoking, increased caffeinated 
coffee intake, chronic increased alcohol intake, and decreased intake and/or 
plasma concentrations of Cbl and folate are associated with increased tHcy 
concentrations (45). Increased tHcy concentrations have been observed in 
conditions as hyper-pro I iterative disease and hypothyroidism (44, 47). Certain 
drugs can cause tHcy to rise such as methotrexate, antiepileptic drugs, L-dopa 
and B12 antagonists (45, 48). During pregnancy, tHcy concentrations decrease 
in the first trimester, reach a trough during the second trimester, and rise at the
23
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end of the third trimester to values comparable to or higher than first trimester 
or preconception concentrations (49).
Concentrations and determinants in children
THcy concentrations in children are different from those in adults. Mean tHcy 
concentrations are approximately 4-8 jumol/L in children aged <15 years. THcy 
increases as a function of age (29). Some studies have observed slight sex 
differences; this effect is enhanced during and after puberty (>15 years) (29). 
A positive association between tHcy and creatinine was found in healthy 
children without renal impairment, probably partially explaining the sex 
difference. In children, as in adults, tHcy concentrations vary according to 
ethnicity, with black children having higher concentrations than white or 
Hispanic children (29). Plasma tHcy concentrations correlate strongly with 
plasmafolate in older children and less so with Cbl; plasmatHcy concentrations 
correlate strongly with Cbl in infancy (29). Smoking also increases tHcy 
concentrations in smoking children. The C677T polymorphism in the MTHFR 
gene (homozygous 7T) resulted in higher tHcy and lower folate in healthy 
teenagers and in teenagers with familial hypercholesterolemia (50, 51) but did 
not influence tHcy concentrations in newborns (52, 53). THcy concentrations 
are elevated in children with chronic renal failure (whether conservative 
management, hemodialysis, renal transplantation) (54).
Treatment of elevated tHcy concentrations
THcy concentrations can potentially be lowered with folate, Cbl, B6 and/or 
betaine supplementation. Folic acid (0.2-5 mg) is effective in decreasing tHcy 
concentrations in cases with elevated tHcy (55). Daily doses of folic acid of 
0.2, 0.4, 0.8, 2.0, and5.0 mg were associated with tHcy concentration reduction 
of 13%, 20%, 23%, 23%, and 25% respectively in a meta-analysis of the 
randomized trials (56). In 1998, folic acid fortification of flour and grain products 
started in North America which resulted in a nearly doubled mean folic acid 
intake and which substantially reduced tHcy concentrations (57). The addition 
of Cbl (median dose: 0.4 mg) to folic acid in incremental doses further 
decreased tHcy concentration by approximately 6% (58). High doses of 
betaine are used to treat patients with classic homocystinuria (37) with a most 
significant effect on post methionine loading tHcy concentrations. Betaine or 
choline supplementation have been shown to decrease tHcy concentrations 
in healthy subjects (59, 60). Vitamin B6 is also used in classical homocystinuria 
patients as a supplement to reduce tHcy concentrations.
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Homocysteine and association with disease
Introduction
Hyperhomocysteinemia, a marker for folate and Cbl deficiency, is defined as 
elevated total Hey concentrations (roughly >15 jumol/L in adults). It is also a 
risk factor for congenital abnormalities such as neural tube defects (NTDs) (17, 
61, 62), congenital heart defects (21, 22), cleft lip/palate (21), mental disorders 
and psychiatric disturbances (32), bone disease (33), cancer, and cognitive 
impairment in the elderly (63, 64).
Given the objectives of this thesis, we would like to put emphasis on the 
associations with pregnancy complications (65) and vascular disease (41, 41, 
66-69).
Vascular complications
Adults
In 1976, Wilcken and Wilcken provided the first evidence that hyperhomo- 
cysteinaemia is associated with increased risk for vascular disease (30). Since 
this observation, epidemiological studies have unequivocally established that 
elevated plasmatHcy concentrations both precede and predictthe occurrence 
of cardiovascular disease. There is a graded association without an apparent 
threshold, which remains after adjustment for potential confounders, between 
elevated tHcy concentrations and ischemic heart disease, stroke, deep vein 
thrombosis, myocardial infarction, cerebrovascular accident and peripheral 
vascular disease (27, 69-72). Humphrey et al concluded in their meta-analysis 
that “each increase of 5 jumol/L tHcy concentration increases the risk of 
coronary heart disease events by approximately 20%, independently of 
traditional coronary heart disease risk factors” (73). Three meta-analyses have 
summarized data on cardiovascular events by MTHFR C677T genotype, and 
from these it seems that approximately 3 jumol/L lower tHcy concentrations 
(CC genotype) is related to 10-15% reduced risk of ischemic heart disease and 
20-25% lower risk of stroke (74-76). This supportive evidence led to the launch 
of large randomized controlled trials using folic acid alone or in combination 
with Cbl and/or B6 to lower tHcy concentrations. These intervention trials 
aiming to reduce the recurrence of above named diseases, failed to show a 
net positive effect of tHcy lowering on prevention of clinically defined 
cardiovascular disease outcomes (77-82). Subgroup analysis seem to reveal a 
decreased risk in patients younger than 70 years for stroke (hazard ratio 
0.75[0.59;0.97] in the HOPE trial (83). Wang et al performed a meta-analysis 
considering tHcy lowering and the risk on stroke and concluded that folic acid 
supplementation could effectively reduce the risk of stroke in primary
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prevention by 18% (78). Possible explanations for the lack of net effect of tHcy 
lowering therapy could be limited power due to relatively little contrast between 
intervention and control groups, limited duration of follow up (3-5 years) to 
evaluate an effect on atherosclerotic processes or relatively low severity of 
abnormalities (mean baseline tHcy concentrations 12-14 jumol/L). A possible 
dual effect of B vitamin supplementation with B vitamins themselves sorting 
an effect on cardiovascular disease or potential toxicity of folic acid with 
stimulation of inflammation and proliferation can also be potential explanations 
which deserve further attention (84).
Children
In sharp contrast to the abundant number of studies considering the association 
between elevated tHcy concentrations and cardiovascular risk in adults are 
the scarce data on this topic in children. THcy concentrations in children have 
been associated with cardiovascular disease in relatives. Children with positive 
family history of early coronary artery disease had significantly increased 
age-adjusted geometric mean (GM) tHcy concentrations than controls (85, 
86). Elevated tHcy concentrations were observed in children with parents or 
grandparents with occlusive artery disease (87,88). H ighertHcy concentrations 
were found in children with familial hypercholesterolemia with parental 
cardiovascular disease than in children without parental cardiovascular 
disease (89).These results might indicate an association between tHcy 
concentrations and risk of (familial) cardiovascular disease.
Few studies explored the potential risk of hyperhomocysteinemia on stroke in 
children. Although the number of participants is definitively smaller compared 
to adult studies, results seem to be comparable. Hyperhomocysteinemia is a 
risk factor for ischemic stroke in children (OR 4.4[1,7;11.6] (90). Cardo et al 
have described elevated tHcy concentrations in 68 children aged two months 
to 18 years with acute ischemic or hemorrhagic stroke compared to 195 
controls (91). Sirachainan et al have found higher tHcy concentrations in 28 
pediatric stroke patients compared to 100 controls (92). Nowak et al have 
observed an OR of 2.6 [1.53;4.5] for ischemic stroke in children aged six 
months to 16 years with C677T polymorphism in the MTHFR gene (93). In 
contrast, Akar et al have found no difference between pediatric stroke patients 
and controls for the distribution of alleles C677T and A1298C in the MTHFR 
gene, G1958A in the methylenetetrahydrofolate dehydrogenase gene and 
A66G in the methionine reductase gene (3, 94). McColl et al have observed 
comparable results in 37 cases with ischemic stroke: OR for stroke in children 
with C677T mutation was 1.7[0.6;4.5] (95). A higher prevalence of hyperhomo­
cysteinemia (71.4%) and the C677T polymorphism (28.6 vs 14.3%) was
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observed in 21 children with stroke compared to 28 healthy children (96). 
Homozygotes for the C677T polymorphism in the MTHFR gene were 
significantly more likely to have a recurrent event of ischemic stroke or transient 
ischemic attack than those who were negative or heterozygous in 118 cases 
aged six months to 17 years, as described by Prengler et al (97). Furthermore, 
homozygosity led to higher tHcy concentrations. Rook et al described an 
increased frequency of homozygosity for the C677T and the A1298C 
polymorphism in the MTHFR gene in 21 pediatric stroke patients compared to 
expected frequencies (98).
Recently, a study of 123 preterm infants did not observe an association with 
tHcy concentrations and the occurrence of intraventricular hemorrhage (n=31) 
(99).
Data of a childhood case-control study comparing 141 children with venous 
thrombosis with 345 healthy controls suggested that elevated tHcy 
concentrations >8.3 jumol/L and the CT genotype of the MTHFR C677T variant 
were risk factors for venous vascular occlusion (100).
To summarize, the published data suggest that tHcy concentrations and/or the 
C677T polymorphism in the MTHFR gene are associated with cardiovascular 
disease, stroke and venous thrombosis in childhood. In contrast to adults, 
intervention trials have not been undertaken. Furthermore, at the start of this 
thesis, no information on the possible association between tHcy and risk on 
CVA in newborn infants had been described.
Pregnancy outcome
Hyperhomocysteinemia has been associated with adverse pregnancy 
outcomes such as recurrent early pregnancy loss, abruptio placentae, 
intrauterine growth retardation, pre-eclampsia and fetal loss. Wouters et al 
were the first to describe the association between elevated tHcy concentrations 
and repeated miscarriages (101). Further studies confirmed this result and a 
meta-analysis performed by Nelen et al showed pooled risk estimates for 
recurrent early pregnancy loss (REPL) of 2.7[1.4;5.2] (3 studies;403 cases, 
269 controls) and 4.2[2.0;8.8] (4 studies;351 cases, 229 controls) for fasting 
and afterload plasma tHcy concentrations (23). Pooled risk estimate for REPL 
for the MTHFR 677TT genotype was 1.4[1.0;2.0], combining results from six 
studies with 599 cases and 498 controls.
In women previously suffering from abruptio placentae, 26-31% were reported 
to have elevated tHcy concentrations compared to 9% in the control group 
(102, 103). Vollset et al observed a threefold risk on placental abruption if tHcy 
>15 jumol/l (24). Nurk et al found an increased risk for placental abruption in
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the MTHFR 677TT genotype mothers (OR 2.6[1.4;4.8]) but not for the 1298AA 
genotype mothers (104).
Burke et al observed a 10% perinatal death rate in 30 women heterozygous for 
CBS mutations (25). Eleven% of 18 patients presenting with intrauterine fetal 
demise had increased tHcy in a study performed by de Vries et al (103). Sup­
plementation with folic acid and multivitamins in a general population, however, 
did not decrease the frequency of fetal death (105). Vollset et al observed no 
increased risk of stillbirth in women in the highest quart ile of tHcy concentrations 
compared to the lowest quartile (24).
Dekker et al reported that 18% of women with severe pre-eclampsia with early 
onset had elevated tHcy concentrations compared with 2% of the general 
population (106). Vollset et al observed more than fourfold increased risk on 
pre-eclampsia <37 weeks of GA in women with increased tHcy (24). Other 
authors observed similar results suggesting that the role of elevated tHcy in 
pre-eclampsia should be investigated further (107-110). In a systematic review 
on prothrombotic genotypes in relation to pre-eclampsia including 25 studies 
with approximately 11,000 patients homozygosity forthe C677T polymorphism 
in the MTHFR gene resulted in an OR of 1.37[1.07;1.76] for developing 
pre-eclampsia (111).
Several authors have addressed the possible association between maternal 
tHcy concentrations and BW of their offspring. Vollset and Malinow have 
observed an association between high maternal tHcy concentrations and risk 
of having LBW offspring (24), and negative correlations between maternal 
homocysteine and BW (26). In contrast, others havefound either no differences 
(112, 113) or even a positive association between maternal tHcy and BW (53). 
Newborns homozygous for the MTHFR C677T variant had decreased risk of 
IUGR (114). A few studies assessed Cbl and/or folate together with tHcy 
concentrations in relation to BW (26, 112, 113). However, none of these studies 
determined methylmalonic acid (MMA) concentrations, a sensitive marker of 
Cbl deficiency. To summarize, studies regarding maternal tHcy in relation to 
BW yield conflicting conclusions.
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Part III Cobalamin
Introduction
Cbl is an essential B vitamin in humans. It is composed of a central cobalt 
atom attached to four pyrrole rings and a nucleotide. The cobalt atom has a 6th 
ligand generally a methyl, hydroxyl, adenosyl or glutathionyl group. The first 
three are physiological analogues. The cobalt atom exists in various forms of 
oxidation: fully oxidized it is termed Cbl3+, partially oxidized Cbl 2+ and fully 
reduced Cbl1+. These oxidation-reduction states are relevant because the 
cobalt atom must be reduced prior to formation of methylcobalamin (meCbl) 
and 5-deoxyadenosylcobalamin (adoCbl), the only two forms of Cbl known to 
function as specific cofactors in mammalian systems (figure 6) (38, 39, 115).
Metabolism
Cbl is present in all animal originating food products such as meat, fish, poultry 
and dairy products. In food, Cbl is bound to protein. After entering the 
stomach, gastric acid and pepsin release Cbl from its protein. Haptocorrin 
(HC), produced by saliva, binds to Cbl and this complex is transported to the 
duodenum. Thereafter, pancreatic proteases cleave this complex, liberating 
Cbl in the duodenal lumen. Hereupon Cbl binds to intrinsic factor (IF), 
synthesized by gastric parietal cells. The Cbl-IF complex is absorbed into the 
enterocyte of the terminal ileum after binding to the ileal endocytic cubam 
receptor formed by the proteins cubilin and amnionless (116). In the enterocyte, 
the complex is dissociated and the vitamin is transported across the basal 
membrane into the portal circulation bound to transcobalamin II (TCII). This 
polypeptide is synthesized by liver, ileal and endothelial cells and is responsible 
for cellular uptake of Cbl. HC constitutes a group of glycoproteins synthesized 
amongst others by hepatocytes, salivary glands and granulocytes and carrying 
the majority of steady state Cbl. It binds approximately 80% of total Cbl in 
plasma. Both peptides, TC and HC, can exist in Cbl saturated (holo) or 
unsaturated (apo) form. The major part of TC is formed by unsaturated TC 
(apoTC). HC is largely saturated (holoHC) (117). Cbl is stored in the liver from 
where it can return to the circulation bound to TCII or can be excreted into bile 
bound to haptocorrin.
In blood, Cbl bound to TCII is transported to the cells and is internalized intact 
via adsorptive endocytosis after which lysosomal degradation activity results 
in release of Cbl from the Cbl-TCII complex (figure 6). Cbl then exits from the 
lysosome and can either be converted to MeCbl in the cytosol or to AdoCbl in 
the mitochondrion. Conversion to AdoCbl requires reduction steps followed 
by adenosylation.
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Conversion of Cbl to MeCbl requires reduction and methylation by first forming 
a complex with MTR and thereafter binding of the methylgroup of 5MTHF to 
form methylCblMTR. Methionine synthase reductase (MTRR) regenerates the 
active form of the CblMTR complex. MeCbl is cofactor in the remethylation of 
homocysteine to methionine utilizing 5-methylTHF and MTR (39). 
D-methylmalonylCoA, derived from propionylCoA, is racemized into L-methyl- 
malonylCoA with the enzyme DL-methylmalonylCoA racemase (EC 5.1.99.1). 
L-methylmalonylCoA is converted into succinylCoA by the enzyme L-methyl- 
malonyl-CoA mutase (MCM) (EC 5.4.99.2), using AdoCbl as essential cofactor. 
Excess methylmalonylCoA can be converted to free methylmalonic acid (MMA) 
which can be excreted in the urine.
Figure 6 Cobalamin metabolism
The transcobalamin-cobalamin complex enters the cell. After lysosomal release into the cytosol 
of Cbl, it can be further metabolized to adenosylcobalamin or methylcobalamin. In the cytosol, 
complementation groups CblF, C, D, E, G, H, A and B are depicted. Cbl_ indicates Cbl in unknown 
exact form of reduction. CblA: unknown function of associated protein. CbIB: cobalamin adenosyl 
transferase. Mut= L-methylmalonylCoA mutase. CbIC: cytosolic step in Cbl metabolism. CbID: 
cytosolic step in Cbl metabolism. CblD-homocystinuria= CblD1 =associated with impaired 
synthesis/function of methylcobalamin. CblD-methylmalonic aciduria=C blH =C blD2=associated 
with impaired synthesis/function of adenosylcobalamin. CblE=methionine synthase reductase. 
CblF=lysosomal Cbl transporter. CblG=m ethionine synthase.
Reproduced with permission from NEJM. Copyright 2008. Massachusetts M edical Society. All 
rights reserved (118).
30
G ENERAL INTRODUCTION
Inborn errors of Cbl metabolism
Transport defects
• Hereditary Intrinsic Factor deficiency
Children with hereditary IF deficiency suffer from a lack of functional IF which 
can be caused by several factors, including production of a physiologically 
inactive IF, an unstable IF protein that is susceptible to acid and trypsin, IF with 
decreased affinity for Cbl and/or ileal receptor or antiparietal cell antibodies. 
Recently, mutations in the GIF gene have been described. Patients with 
hereditary IF deficiency present with pernicious anemia having its onset 
between one and five years of age, developmental delay, megaloblastic 
anemia, low serum Cbl concentrations but normal gastric function, and 
absence of IF antibodies. Providing human IF corrects the malabsorption, to 
be shown with the two stage Schilling test (119). This classic test, a Cbl loading 
test to observe absorption of Cbl with and without additional IF is now in most 
cases replaced by determination of MMA and tHcy concentrations and 
antibody tests.
• Cubilin or amnionless deficiency
Defective transport by enterocytes, the so-called Imerslund-Grasbeck 
syndrome, is a rare autosomal recessive disorder which encompasses 
disturbances in the Cbl-IF complex transport across the ileal enterocyte. Two 
genes encoding IF receptor components, 1) CUBN encoding cubilin located 
on chromosome 10, and 2)AMN  encoding amnionless, located on chromosome 
14, have been described. Both proteins are components of the intestinal 
receptor fo rt he Cb-IF complex. The receptor also mediates tubular reabsorption 
of protein from the primary urine. Patients present between six months and 
five years of age with clinical signs of juvenile pernicious anemia as described 
above, but with normal gastric and IF function and the absence of correction 
of the malabsorption by providing human IF.
• Transcobalamin II deficiency
TCI I is required for the movement of Cbl from ileal cells into the cells throughout 
the human body. This disorder seems to present much earlier, within the first 
moths after birth. Symptoms are failure to thrive, gastrointestinal symptoms, 
megaloblastic anemia and, eventually, neurological symptoms. Serum Cbl 
concentrations are normal to near normal, due to the fact that most circulating 
steady state serum Cbl (—80%) is attached to haptocorrin.
• Haptocorrin deficiency
Patients with absent haptocorrin in blood cells, plasma/serum and saliva have 
decreased serum Cbl concentration but are without signs of Cbl deficiency, 
probably due to the fact that TC II is normal. Patients do not have symptoms. 
The exact function of HC remains unclear.
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Defects in intracellular Cbl metabolism
Disorders are historically named by complementation group. Complementa­
tion means that two different sources of genetic information together (usually 
different gene loci); each provides the part the other lacks. Any two defective 
strains that fail to complement are in the same complementation group. Each 
group represents one of the enzymes in the pathway under investigation. 
However, in the past years, genes involved in Cbl metabolism have been 
discovered. Clinical presentations of these disorders can be highly variable 
even within one complementation group. Disorders involving defects in MUT 
function are characterized by severe methylmalonic acidemia and can be 
caused by defective MUT enzyme (MUT gene) or dysfunction of Cbl cofactor 
(.MMAA or MMAB gene) (table I). Disorders involving defective MTR function 
only are associated with hyperhomocysteinemia. They can be caused by 
deficient MTR protein (MTR gene) or defective MTRR enzyme (MTRR gene). 
Recently, a variant of CbID due to mutation in MMADHC gene was described 
((118, 120). Combined disorders leading to both increased MMA and tHcy 
concentrations are called CbIC, CbID and CbIF and are now known to be 
caused by mutations in the MMACHC gene (CbIC) and the LMBRD1 gene 
(CblF).
• Methylmalonaciduria
Severely increased MMA concentrations in plasma and urine can be caused 
by defective MUT enzyme or disturbances in Cbl metabolism. MMA metabolism 
is inextricably related to Cbl intake, uptake, transport and metabolism. The 
mut° and m ut defects result from deficiency of MMCoA mutase due to 
mutations in the MUT gene. Mut0 and mut'can be differentiated based on the 
absence or presence of residual enzyme activity in cultured fibroblasts. 
Lesions at two different loci can be responsible for defective AdoCbl synthesis: 
they are called CblA and CbIB complementation group. Mutations in MMAA 
gene (CblA) are thought to lead to dysfunction or absence of a protein playing 
a role in the assembly and stabilization of MMCoA mutase. Mutations in the 
MMAB gene (CbIB) are now known to result from impaired AdoCbl synthesis 
due to defective Cbl adenosyltransferase (EC 2.2.1.17) function. Patients with 
methylmalonaciduria may present with lethargy, failure to thrive, hypotonia, 
vomiting, dehydration, tachypnoea and developmental delay. Serum Cbl 
concentrations are normal. Metabolic acidosis, hyperammonemia, hypo­
glycemia and pancytopenia are common. Chronic renal failure is a significant 
long-term problem.
• Combined methylmalonic aciduria and hyperhomocysteinemia
There are a significant number of patients with inherited combined homocystinuria 
and methylmalonic aciduria. Clinical manifestations are highly variable. CbIC
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is the most common of these disorders: mutations in the MMACHC gene 
appear to code for a protein located in the cytosol probably involved in 
intracellular channeling of Cbl. One mutation, 271dupA, accounts for 
approximately 40% of all cases (40). Patients present with clinical symptoms 
varying from SGA, microcephaly, failure to thrive and feeding problems, 
neurologicsymptoms, cytopenias, developmental delay, mental state changes, 
cognitive decline to megaloblastic anemia. Dermatological and ophthalmo- 
logical abnormalities have also been observed. The most severely affected 
patients often present at younger age. The CbID complementation group 
defect was first described with combined methylmalonic aciduria and hyper- 
homocystinuria. Recently, two variants have been described: CblD-1, resulting 
in isolated homocystinuria, and CblD-2, due to mutations in MMADHC gene, 
resulting in isolated MMAuria. CblF group is caused by mutations in the 
LMBRD1 gene and is characterized by deficient lysosomal release of Cbl into 
the cytosol resulting in impaired Ado- and MeCbl synthesis. Patients suffer 
from feeding difficulties, developmental delay, hypotonia and megaloblastic 
anemia (38, 40, 115).
Table I Defects in intracellular cobalamin metabolism
group protein impaired
synthesis
gene locus elevated
metabolite
mut°/mut_ MMCoAmutase Mutase MUT 6q21 MMA
CblA Adocbl MMAA 4q31.1 MMA
CbIB
ATP-Cbl
adenosyltransferase
Adocbl MMAB 12q24 MMA
CbIC Adocbl, Mecbl MMACHC 1p34.1 MMA +  Hey
CbID Adocbl, Mecbl MMADHC 2q23.2 MMA ±H cy
CblE Methionine synthase 
reductase
Mecbl MTRR 5p15.3-2 Hey
CblF Lysosomal Cbl 
transporter
Adocbl, Mecbl LMBRD1 6q13 MMA +  Hey
CbIG Methionine synthase Mecbl MTR 1q43 Hey
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Concentrations and determinants of cobalamin
Adult Cbl reference ranges vary between 160 and 750 pmol/L. No gold 
standard exists to define cut-off concentrations below which Cbl deficiency is 
defined. Adults with Cbl concentrations below 150 to 250 pmol/L are usually 
considered deficient but Cbl concentrations are not sufficient to prove 
intracellular Cbl deficiency. This can be explained by the fact that about 80% 
of total plasma Cbl is bound to haptocorrin, which is not taken up by the cells. 
The remaining 20% of total plasma Cbl is bound to TC and this complex is 
responsible for transport and cellular uptake of Cbl. Plasma Cbl measurement 
shows the sum of both bound forms of Cbl and thus does not necessarily 
reflect intracellular Cbl status (121). Determination of MMA and/or tHcy and/or 
holoTCII adds to the sensitivity of diagnosing Cbl deficiency. Several authors 
have described a gradual fall in Cbl concentrations of approximately 30% 
during pregnancy, which normalizes after delivery (122, 123).
Pediatric reference ranges for Cbl are even more ill-defined. Moreover, Cbl 
concentrations undergo marked changes from infancy to adulthood. Bjorke 
Monsen et al describe median Cbl concentrations in 173 newborns of 314 
pmol/L, decreasing to reach a nadir between six weeks and six months (217 
pmol/L), then increasing to reach a peak between one and ten years (515 
pmol/L), followed by a gradual decrease towards adult concentrations (29). 
Newborn and/or umbilical cord blood Cbl concentrations varying from 171 to 
800 pmol/l have been described (29, 124-129). Besides classical inborn errors 
of Cbl metabolism several other determinants of Cbl in adults and children 
have been described. Main factors are dietary intake or disturbed absorption.
Treatment of cobalamin deficiency
Several regimens are used to treat Cbl deficiency. Most of them start with 
hydroxyCbl orcyanoCbl in dosesfrom  250to 1000jug intramuscularly for three 
to seven times in the first one to two weeks, then weekly until normalization of 
laboratory results. Maintenance doses every one to three months may be 
necessary (130). Oral Cbl supplementation seems to be as useful as 
intramuscular Cbl in adults, although its use is still not widespread (131). 
Sublingual Cbl administration has also proven to be successful in restoring 
Cbl concentrations to normal (132, 133). In children, there might be a stronger 
rationale for oral supplementation based on the fact that Cbl deficiency in 
infancy and childhood is mainly due to insufficient intake. Changes in diet 
might even be sufficient. One intramuscular injection containing 400 jugram 
hydroxyCbl at six weeks after birth increased Cbl concentrations and was 
accompanied by a remarkable decrease in tHcy and MMA concentrations at 
four months in 54 infants as described by Bjorke Monsen et al (134). In inborn
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errors of Cbl metabolism, pharmacological doses of Cbl can be used for those 
who respond. Oral supplementation of Cbl (0.5 mg/kg/day) has proven to be 
successful in patients with CbIB defect (135).
Cobalamin and association with disease
Cobalamin deficiency in adults
Causes of Cbl deficiency
Main reasons for Cbl deficiency are decreased intake and malabsorption. In 
adults, decreased intake is mainly caused by dietary restraints, such as in 
macrobiotic, vegan or vegetarian diets. Nutritional deficiency may also occur 
in developing countries and impoverished communities with limited access to 
animal food sources. Malabsorption can be caused by IF deficiency, IF 
antibodies, Imerslund-Grasbeck syndrome, selective Cbl food malabsorption 
or more generalized absorption disturbances such as parasite infection, 
inflammatory bowel disease, short bowel syndrome, cystic fibrosis, celiac 
disease, ileal damage or resection, achlorhydria, or gastric bypass surgery. It 
is suggested that in situations with bacterial overgrowth in the intestine, 
increased consumption of bacteria can give rise to decreased transport into 
the circulation. Cbl food malabsorption is a condition with neurologic 
manifestations with or without hematological abnormalities; low serum Cbl 
and normal Schilling test have been described in several patients. An inability 
to release Cbl from the protein-bound state encountered on food is the most 
likely pathophysiological cause. Any underlying disorder leading to decreased 
gastric function can be the cause.
Some medications are associated with an increased risk for Cbl deficiency, 
e.g. H2 receptor antagonists, proton pump inhibitors and metformin in adults 
(136). In children, such an association could not be confirmed (137, 138).
Symptoms of Cbl deficiency
The classical presentation of Cbl deficiency in adults is with megaloblastic 
anemia and neurological symptoms such as sensory disturbances (due to 
damage to peripheral nerves caused by demyelization), numbness, tingling of 
the extremities, altered propioception, impaired sense of smell, disturbed 
coordination, ataxia and sometimes even subacute combined degeneration of 
the spinal cord. Early symptoms such as tiredness, decreased mental work 
capacity, weakened concentration and memory, irritability and depression 
have been described.
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Mechanisms of symptoms in Cbl deficiency
Long-term Cbl deficiency causes impaired myelination or even demyelination 
of the spinal cord and brain (139). A disturbed conversion of methylmalonyl 
CoA to succinyl CoA results in excess of propionyl CoA, possibly leading to 
aberrant odd chain fatty acid synthesis. Incorporation of unusual fatty acids 
into nerve sheaths results in altered myelin (140,141). A disturbed remethylation 
of homocysteine to methionine will result in decreased availability of AdoMet, 
the methyl donor for de novo synthesis of phosphatidylcholine, an essential 
lipid component of myelin and a neurotransmitter itself. Cbl deficiency will 
lead to decreased MTR activity and decreased remethylation to methionine. 
Hence, decreased availability of AdoMet for methylation reactions is the 
consequence. This will lead to a diversion of folate cofactors away from DNA 
biosynthesis and into remethylation. The methylfolate trap hypothesis states 
that 5MTHF becomes metabolically trapped due to Cbl deficiency because 
5MTHF can not be transformed back to its precursor 5,10-methyleneTHF due 
to the irreversibility of this reaction. Furthermore, it can not be metabolized 
through remethylation due to decreased MTR activity. Thus, although folate is 
present within the cells it is not available in a form that can participate in DNA 
biosynthesis. This leads to megaloblastic anemia and eventually, due to hy- 
pomethylation, to decreased and hypomethylated myelin and neurological 
symptoms. Furthermore, eventually intracellular folate concentrations will 
decrease due to diminished folypolyglutamate synthase activity, since the 
latter is depending on methionine and Cbl concentrations. This folate trap has 
been demonstrated in a human being by Smulders et al (142). The altered 
AdoMet:Adohcy ratio could result in impaired methylation reactions needed 
for synthesis of proteins, lipids and neurotransmitters of the central nervous 
system. It also implies inhibition of DNA synthesis and cell division since folate 
cannot be recycled (143). It has been postulated that elevated MMA 
concentrations are nephrotoxic. Conflicting conclusions have been reported 
considering the involvement of MMA in the inhibition of mitochondrial complex 
II leading to secondary excitotoxic mechanisms (144, 145).
Diagnosis of Cbl deficiency
Cbl is a cofactor in two reactions in the body, hence, deficiency will lead to 
elevated concentrations of homocysteine and methylmalonic acid (figure 6). In 
adults, tHey and MMA are used for the diagnosis and follow-up of Cbl deficiency 
(146, 147). THcy is influenced by many environmental factors such as folate 
and cobalamin status, renal or thyroid function, age, sex, lifestyle factors such 
as smoking, coffee intake and several drugs, as well as genetic factors 
including the MTHFR c.677 C > T polymorphism (41, 46, 148, 149). Plasma
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MMA is increased in severe renal failure and rare inborn errors of metabolism 
and is therefore a more specific marker of Cbl deficiency (150-152). Several 
studies highlight the usefulness of urinary and plasma or serum MMA 
concentrations as a marker of functional Cbl deficiency in children and adults 
(153-157). High sensitivity and specificity of MMA were reported in a study on 
clinically confirmed Cbl deficient patients (158). Schneede et al describe that 
simultaneous use of MMA and tHcy increases test sensitivity with remaining 
high specificity (98% and 92% respectively). MMA is stable in blood, urine, 
serum and plasma at room temperature and no special precautions for blood 
sampling and storage are required. In juvenile Cbl deficiency not explained by 
dietary intake or general malabsorption, genetic testing can be performed and 
should include the CUBN and AMN genes for Imerslund-Grasbeck syndrome 
and the GIF gene for hereditary intrinsic factor deficiency.
Cobalamin deficiency in infancy and childhood
Causes
Acquired Cbl deficiencies in infancy and childhood are generally caused by 
dietary deficiency of either the mother or the child. Infant Cbl status is critically 
dependent on fetal accumulation and, thereby, maternal Cbl status in 
pregnancy. The adequacy of maternal Cbl status in pregnancy and lactation 
has a stronger influence on fetal and infant Cbl status than on maternal stores; 
even short-term maternal dietary restriction can result in decreased Cbl 
availability and storage and status in the newborn. If maternal Cbl intake and 
stores are decreased during pregnancy, the newborn infant will have limited 
hepatic reserves and can develop symptoms of Cbl deficiency within short 
time after birth. Maternal Cbl concentrations strongly influence breast milk Cbl 
content (159-161). Mean breast milk concentrations between 139 and 378 
pmol/L are reported, the difference probably explained by different assays 
used and timing after delivery (159, 160). Ford et al describe a gradual decline 
in Cbl concentrations in breast milk from 261 to 139 pmol/L (GM) at 1-2 weeks 
to 27-35 weeks postpartum (160). Infant formulas are enriched to Cbl 
concentrations of approximately 1000-1300 pmol/L (160, 162).
Symptoms
During intrauterine development and infancy, Cbl is important for normal 
growth and central nervous system development (40, 163). Cbl is indirectly 
involved in DNA synthesis and amino acid conversions. In recent studies, 
evidence was obtained that Cbl deficiency is a relatively common finding in 
infants and children and is often not characterized by the classical symptoms, 
but can give rise to non-specific symptoms such as developmental delay or
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regression, progressive or persistent neurological sym ptom s, abnorm al 
movem ents, feeding problem s and failure to thrive (139, 164-166). Skin 
abnorm alities have also been described (167).There is increasing evidence 
that low Cbl status in ch ildhood may cause im pairm ent of grow th and 
developm ent and may even lead to irreversible neurological dam age depending 
on severity and duration of defic iency (139, 164-166).
In adolescents from  m acrobio tic  fam ilies, functiona l Cbl defic iency and clear 
evidence fo r im paired cognitive function  were observed, despite in troduction 
of animal p roducts in the diet a fte rthe  age of s ixyears  (168,169). This suggests 
that even m oderate defic iency can be harmful. Sym ptom s may be evident as 
early as three weeks of age but recognition can be d ifficu lt due to the variety 
of possib le sym ptom s and the large variation in normal developm ent in 
infancy.
Infancy
Increasing awareness of the existence of Cbl defic iency has been raised by 
several studies, a lthough in general practice the index of susp ic ion  is probably 
still not high enough (124, 170, 171). Most of the initial data considering Cbl 
defic iency in infancy and ch ildhood came from  case studies reporting on 
exclusively breastfed children of mothers on vegetarian, vegan, or sim ilar 
d iets. In developing countries high rates of Cbl defic iency in infants and 
pregnant or lactating wom en have been dem onstrated (172-174). Several 
authors have observed an inverse corre lation between breast m ilk Cbl 
concentra tion and infant urinary M M Aconcentra tions (157,159,175). Breast-fed 
infants of vegetarian m others had higher urinary MMA concentra tions 
com pared w ith infants of om nivorous m others and maternal serum Cbl 
concentra tions were inversely corre lated to infant urinary MMA (r= -0.681) 
(157). Lower Cbl concentra tions in breast-fed infants com pared w ith form ula 
m ilk fed infants were observed by Minet et al in 60 infants (176) and confirm ed 
by others (177). Bjorke Monsen et al observed that low maternal Cbl 
concentra tions were associated w ith increased maternal tH cy and MMA. Low 
maternal Cbl concentra tion was the principal p red icto r fo r Cbl status in the 
newborn (124). O lder children fo llow ing a diet lacking animal p roducts 
them selves are at increased risk of developing Cbl deficiency.
The consistent find ing of elevated MMA concentra tions in apparently healthy 
infants is giving rise to a debate w hether th is could be a reflection of true 
im paired Cbl status or related to bacterial p roduction in the intestinal tract or 
im m aturity of enzyme function. The fact that increased MMA concentra tions 
occur s im ultaneously w ith decreased Cbl and increased tH cy concentrations, 
com bined w ith the results from  the study by Bjorke Monsen et al describ ing an
38
G ENERAL INTRODUCTION
increase in Cbl concentra tions and s im ultaneous decrease in MMA and tHcy 
concentra tions in 54 infants treated w ith Cbl, supports  the form er (134). All 
together, evidence is accum ulating that Cbl defic iency is a major concern in 
breastfed infants, not only in developing but also in W estern countries. Infants 
of vegetarian m others are at an even greater risk. This deserves serious 
attention.
Cobalamin and adverse pregnancy outcome
Excellent reviews have outlined the im portance of adequate maternal Cbl 
status fo r normal pregnancy outcom e (178-180). Im paired maternal functiona l 
Cbl status has been associated w ith in fe rtility  (181), recurrent early pregnancy 
loss (181, 182), NTDs (183, 184), congenita l heart defects, increased risk for 
pre-eclam psia, and preterm  delivery (185, 186). Afman et al have described a 
tw o to sevenfold increased risk fo r NTD in wom en w ith increased MMA 
concentra tions (187).
In 1977 Baker et al described lower Cbl concentra tions in 50 LBW neonates 
com pared w ith normal BW neonates (188). W omen in the lowest fe rtile  of Cbl 
concentra tions during pregnancy had increased risk fo r IUGR in the ir newborns 
and cord Cbl concentra tions were positive ly corre lated to BW in studies 
described by Muthayya et al (189, 190). Frery et al observed a negative 
corre lation between BW and cord Cbl concentra tions, which becam e stronger 
among sm oking mothers (125). L indblad et al could not detect an association 
between maternal nor cord blood Cbl concentra tions and BW in 128 
m other-baby pairs (127). Ronnenberg et al observed no association between 
maternal preconception  Cbl concentra tion and LBW or SGA in the ir o ffspring 
(112). Cbl concentra tions in all three trim esters was not corre lated to BW in a 
study described by Takimoto et al (191). Neonatal Cbl concentra tions exerted 
a small e ffect on BW in univariate but not in m ultivariate analysis in 522 
newborns (126). To summ arize, several studies have evaluated the possib le 
re la tionsh ip  between maternal Cbl concentra tions and BW in the ir o ffspring, 
y ie ld ing  conflic ting conclusions. However, none of these studies evaluated 
MMA, the sensitive marker of in trace llu lar Cbl deficiency.
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Part IV Choline
Introduction
Choline is an essential nutrient and necessary fo r normal function ing  of all 
human cells. Choline functions in m ultip le m etabolic pathways: choline, or its 
m etabolites, contributes to lipid transport from  the liver; it is a precursor of 
acetylcho line; it is a major source of methyl groups, hence possib ly in fluencing 
m ethylation and gene expression. Furthermore, it assures the structura l 
in tegrity  and signa ling functions of cell mem branes and plays a role in brain 
developm ent and neurotransm ission (192, 193).
Choline metabolism
De novo synthesis is not suffic ient to meet m etabolic dem ands when humans 
are deprived from  die tary choline (194). Estimates of adequate intake required 
by humans are approxim ately 0.5 gr/day. Choline is found in a w ide variety of 
foods that contain membranes either as free choline or in esterified forms (as 
phosphocholine, g lycerophosphocholine, phosphaditylcholine and sphingo­
myelin). Examples include liver, eggs and wheat germ (for fu rthe r details, see 
the follow ing database: (h ttp ://w w w .nal.usda.gov/fn ic/foodcom p/Data/choline/ 
choline.htm l). D ifferent form s of choline may have d ifferent bioavailability.
An im portant use fo r choline is the synthesis of mem brane phospholip ids. 
Choline can be phosphory la ted and then converted in several steps to phos­
phatidylcho line, w hich is the predom inant phospho lip id  in cell mem branes. A 
small fraction of choline is acetylated to form  acetylcholine, an im portant neu­
rotransm itter. The methyl groups of choline can be made available upon 
oxidation to betaine in tw o steps involving choline dehydrogenase (EC 1.1.99.1) 
and betaine aldehyde dehydrogenase (BAD, EC 1.1.1.8) as enzymes (figure 7). 
Choline is first oxidized to betaine aldehyde in the m itochondrion, w hich is 
then converted to betaine in the m itochondrion  or the cytoplasm . Betaine can 
be used as methyl donor in the rem ethylation of hom ocyste ine to m ethionine 
leaving d im ethylg lycine (DMG). This reaction is catalyzed by beta ine-hom o- 
cyste ine m ethyltransferase (BHMT) (figure 7). This reaction generates DMG. 
Both processes can take place in liver and kidney. De novo synthesis of choline 
is catalyzed by phosphatidyle thanolam ine N -m ethyltransferase, (PEMT, EC 
2.1.1.17), a reaction in w hich phosphatidyle thanolam ine is converted to phos­
phatidylcho line. This reaction consum es three m olecules of AdoM et as methyl 
donor and produces three m olecules of AdoHcy. PEMT activ ity  may play an 
im portant role in determ in ing m ethylation dem and in humans. Thus, pathways 
of choline and fo late act parallel to lower hom ocyste ine concentra tions and 
in tersect at the point that hom ocyste ine is converted to methionine.
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D ifferences in d ie tary choline requirem ent in adults can be explained by 
estrogen status as described above, by fo late status, pregnancy, and also by 
genetic variation. Polym orphism s in the fo late pathway could change the 
availability  of m ethyltetrahydrofo late as methyl donor and thus enhance the 
im portance of choline in methylation.
Inborn errors in choline metabolism
As far as we know, no inborn error of choline metabolism has been described. 
Concentrations and determinants of choline
P hosphatidylcho line is the most abundant choline species and accounts for 
approxim ately 95% of the human tissue choline pool (195). Choline, 
phosphocholine, g lycerophosphocho line , cytid ine -d iphospha te -cho line  and 
acety lcho line  form  the rem aining 5% (196,197). Plasma choline concentra tions 
in healthy fasting humans are 7-10jumol/. Plasma concentra tions are influenced 
by diet, exercise and renal function  (194, 198, 199). An intake of 425 m g/day 
fo r wom en and 550 m g/day fo r men has been recom m ended since 1998 (200). 
Choline requirem ent is dependent on sex and m enopause, w ith men and post­
m enopausal wom en being more sensitive to deficiency, p robably due to estro- 
gen-dependency of PEMT (201). Furthermore, fo late intake and MTHFR 
genotype influence choline status (202-205).
Choline dem and is high in pregnancy and lactation: active transport from 
m other to fetus against a concentra tion gradient depletes maternal choline 
stores in humans (206-208). The placenta is able to store large am ounts of 
acety lcho line  (209). Choline concentra tions in am niotic flu id are tenfo ld  higher 
than maternal b lood concentra tions (210). This h igh-choline environm ent 
p robably ensures choline availability  to the fetus. Human m ilk conta ins high 
am ounts of choline; lactation increases maternal choline demand. Maternal 
p lasm a choline concentra tions increase during pregnancy and show no 
relation w ith tH cy concentra tions, whereas betaine becom es a stronger 
p red icto r of tHey during the course of pregnancy (211). Another s tudy described 
that both maternal and cord blood choline concentra tions showed positive 
associations w ith tH cy at delivery. This m ight be due to increased tHcy 
production during increased de novo synthesis of phosphatidy lcho line  (212). 
Choline concentra tions are rem arkably higher in newborns com pared w ith 
adults. Zeisel has reported plasm a choline concentra tions of 39 .8±22.4  
jUmol/L in 16 newborns aged 25 to 43 weeks (213). McM ahon has observed 
plasm a choline concentra tions of 44 .9±6 .4  jumol/L in five preterm  infants w ith 
respiratory distress syndrom e (208). Buchman et al have described mean 
venous um bilica l cord plasma
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concentra tions of 28.1±13.0jum ol/L in n = 64  newborns and of 68.1±16.9jum ol/L 
in n=50  newborns in the ir s tudy (192). Ozarda llco l et al have found serum free 
choline concentra tions in arterial um bilica l b lood of 27.6±1.7 jumol/L in 25 
newborns and mean venous serum free choline concentra tions in newborns at 
day two of life of 35 .8±1 .5 jumol/L (214).
Treatment
Choline defic iency can be treated w ith choline supplem entation, mainly in the 
form  of phosphatidy lcho line . Oral betaine or choline have a hom ocyste ine 
lowering effect, both at fasting tH cy concentra tions and post m ethionine load 
tH cy concentra tions (59, 60).
Choline and association with disease
Choline and adverse pregnancy outcome
Choline and betaine are involved in rem ethylation of hom ocyste ine to 
m ethionine and therefore can affect the availab ility  of Adom et, the universal 
m ethylgroup donor. Changes in concentra tions of Adom et can influence DNA 
synthesis and m ethylation and thus gene transcrip tion, im printing and stab ility  
(195, 215). Variation in maternal choline status may influence fetal outcom e 
th rough changes in acety lcho line production, d isturbances in cell mem brane 
synthesis, increase in hom ocyste ine concentra tions and/or perturbation of 
m ethylation reactions. Choline is needed fo r normal neural tube closure in 
early pregnancy in rodents (216). Shaw et al observed a decreased risk for 
NTD in a fo lic  acid fo rtified  popula tion when maternal intake of choline or 
m id-pregnancy choline concentra tion was in the highest quartile  (19, 217). 
Choline is also im portant in later pregnancy, since it influences stem cell 
pro life ra tion and apoptosis in the brain (218, 219). It especially influences the 
developing h ippocam pus (m emory center). Maternal choline defic iency during 
critica l periods in pregnancy causes life long detrim enta l changes in brain 
s tructure and function  in rodents (220, 221). Perinatal choline supp lem enta­
tion  seems to prevent age-related m em ory decline in animals and d im inishes 
the tox ic  effects of a lcohol. Furthermore, choline is needed fo r cell mem brane 
developm ent in the rapid ly grow ing fetus. Anim al studies show exacerbated 
m em ory loss or decreased perform ance while being choline deprived (220, 
222). In contrast, in the only human study perform ed so far, neither maternal 
nor um bilica l choline status was associated w ith in te lligence at the age of five 
years in the o ffspring in 404 m other-baby pairs (223).
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Figure 7 Simplified scheme of choline metabolism
glycine
î
sarco s ine
A c ety lch o lin e
AdoM et= S-adenosylm ethionine. AdoHcy= S-adenosylhomocysteine. BAD = betaine aldehyde 
dehydrogenase. BHMT= betaine homocysteine methyltransferase. ChAT= choline acetyltrans- 
ferase. ChD= choline dehydrogenase. ChK= choline kinase. CDP-choline=cytid ine diphos- 
phate-choline. C TP=cytidine triphosphate. DMG= dimethylglycine. PhChCT= CTP-phospho- 
choline cytidyl transferase. PhChGT= phosphatidylcholine g lyceride transferase. PEMT= phos- 
phatidylethanolam ine-N-methyltransferase.
Choline deficiency
Most adult men and postm enopausal wom en develop fa tty  liver, liver and 
muscle damage, and post loading hyperhom ocyste inem ia when choline 
depleted (194, 224). Low plasm a free choline concentra tions in patients 
requiring tota l parenteral nutrition is associated w ith hepatic steatosis and 
am inotransferase abnorm alities in adults and children (225). P regnancy and 
lactation, fasting fo r a pro longed period and diseases such as cystic  fibrosis 
may cause decreased choline concentra tions (226-229). Several studies 
regarding choline supplem entation and perform ance on m em ory and learning 
tasks tests in e lderly adults y ie lded conflic ting  results (195). Also, an association 
between anxiety and low choline concentra tions was observed (230). 
Furthermore, results from  a m eta-analysis including stroke patients receiving
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CDP-choline suggest that supplem entation reduced risk of m orta lity  and 
m orb id ity  (231). Low choline intake was associated w ith an increased risk of 
breast cancer in humans and increased hepatic carcinogenesis in rodents 
(232, 233). Furthermore, decreased choline concentra tions were correlated 
w ith lym phocyte apoptosis and DNA dam age (234).
Betaine becom es a stronger determ inant of tH cy concentra tions in subjects 
w ith low fo late and/or MTHFR C677T genotype (235), em phasizing its 
im portance as a methyl donor under cond itions of im paired Cbl and/or fo late 
status. Also, genetic po lym orphism s in the PEMT gene and choline 
dehydrogenase gene have been described in relation to the occurrence of 
organ dam age (236, 237).
Part V Summary
Hey is an amino acid playing an essential role in one carbon metabolism . 
Increased tH cy concentra tions were identified as risk factor fo r vascular 
diseases in adults and children. The occurrence of CVA in the newborn is a 
relevant clin ica l problem  and can result in s ign ificant m orb id ity; therefore, 
identify ing m odifiable risk factors is im portant. The possib le association 
between tH cy and CVA in newborns had not been stud ied at the start of th is 
thesis.
Furthermore, one carbon m etabolism  is linked to adverse pregnancy outcom es 
such as recurrent early pregnancy loss and pre-eclam psia  and NTDs. 
A ssocia tions between BW and increased risk on card iovascu lar diseases in 
adulthood have been described. Low birth w eight is one of the four main 
causes of perinatal death in the Netherlands. Few studies assessed maternal 
tH cy or maternal Cbl in relation to b irth  weight; those who did yie lded conflic ting 
conclusions.
Cbl defic iency in infants is generally caused by d ie tary defic iency of either the 
m other or the child. Infant Cbl status is critica lly  dependent of maternal Cbl 
status during pregnancy and evidence is increasing that Cbl defic iency is a 
m ajor concern in breastfed infants. MMA is a sensitive marker of in tracellu lar 
Cbl deficiency. M ethods fo r the determ ination of MMA at the start of this thesis 
were laborious and tim e consum ing.
Choline is an essential nutrient and choline intake, concentra tions or defic iency 
have been associated w ith NTD, d isturbed brain structure and function  in 
humans and rodents. Choline is im portant fo r cell mem brane developm ent in 
the rapid ly grow ing fetus and could potentia lly  contribu te  to fetal growth.
In conclusion, d isturbances in one carbon metabolism , a netw ork characterized
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by transfer of one carbon groups, are associated w ith a variety of abnorm alities 
and diseases in adults, but data on these associations in infants and children 
are scarce.
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Outline of this thesis
The next chapter w ill in troduce hom ocysteine, cobalam in and choline and 
the ir association w ith a variety of cond itions in infants and children possib ly 
influencing long term  outcom e. The overw helm ing num ber of studies 
describ ing the association between hom ocyste ine concentra tions and risk for 
card iovascular disease in adults but also in o lder children called into question 
w hether s im ilar associa tions could be present in infants as well.
The main objectives of this thesis are to elucidate some aspects of one carbon 
m etabolism  in relation to health and disease in infants and children. Chapter 
1 provides an overview  of one carbon m etabolism  focusing  on hom ocysteine 
(Hey), cobalam in (Cbl) and choline, in relation to disease. We put em phasis on 
the possib le association between one carbon m etabolism  and the im portant 
clin ica l problem s of low birth w eight (LBW), cerebrovascu lar accident (CVA) 
and Cbl deficiency. Chapter 2 describes the outline of th is thesis.
The first part of th is thesis focuses on hom ocyste ine in association w ith 
disease in newborn infants. The incidence of cerebrovascu lar accidents  in 
newborns is relatively high, especially in newborns adm itted to a Neonatal 
Intensive Care Unit. Approxim ate ly 30% of cases remain unexplained and 
perinatal CVA can lead to s ign ifican t long term  m orbid ity. Therefore, looking 
fo r possib le and treatable risk factors is of utm ost im portance. In adults, hy- 
perhom ocyste inem ia is associated w ith an increased risk of CVA. Several 
authors observed this increased risk in o lder children as well. Chapter 3 
investigates hyperhom ocyste inem ia as risk facto r fo r CVA in newborns in a 
retrospective case-contro l study. Total hom ocyste ine (tHcy) concentra tions in 
newborns w ith established CVA are com pared w ith Hey concentra tions in 
healthy newborns.
THcy concentra tions can be e ffective ly lowered w ith fo lic  acid supp lem enta­
tion in adults and o lder children. However, no inform ation on the effect of fo lic  
acid on tH cy concentra tions in newborns were available. In Chapter 4, 
therefore, we explore the potentia l tH cy lowering e ffect of fo lin ic  acid supp le ­
m entation in newborns in a prospective study. We choose fo lin ic  acid since it 
is an active form  of fo lic  acid w hich can also be supplem ented intravenously. 
This inform ation is of great value because if fo lin ic  acid effective ly lowers tHcy, 
theoretica lly, prevention of tH cy related CVA’s could be studied.
The next studies focus on low  b irth  weight, m ainly in relation to hom ocyste ine 
and Cbl. C onclusions from  studies regarding the possib le association between 
maternal and/or um bilica l tH cy and risk fo r LBW are conflic ting. LBW puts the
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newborn at increased risk fo r m orb id ity  and m orta lity in the first episode after 
birth, but also enhances the risk of chron ic disease in adulthood, such as 
diabetes, hypertension, card iovascu lar disease. A negative e ffect of increased 
maternal tH cy on birth w eight could possib ly be due to fo late and/or Cbl 
defic iency w ith tH cy as marker. Therefore, we measured tH cy as well as 
m ethylm alonic acid (MMA), both markers of in trace llu lar Cbl deficiency, and 
related B vitam ins Cbl and fo late, and stud ied the possib le relation between 
BW and maternal analytes in a large prospective study described in chapter 
5. A fterwards, we have perform ed a m eta-analysis on available studies 
investigating the association between maternal tH cy and BW. These results 
w ill be described in chapter 6.
The second part of th is thesis focuses on Cbl and its marker MMA. There is 
Increasing evidence that cobalam in  defic iency is prevalent in infancy and 
ch ildhood. Cbl defic iency gives rise to several non-specific  sym ptom s in 
children such as fa ilure to thrive, developm ental delay or regression, hypotonia 
or convuls ions and can lead to irreversible neurological damage. In order to 
be able to study Cbl defic iency more accurately, determ ination of its m etabolic 
marker MMA is necessary. MMA determ ination orig ina lly  required intensive 
laborious chrom atograph ic techniques, therefore a new sim ple high th roughput 
method for the determination of MMA concentrations is described in chapter 7. 
C oncentra tions of MMA, Cbl and tH cy in newborn infants may be d ifferent 
from  older children. Since data on plasm a MMA concentra tions and predictors 
in ch ildhood are scarce, and in the light of the suggested high prevalence of 
Cbl defic iency in children, we analyzed plasm a MMA concentra tions in a group 
of Dutch children and evaluated possib le determ inants. These data can be 
relevant to explore the prevalence of Cbl defic iency among children and 
infants. They are also relevant to evaluate possib le long-term  effects of Cbl 
deficiency. The results w ill be described in chapter 8.
The th ird  part of th is thesis focuses on choline and related m ethylam ines 
betaine and DMG. The variation in plasm a choline concentra tions in newborns 
suggests that pathways fo r maternal to fetal choline transfer are not saturated 
and may at least partly be influenced by maternal choline. On the other hand, 
the fact that the placenta itself is a m ajor source of choline utilization, suggests 
that neonatal choline concentra tions are at least also influenced by placental 
and fetal choline m etabolism  and d istribution, and not only by the orig inal 
maternal source. The apparent im portance of choline fo r the rapid ly grow ing 
and developing fetus, the m ultip le functions of choline in the body, and the 
fact that b irth w eight is the end result of intrauterine grow th, led us to
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hypothesize that um bilica l and/or maternal choline, betaine and DMG 
concentra tions could be related to birth w eight. To study th is potentia l 
corre lation we perform ed a large prospective study described in chapter 9.
This thesis concludes w ith sum m ary and general d iscussion in chapter 10. 
A Dutch sum m ary (sam envatting) is provided in chapter 11.
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CHAPTER 3
Abstract
Background Cerebrovascular lesions occur in newborn infants and many 
cases remain unexplained. H yperhom ocyste inem ia is a risk facto r fo r cerebro ­
vascu lar lesions in adults and also in children.
Methods We retrospective ly co llected data from  24 newborns infants w ith 
gestational age > 34 weeks w ho had a cerebrovascular accident (CVA) in the 
neonatal period. Total hom ocyste ine (tHcy) concentra tions were determ ined. 
We prospective ly co llected blood sam ples fo r tH cy determ ination in 94 healthy 
newborn infants and stud ied the association between plasm a total 
hom ocyste ine concentra tions and the risk of CVA in newborn infants.
Results Newborn infants w ith CVA had s ign ifican tly  higher mean total 
hom ocyste ine concentra tions com pared w ith 94 healthy newborn infants (9.3 
vs 7.4 jUmol/L). The odds ratio fo r neonatal CVA was 3.95 (95% Cl 1.53-10.16) 
at the 80% cuto ff level.
Conclusion Elevated tH cy concentra tions were associated w ith increased 
risk on CVA in newborn infants. W hether tH cy is the cause or a marker remains 
to be solved. If tH cy is a causal factor, in tervention to reduce tH cy concentra tions 
m ight becom e a possib le preventive strategy.
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Introduction
Hyperhom ocyste inem ia is a risk fac to r fo r cerebrovascular accident (CVA) in 
adults (1, 2). Van Beynum et al dem onstra ted that hyperhom ocyste inem ia is 
also associated w ith an increased risk of CVA in children (3). A lthough several 
risk facto rs are known to play a role in the pathogenesis of CVA in newborn 
infants, many cases remain unexplained (4, 5). Gunther et al reported in term 
newborn infants w ith sym ptom atic  stroke an elevated MTHFR T677T genotype, 
w hich is a genetic p ro throm botic  risk facto r involved in hom ocyste ine 
m etabolism , a lthough the elevation was not s ign ifican t (6). The aim of th is 
s tudy was to determ ine w hether hyperhom ocyste inem ia is associated w ith the 
occurrence of CVA in infants born at or near term.
Subjects and methods
Patients
In th is retrospective study we enrolled all 24 newborn infants born between 
1993 and 2000 w ith a gestational age of >34  weeks who had a CVA in the 
neonatal period. In all infants, p lasm a tota l hom ocyste ine concentra tions 
(tHcy) were determ ined. Exclusion criteria  were m idline closure defects and/or 
severe organ failure. G estational age was based on maternal dates and/or 
early u ltrasonograph ic exam ination. The cerebrovascu lar lesions were 
d iagnosed w ith cerebral u ltrasonogram  and com puted tom ograph ic  scanning 
and/or m agnetic resonance imaging. THcy concentra tions of these patients 
were com pared w ith values obta ined from  a contro l group consisting of healthy 
newborn infants born at or near term  in our hospita l in 2000. C lin ical data of 
the study group were co llected re trospective ly from  hospita l charts. The data 
from  the contro l group were recorded prospectively.
tHcy determination
Blood was drawn by ven ipuncture or obta ined from  heel-stick procedure. 
B lood sam ples were im m ediate ly placed on ice, centrifuged at 3000 rpm for 
10 m inutes, and im m ediately stored at -30°C . tH cy was determ ined in EDTA 
plasm a as described before (7).
Statistics
Because tH cy values were not equally d istributed in both groups, log-trans- 
form ed tH cy values were analyzed. D ifferences between the two groups were 
assessed by com paring the geom etric means of the groups (analysis of
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variance). C orre lations were determ ined w ith the Pearson corre lation 
coeffic ient. Log istic regression analysis was used to calculate odds ratios 
(ORs) and 95% Cl to estimate the relative risk of hyperhom ocyste inem ia for 
neonatal CVA. A p-value of < 0.05 was considered sign ifican t. The institu tional 
review board approved the study.
Results
Mean ±  SD birth w eight did not d iffe r between the patients w ith CVA and the 
contro l infants (3229 ±  488 vs 3143 ±  695 g). However, the mean ±  SD 
gestational age of the patients w ith CVA was s ign ifican tly  longer than of the 
contro l infants (39.3 ±  1.9 vs 37.5 ±  3.0 weeks). The median age (range) at 
w hich stroke was diagnosed was 8 days (1-24).
Eleven patients were d iagnosed w ith an ischem ic CVA; in 8, the stroke occurred 
in the area of the m iddle cerebral artery and in 3 at m ultip le sites. Thirteen 
patients had a hem orrhagic CVA. In all except one patient, the hem orrhage 
was located in the parenchym a. One patient had a hem orrhage in the basal 
ganglia. Platelet count, activated partial th rom bop lastin  time, prothrom bin 
time, in ternational norm alized ratio, protein S, protein C, and antithrom bin III 
were w ith in  the normal range in all patients w ith CVA.
Table I Plasma total homocysteine concentrations (jumol/L) in patients with 
CVA and control infants
Geometric mean 95% Cl Range
Control infants (n = 94) 7.4 7.13-7.67 4.8-18.0
Patients with CVA (n = 24) 9.3 9.1-9.6 4.0-17.0
Ischemic CVA (n = 11) 8.6 6.8-10.4 4.0-16.0
Hemorrhagic CVA (n = 13) 9.9 9.1-10.7 5.0-17.0
C V A =  c e re b ro v a s c u la r  a c c id e n t. n =  num ber.
*P =  0 .001 ; p a tien ts  w ith  C V A  vs co n tro l in fants , 
t P =  0 .3 ; isch em ic  vs h em o rrh a g ic  CVA.
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The median age (range) at which the blood sam ples were drawn fo r tH cy was 
10 (2-37) days in the patients w ith CVA and 4 (2-22) days in the contro l infants 
(P < .001). Eighteen of the 24 patients w ith CVA were treated w ith an ticonvu l­
sants at the tim e the blood sam ples were drawn. The tH cy concentra tions in 
the patients w ith CVA did not change during the 8-year s tudy period.
A s ign ifican t d ifference between the geom etric mean of the patients w ith CVA 
and the contro l infants was found (table I). No s ign ifican t d ifference between 
the infants w ith an ischem ic and a hem orrhagic CVA was observed. The mean 
tH cy level in the patients w ith CVA treated w ith anticonvulsants did not 
s ign ifican tly  d iffe r from  that in the patients w ith CVA not treated w ith an ticon­
vulsants. Neither in the patients w ith CVA nor in the contro l infants were 
s ign ifican t corre lations between postconceptiona l age and sex, respectively, 
and tH cy found.
To determ ine the risk of developm ent of a CVA at various tH cy levels, ORs and 
95% CIs were calculated. Twelve of the 24 (50%) patients w ith CVA and 19 of 
the 94 (20%) contro l infants had tH cy greater than the 80% cuto ff level. An OR 
for neonatal CVA of 3.95 (95% Cl 1.53-10.16) was calculated. The ORs of the 
tw o subgroups were sim ilar after the patients w ith CVA were d ivided into 
patients w ith an ischem ic CVA and patients w ith a hem orrhagic CVA.
Discussion
In th is retrospective study in newborns, we found hyperhom ocyste inem ia to 
be associated w ith an increased risk fo r neonatal CVA in infants born at or 
near term.
Reference values fo r tH cy in newborn infants are scarce. We stud ied 94 healthy 
newborn infants born at or near term . The mean tH cy was 7.4 jUmol/L. Bohles 
et al found in 50 newborn infants a mean tH cy of 5 .8 4 jumol/L, measured in the 
firs t 48 hours (8). Minet et al reported a mean tH cy of 7.8 jumol/L in 123 healthy 
newborn infants, w hich is in line w ith our results (9). Our contro l group 
consisted of healthy infants born at or near term in our hospita l. In the 
Netherlands, 30% to 40% of all newborn infants are born at home. Only those 
pregnant wom en w ith an increased risk of antenatal or perinatal com plica tions 
(eg, preterm  birth, post-term  birth, pro longed rupture of mem branes, maternal 
hypertension, breech presentation) qua lify fo r hospita l delivery. Recruitm ent 
of a contro l group of healthy infants born at home w ould not have been 
feasible.
Neonatal determ inants of tH cy are not known. In our study, we did not find 
postconceptiona l age- or sex dependent hom ocyste ine concentra tions in the
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contro l infants. We found a d ifference in postnatal age between the patients 
and contro l infants. S ince there was no s ign ifican t relation between tH cy and 
postconceptiona l age, the d ifference in postnatal age between the two groups 
has not in fluenced our results. Moreover, correction fo r postconceptiona l age 
in the analysis of variance did not alter the d ifference in tH cy between patients 
and contro l infants. Established risk factors fo r neonatal CVA, such as 
asphyxia, bacteria l septicem ia, b irth traum a, intrauterine grow th retardation, 
and c lo tting  d isorders/d is turbances, did not occur in the patients w ith CVA. 
A lthough there was an overlap in tH cy between the tw o groups, our find ings 
have not been confounded by other risk factors fo r neonatal CVA. Anticonvulsant 
drugs affect the hom ocyste ine m etabolism  and therefore tHcy. Eighteen of the 
24 infants w ith CVA (17 of the 19 patients w ith seizures) used anticonvulsants 
at the tim e blood was co llected fo r tH cy m easurem ents. Anticonvulsant 
treatm ent was in itiated shortly  before blood w ithdrawal; therefore, interference 
w ith hom ocyste ine m etabolism  was unlikely. Like Cardo et al we observed no 
d ifferences in tH cy between infants w ith CVA w ho used anticonvulsant drugs 
and those who did not (10). There is no evidence that seizures increase tHcy 
concentra tions.
Bohles et al reported  a positive  corre la tion  between hom ocyste ine 
concen tra tions  in m other and new born infant (8). We were unable to obta in 
m aternal p lasm a hom ocyste ine  concen tra tions in th is  study, but the 
maternal Hey status probably in fluenced the tH cy in the newborn, since all 
determ inations in the contro l infants were perform ed w ith in  the firs t 4 days 
of life.
Gunther et al described a higher though not s ign ifican t incidence of the 
MTHFR T677T genotype in term newborn infants w ith CVA (6). This m utation is 
considered to be a risk fac to r fo r adult CVA if fo late and vitam in B12 plasma 
levels are low. Because of the retrospective design of our study, we were 
unable to determ ine w hether hyperhom ocyste inem ia is the cause or the 
consequence of CVA in the newborn infant. If hyperhom ocyste inem ia is a 
causal factor, p rophy lactic  supp lem entation w ith fo late and vitam in B12 to 
reduce tH cy very soon after b irth may becom e a possib le stra tegy in the near 
fu ture to reduce the risk of neonatal CVA.
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Abstract
Background The incidence of cerebrovascular accidents (CVA) occurring 
perinata lly is relatively high and aspects of the m ultifactoria l pa thophysio logy 
remain unclear. Elevated hom ocyste ine concentra tions have been shown to 
be associated w ith an increased risk fo r CVA in children and even in 
newborns.
Methods We studied the possib le hom ocyste ine lowering effect of fo lin ic  acid 
in newborns. We included 37 newborns in our prospective random ized fo lin ic  
acid (given as 5-form yltetrahydrofo late) in tervention study from  patients 
adm itted to our Neonatal Intensive Care Unit (18 contro ls, 19 intervention 
group). We measured tota l hom ocyste ine (tHcy) and plasm a folate 
concentra tions at three tim e points (baseline, one and tw o weeks after 
intervention). The in tervention group was treated w ith fo lin ic  acid (70 jug/kg/ 
day) fo r tw o weeks. We calculated median concentra tions [25th and 75th 
percentiles].
Results Median tH cy concentra tions at the three tim e points did not d iffer 
from  each other in the contro l group nor in the intervention group. We also 
could not observe d ifferent tH cy concentra tions between both groups. Plasma 
fo late concentra tions increased in the intervention group (mean increase 
167% (95% Cl -291;625)) com pared to contro l group (mean increase -12% 
(95% Cl -132;108)), p fo r treatm ent effect: 0.03.
Conclusion We could not dem onstrate a hom ocyste ine lowering e ffect of 
fo lin ic  acid adm inistration in newborns. This indicates that one carbon 
m etabolism  in newborns d iffers from adults. Cobalam in m ight be a better 
stra tegy to lower tH cy concentra tions in newborns.
C lin ica ltria ls.gov, NCT00877227
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Introduction
The overall incidence of cerebrovascular accident (CVA) in ch ildhood is very 
low (approxim ately 3/100.000 per year) (1). In strong contrast, CVA’s occurring 
in the perinatal period have a much higher incidence (1). It is estim ated that 
the incidence of ischem ic perinatal CVA is 1 in 2300 to 5000 b irths and 
accounts fo r 30% of ch ildren affected w ith cerebral palsy (1). Of major 
im portance is the fact that about 10% of newborns adm itted to a neonatal 
intensive care unit suffer from  a CVA. Known potentia l risk factors of the latter 
are prem aturity, asphyxia, hypoglycem ia, polycythem ia, catheter-related 
com plica tions, in fectious factors, persistent fetal c ircu lation, intrauterine 
grow th restriction and maternal factors such as diabetes or an tiphospho lip id  
syndrom e (1,2). Independent of the possib le cause CVA can result in s ign ifican t 
m orbidity, varying from mild hem iplegia to severe cerebral palsy, sensory 
im pairm ents, mental retardation and even death. Yet aspects of the m ultifactoria l 
pa thophysio logy leading to CVA in the newborn remain unclear and in about 
one th ird  of cases no obvious cause or risk factors can be d iagnosed (3). 
Elevated tota l hom ocyste ine (tHcy) concentra tions have been found to be a 
risk factor in adults fo r developm ent of card iovascu lar disease and venous 
and arterial th rom bosis including CVA. Elevated tH cy concentra tions can, 
am ongst others, be caused by genetic po lym orphism s of the m ethylenetetra- 
hydrofolate reductase gene and/or cysta th ion ine B synthase gene (4). 
N on-genetic factors such as folate, vitam in B12 and/or B6 intake, age, sex, 
estrogen, alcohol consum ption and sm oking can also influence tH cy (5-7).
In adults, tH cy can be easily, safely and qu ick ly  lowered by 0.2 to 5 mg fo lic  
acid each day, even in the absence of elevated tH cy concentra tions (8-10). 
Current in tervention tria ls show negative results from  secondary prevention 
regarding the card iovascu lar risk reduction. Meta-analyses on CVA and 
elevated tHcy concentrations however suggest that B-vitamin supplementation 
may lower the risk of CVA by approxim ately 20-25% (11, 12). Wang et al 
perform ed a m eta-analysis on fo lic  acid supplem entation in relation to stroke 
and observed an overall decrease of 18%. Furthermore, the ir results suggested 
that fo lic  acid supplem entation can s ign ifican tly  reduce the risk of stroke in 
prim ary prevention (RR 0.75[0.62;0.90]) (13).
Van Beynum et al dem onstrated that elevated tH cy concentra tions increased 
the risk of ischem ic stroke in Dutch children aged 0-18 years (14). S irachainan 
et al found an odds ratio of 8.2 [95% Cl 1.4-47.2] fo r developing ischem ic 
stroke in patients aged < 18 years w ith elevated tH cy concentra tions (15). In a 
previous study, we described s ign ifican tly  higher mean tH cy concentra tions in 
24 newborn infants w ith CVA com pared to 94 healthy newborn infants (OR
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3.95 [95% Cl 1.53-10.16 ]) (16). These studies suggest that elevated tH cy 
concentra tions are also a risk fac to r fo r CVA in children and newborns. Since 
the incidence of CVA in patients adm itted to a neonatal intensive care unit is 
relatively high, we conducted the firs t prospective random ized fo lin ic  acid 
in tervention study in newborns to study w he the rth is  r isk fac to r can be m odified 
in th is age category.
Subjects and Methods
Subjects
We conducted a prospective random ized intervention study. All newborns 
adm itted to the neonatal intensive care unit in the University Medical Centre 
Nijmegen, the Netherlands in 2003 were e lig ib le to the study. Those w ith mid- 
line-defects, ECM O-treatm ent, overt renal fa ilure or blood transfusion were 
excluded. A fter w ritten inform ed consent was obtained, the sub jects were 
random ized fo r receiving daily fo lin ic  acid supplem ent (intervention group) or 
no supplem ent (control group). No supplem ent was given because a 
p lacebo-e ffect is unlikely in this age category. Parents, nurses and physicians 
were not b linded to g roup assignm ent. Patients received normal m edical care 
during th is research project. Evaluations of cerebral u ltrasounds and/or scans 
were perform ed by physicians not involved in th is pro ject and unaware of sup ­
plem entation. Random ization was centralized but not com puterized. This 
means that fo r each partic ipant an envelope was drawn by the research 
assistant at the tim e of inclusion. These envelopes, filled  w ith “ in te rvention” or 
“con tro l” notes were mixed thorough ly  before they were stored in a box. This 
s tudy was approved by the local ethics com m ittee (Com m ittee on Ethics in 
Research w ith Human Subjects N ijmegen).
Data collection
Clinical data from  the newborn were obta ined daily from  the m edical record. 
We obta ined data on gestational age, birth w eight, newborn sex, days on 
ventilator, laboratory results, sepsis/m ening itis , in traventricular b leeding or 
stroke. W hen newborns were transferred to another hospita l during the study 
period daily fo lin ic  acid supp lem entation (intervention group) was continued 
and blood sam ples were drawn as planned.
Blood sampling
Blood was drawn either cap illa ry or arteria lly  during routine blood sam pling. 
Sam ples were taken w ith in 48 hours after b irth (baseline), at day 8 ±1 day (one
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week) and at day 15 ±1 day (two weeks). EDTA blood (0.5-1.0 ml) was placed 
on ice im m ediate ly and centrifuged w ith in  2 hours. Plasma and cell pellets 
were separated and stored at -30°C until analysis.
Folinic Acid supplementation
Folinic acid was given fo r two weeks as 5-form ylte trahydrofo la te  (10 mg/ml) 
(Pharm achem ie bv, Haarlem, the Netherlands). This so lu tion was adm inistered 
either intravenously (first week) or orally. To lower tH cy in adults 5 m g/day fo lic  
acid is frequently  used. Using an average bodyw eight of 70 kg fo r adults we 
calculated a daily dose of 70 jugram /kg/day fo r our newborns.
Biochemical analyses
Plasma tH cy was determ ined in EDTA plasm a by an autom ated h igh-perfor- 
mance liquid chrom atography method w ith reverse-phase separation and 
fluorescent detection (Gilson 232-401 sam ple processor, Spectra Physics 
8800 solvent delivery system and Spectra Physics LC 304 fluorom eter) as 
described by Poele-Pothof (17).
Plasma fo late was determ ined in EDTA plasm a in a com petitive  im m unoassay 
(Immulite 2000, Siemens Medical Solutions D iagnostics).
Statistical analysis
Results were presented as median values w ith the ir 25th and 75th percentiles. 
D ifferences between groups were determ ined by Mann-W hitney test or 
independent sam ples T-test where appropriate. S tatistica l analyses were all 
perform ed using SPSS 14.0 fo r W indows.
Results
We have included 37 newborns in our s tudy (19 in tervention group, 18 contro l 
group). C haracteristics of both groups are presented in Table I. Newborns 
were adm itted because of prem aturity, respiratory, in fectious or c ircu la tory 
problem s. They were between 26 and 40 weeks of gestational age and between 
600 and 3500 grams. Parameters were not s ign ifican tly  d ifferent at baseline 
between the in tervention and contro l group.
Figure 1 shows individual plasm a tH cy and fo late concentra tions at baseline 
and after one and tw o weeks from both groups. Due to transfer to another 
hospita l, death, loss of sam ples and/or too little  am ount of blood data were not 
com plete fo r all newborns. In tab le II m edian tH cy and folate concentra tions 
at three tim e points in both groups and mean change between baseline and 2
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weeks are shown. Neither plasm a tH cy nor fo late concentra tions were 
corre lated to gestational age, birth w eight or creatin ine at the three tim e points. 
Plasma tH cy concentra tions did not d iffer s ign ifican tly  at the three tim e points 
in the in tervention group nor the contro l group. Plasma tH cy concentra tions in 
the intervention and contro l group were not d ifferent. Plasma folate 
concentra tions at tw o weeks in the intervention group were s ign ifican tly  higher 
com pared to concentra tions at tw o weeks in the contro l group.
Table I Population characteristics
Intervention group Control group p-value
Number of children 19 18
Gestational age (weeks) 29.7 [28.4;31.3] 29.7 [29.6;34.9] 0.55
Birth weight (grams) 1349 [1108; 1640] 1256 [956; 1712] 0.63
Male sex, n(%) 9 (47%) 11 (61%) 0.51
Days on ventilator, n [range] 1 [0;2.9] 1.5 [0.5;3.0] 0.90
Sepsis, n(%) 7 (37%) 11 (61%) 0.19
CVA, n(%) 1 (5%) 3 (17%) 0.34
tHcy baseline (pmol/L) 5.6 [3.9;15.1] 7.0 [5.8;13.9] 0.43
Folate baseline (nmol/L) 23 [16;44] 45 [35;53] 0.09
D a ta  a re  e x p re s s e d  as  m ed ian  [2 5 th -7 5 ,h p erce n tile ] o r n u m b e r (p e rc e n ta g e ). C V A  =  c e re b ro ­
v a s c u la r a c c id e n t. tH c y  b a s e lin e = to ta l h o m o c y s te in e  c o n c e n tra tio n  a t bas e lin e . F o la te  
c o n c e n tra tio n = fo la te  c o n c e n tra tio n  a t b as e lin e . In d e p e n d e n t s a m p le s  t-tes t w as  u sed  to  
c o m p a re  g ro u p s. P v a lu e s  a re  c a lc u la te d  using  M a n n -W h itn e y  U tes t o r F ish er ex a c t tes t w h ere  
a p p ro p ria te .
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CHAPTER 4
Figure 1 Two weeks follow-up of homocysteine and folate concentrations in 
newborns in the control and intervention group
a Plasma homocysteine concentrations in the control group
baseline 1 week 2 weeks
b Plasma homocysteine concentrations in the intervention group
baseline 1 week 2 weeks
Individual data are shown. Concentrations at baseline, after 1 and 2 weeks are depicted.
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Figure 1 Continued
c Plasma folate concentrations in the control group
baseline 1 week 2 weeks
d Plasma folate concentrations in the intervention group
baseline 1 week 2 weeks
Individual data are shown. Concentrations at baseline, after 1 and 2 weeks are depicted.
83
CHAPTER 4
Discussion
In contrast to our expectation we could not dem onstrate a hom ocyste ine 
lowering effect of fo lin ic  acid adm inistration in newborns in th is prospective 
random ized intervention study. This unexpected find ing  m ight be influenced 
by fo lin ic  acid dose, tim e of b lood sam pling, way of adm in istra tion or other 
factors. However, it could also indicate that hom ocyste ine m etabolism  in the 
neonate may d iffer from  m etabolism  later in life.
We are fu lly  aware that th is is a small s tudy w ith only 37 patients included. 
Still, since data on fo late and hom ocyste ine in newborns are scarce, we believe 
that our results add inform ation on one carbon m etabolism  in th is age category. 
We have perform ed an intervention study w ithout p lacebo group because a 
p lacebo-e ffect is unlikely in th is age category. We strong ly do believe that th is 
did not influence our results since every newborn received routine neonatal 
intensive care. Furthermore, cerebral u ltrasounds and/or scans were judged 
by physicians who were not aware of th is study.
Fuller et al routinely supplem ented preterm  infants w ith 1 mg fo late orally 
(p teroylg lu tam ic acid) to encourage grow th rates in e ry th rob lasto tic  newborns 
w ithou t gross side effects. This is, on a body-w eight basis, around 250 tim es 
the recom m ended am ount fo r adults and around 5-20 tim es the am ount 
recom m ended at that tim e fo r (premature) infants. Based on results from  other 
studies, they extrapolated that 0.05-0.2 mg/day fo late appear safe fo r preterm 
infants w hich is com parable to our dose (18). In adults, fo lic  acid supp lem en­
ta tion (0.4-5mg per day) reduces tH cy between 13 and 25% even in the 
absence of fo late defic iency or elevated tH cy concentra tions (19). In a 
meta-analysis by the Hom ocyste ine Lowering Tria lists’ C ollaboration the effect 
of fo lic  acid supplem entation was more profound w ith increm ental doses of 
fo lic  acid, h igher pretreatm ent tH cy concentra tions or lower pretreatm ent 
fo late concentra tions (19). In the present study, we supplem ented the newborns 
w ith 0.07m g/kg/day fo lin ic  acid w hich is com parable to 5 mg fo lic  acid a day in 
adults. We considered th is dose to be high enough to expect an effect in 
newborns since in adults 0.2 mg fo lic  acid or higher a day decreases tHcy 
concentra tions. B lood sam ples were obta ined at baseline and one and two 
weeks after b irth. Since several authors have described a s ign ifican t tH cy 
concentra tion reduction w ith fo lic  acid w ith in 14 days in adults we considered 
th is a su ffic ien t period of tim e to study if fo lin ic  acid decreases tH cy 
concentra tions (10, 20).
Folic acid supp lem entation was given as 5-form ylte trahydrofo la te  (fo lin ic acid), 
an active form  of fo late conta in ing a one carbon group fo r m etabolism . Several 
studies show that fo lin ic  acid given either intravenously or ora lly was as
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effective or even better than fo lic  acid in lowering plasm a tH cy concentra tions 
(21-24). Ducloux et al showed a s im ilar tH cy lowering effect of fo lin ic  acid 
adm inistered intravenously com pared to orally supplem ented fo lin ic  acid. 
They also observed a s im ila rtH cy  lowering e ffect of intravenously adm inistered 
fo lin ic  acid com pared to fo lic  acid in adults (25). Based on these results and 
the poss ib ility  of intravenous adm inistration we considered fo lin ic  acid as the 
best way to study its lowering effect on tH cy in newborns.
Data on the pattern of neonatal tH cy and plasm a folate concentra tions are 
scarce. Median tH cy between 6.3-6.8 jumol/L and mean tH cy between 6.1-7.8 
jumol/L have been described in um bilica l cord blood or the firs t days after b irth 
(26-32). At day 7 Jyothi et al describe m edian tH cy concentra tions of 6.3 
jumol/L [p25-p75:2.8-8.4 jumol/L] whereas Fokkema et al observed mean tHcy 
concentra tions of 6 .4±2.6  jumol/L at day 10 and 6 .7±2.4 jumol/L at day 20 (33, 
34). Our data are com parable w ith these results. H ongsprabhas et al describe 
an increase in mean tH cy concentra tions in the firs t tw o weeks of life (32). In 
our study, tH cy concentra tions do not d iffer between baseline and one and 
two weeks after birth neither in the control group nor in the intervention group. 
W ith respect to fo late, mean neonatal p lasm a concentra tions of about 25 
nm ol/L have been described (26, 28, 29, 31, 35) w hich is com parable  to our 
results. These relatively high plasm a fo late concentra tions in newborns 
com pared to adults m ight explain the loss of corre la tion w ith tHcy 
concentra tions in th is age category.
The past few years, several authors describe a stronger re lationship in infants 
between cobalam in and tH cy than between plasm a fo late and tH cy (26, 29, 
34, 36, 37). B jorke-M onsen et al describe even an absence of corre lation 
between plasm a folate and tH cy (r= -0.06) in 173 apparently healthy newborns 
at day 4 w hile corre la tion between cobalam in and tH cy was high (r=-0.52) 
(36). Minet et al also describe a better corre lation between cobalam in and 
tH cy in com parison to plasm a folate and tH cy (r= -0 .64and  r= 0.30 respectively)
(26). Van Beynum et al suggest that hom ozygosity  fo r MTHFR 677C->T 
po lym orphism  only influences hom ocyste ine concentra tions in children (0-19 
years) w ith low folate status (38). Taken together, cobalam in m ight be a more 
im portant determ inant of tH cy than plasm a fo late in infants and thus cobalam in 
treatm ent may be a better choice to decrease tH cy concentra tions in infants 
and newborns (39).
During our study period, fou r ch ildren suffered from  a CVA. A lthough th is study 
was not designed to explore the effect of fo lin ic  acid supp lem entation on the 
incidence of CVA, only one patient from  the in tervention group had a CVA 
com pared to three newborns in the contro l group.
In conclusion: we could not observe a hom ocyste ine lowering effect of fo lin ic
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acid supplem entation in a tw o weeks intervention study in newborns. This 
observation was unexpected because sim ilar cond itions in adults substantia lly  
lower tH cy concentra tions. Our find ings indicate that one carbon m etabolism  
in newborns d iffers from  adults. Recent data suggest that cobalam in is a 
s tronger determ inant of tH cy concentra tions in newborns. Thus, cobalam in 
supp lem entation offers an attractive alternative and fu rther studies should 
focus on cobalam in.
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CHAPTER 5
Abstract
Background Revealing possib le and treatable factors fo r low birth weight 
(LBW) is im portant because LBW increases risk of m orb id ity  and death in 
infancy but also the risk on card iovascu lar diseases as adult. Maternal 
hom ocyste ine concentra tions have been linked to several adverse pregnancy 
outcom es. We designed a large prospective study to explore the relationship 
between maternal hom ocyste ine concentra tions and related B vitam ins and 
birth w eight (BW).
Methods Blood was sam pled from pregnant wom en at 30-34 weeks of 
gesta tion and the ir newborn infants (n=366). C oncentra tions of hom ocyste ine 
(tHcy), cobalam in (Cbl), m ethylm alonic acid (MMA), fo late and creatin ine were 
determ ined in maternal and um bilica l plasma.
Results C oncentrations of all analytes were higher in venous um bilica l cord 
blood com pared to venous maternal b lood samples. BW was related negatively 
to maternal tH cy (r=-0.12) but not related to maternal Cbl, MMA and folate 
(r=0.02, r=0 .06  and r=0.04, respectively). Regression analysis revealed 
sm oking (B=-313 [95% Cl -479;-149]), gestational age (P=150 [95% Cl 118;182]), 
fem ale gender (P=-146 [95% Cl -256;-35]) and parity (13=104 [95% Cl 37;171]) 
as strong determ inants of BW. Maternal tHcy, Cbl, MMA and folate were no 
determ inants of BW in m ultivariate analysis.
Conclusion Maternal tH cy and B vitam ins are not related to BW in a m ultivariate 
m odel that was adjusted fo r potentia l confounders.
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Introduction
Homocysteine and methionine and related B vitamins like cobalamin (Cbl) and 
folate have been shown to play a critical role in fetal nutrition, growth and 
development (1-5). Several authors have described relationships between total 
homocysteine (tHcy), B vitamins and pregnancy complications or adverse 
pregnancy outcomes. Elevated tHcy and low B vitamin concentrations are 
associated with increased risk of neural tube defects and pregnancy complications, 
such as pre-eclampsia, recurrent early pregnancy loss and abruptio placentae (6-9). 
Revealing possible and treatable factors for low birth weight (LBW) is of utmost 
importance because LBW increases the risk of m orbidity and death in infancy 
(10). Associations between LBW and chronic diseases in adulthood, like 
hypertension, coronary heart disease, stroke or diabetes mellitus have been 
described (11-13). Several studies demonstrated an association between high 
maternal tHcy concentrations and risk of having LBW offspring (8, 14-19), and 
negative correlations between maternal homocysteine and birth weight (BW) (3, 
15-17). In contrast, others have found either no differences or even a positive 
association between maternal tHcy and BW (20-23). However, some of these 
studies are relatively small (15-18). Others use BW below 2500 grams as a cut-off 
point instead of BW related to or corrected for gestational age (GA) (8, 20). Also, 
the different tim ing of maternal blood sampling might contribute to inconsistent 
results (8, 14, 16, 22, 23).
Several studies determined Cbl and/or folate together with tHcy concentrations in 
relation to BW (3, 14, 15, 19-21, 24). However, none of these studies determined 
methylmalonic acid (MMA) concentrations, a sensitive marker of intracellular Cbl 
deficiency.
We collected plasma samples from pregnant women and their offspring and 
prospectively explored whether maternal tHcy, folate, Cbl and MMA are risk 
factors for LBW.
Subjects and Methods
Participants
In the Netherlands, pregnant women visit either a m idwife or a gynecologist, 
depending on medical and obstetric history or com plications during pregnancy. 
Delivery can take place at home or in the hospital supported by the m idwife 
(uncom plicated pregnancies and deliveries) or in the hospital supported by a 
gynecologist. In the Netherlands, approxim ately 70% of pregnant women deliver 
in the hospital.
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Patients were included in our study when they visited the outpatient c lin ic  of 
the departm ent of O bstetrics and G ynecology at the Canisius W ilhelm ina 
Hospita l in N ijmegen, the Netherlands between 2002-2004. All wom en who 
attended the c lin ic  were potentia lly  e lig ib le. Our aim was to study the relation 
between maternal hom ocyste ine concentra tions in the general population; 
therefore, we have included pregnant w om en from  this large regional hospital. 
W omen w ith h igh-risk pregnancies or serious illnesses them selves were 
referred to a te rtia ry  hospita l, m ostly before 30 weeks of gestation. Women 
were asked to partic ipate  when tim e schedule of the clin ician, the nurses and/ 
or the adm inistrative w orker allowed this. Approxim ate ly 25% of all women 
w ho delivered in this hospita l during the study period were included. To check 
w hether the included wom en were representative fo r the entire popula tion that 
v is ited th is hospita l we random ly se lected 500 additiona l wom en from  the 
same period and found com parable results fo r maternal age, GA, BW and 
newborn infant sex.
In the Netherlands, wom en are evaluated routinely fo r irregular antibodies 
between 30 and 34 weeks of gestation. A fter w ritten inform ed consent had 
been obtained, 478 maternal b lood sam ples were drawn during routine blood 
sam pling of wom en between 30 and 34 weeks of gestation. Only eight m others 
refused partic ipa tion  after being asked. Of m others w ith blood sam ples, 386 
vis ited the hospita l fo r the delivery of the ir child and delivered a tota l of 406 
babies from  w hich venous um bilica l cord blood was drawn (includ ing 20 tw in 
pairs). We decided to exclude tw in pregnancies because of a higher risk of 
lower BW in tw ins, w hich left 366 m other-baby pairs.
All m others were asked to fill out a questionnaire. The study protocol was 
approved by the local m edical ethics com m ittee.
Blood sampling
Maternal venous blood was co llected in tubes that conta ined 3.5 ml ethylen- 
ed iam inetetraacetic acid (EDTA). Im m ediately after birth, the um bilica l cord 
was clam ped, and venous cord blood was co llected into a vacuum  tube that 
conta ined 3.5 ml EDTA. Samples from  m others and cords were im m ediately 
placed on ice. A fter centrifugation (w ithin 2 hours after sam pling), p lasm a was 
separated and EDTA plasm a and blood cells were stored separate ly at -2 0 ° C 
until analysis.
Biochemical analyses
THcy, fo late, Cbl and MMA were determ ined in both maternal and um bilical 
cord EDTA plasma. Plasma tH cy was determ ined by liquid chrom atography- 
mass spectrom etry-m ass spectrom etry. Deuterated hom ocystine was added
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as internal standard, and sam ples were treated w ith d ith ioerythrito l, fo llowed 
by acid precip ita tion. Supernatants were analyzed by reversed-phase 
chrom atography. The betw een-day coeffic ien t of variation was approxim ately 
5%. The method has been validated against existing m ethods accord ing to the 
protocol described by Nexo e ta l (25) and shows excellent corre la tion w ith a 
method based on HPLC and fluorescence detection (26). Plasma folate 
concentra tions were determ ined by a Lactobac illus casei m ic rob io log ic  assay
(27) and plasm a Cbl concentra tions were determ ined by a Lactobacillus  
rham nosus  m ic rob io log ic  assay (28). Both the fo late and the Cbl assays were 
adapted to a m icro titer plate form at and carried out by a robotic  w orksta tion 
(M icrolab AT plus 2; Ham ilton Bonaduz AG, Sw itzerland) (29). Plasma MMA 
values were measured w ith a newly developed liquid chrom atography tandem  
mass spectrom etry method (30).
Statistical analyses
Results are presented as median values w ith the in terquartile  range, except 
when otherw ise stated. A fter logarithm ic transform ation, Z scores fo r variables 
were calculated before fu rther analysis. Linear regression was used to 
determ ine pred ictors of BW. Because BW and GA were s trong ly related, we 
calculated birth w eights that were standardized fo r GA (SBW). Again, linear 
regression analyses were perform ed w ith SBW as dependent variable. To 
reveal nonlinear relations, association curves were constructed  to show 
associations between maternal concentra tions and BW, w ith the use of 
Gaussian generalized additive regression models. C orrelations between 
variables were calculated by Pearson corre la tion after logarithm ic 
transform ation of data. STATA sta tistica l software (version 10.0; Stata 
C orporation, College Station, TX) was used fo r all s ta tistica l analyses.
Results
Population characteristics
Population characteristics that include blood indices are presented in Table I. 
Babies were born at or near term. All maternal analytes were lower, com pared 
w ith um bilica l analyte concentrations.
Maternal tHcy concentrations, related B vitamins and birth weight
Possible relations between maternal tHcy, Cbl, MMA and fo late concentra tions 
w ith BW are shown as regression model curves (Figure 1). There were no 
s ign ifican t corre la tions between BW and maternal MMA (r=0.02), Cbl
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Table I Population characteristics of 366 maternal and umbilical samples
Characteristics Mother Child
Median
(25,h-75t,h percentile)
Median
(25th- 75th percentile)
Age at delivery (years) 33.3 (30.7-35.5)
Gestational age (weeks) 39.7 (38.4-40.7)
Birth weight (grams) 3425 (3075-3855)
tHcy (pmol/L) 5.5 (4.5;6.7) 5.8 (4.6;7.2)*
MMA (pmol/L) 0.16 (0.13;0.22) 0.28 (0.24;0.37)*
Folate (nmol/L) 9.1 (6.1;16.4) 30 (21.7;45.9)*
Cbl (pmol/L) 179 (134;219) 208 (156;307)*
Creatinine (pmol/L) 45 (40;50) 54 (48;61)*
n/N (%) n/N (%)
Primiparity 172/358 (48%)
Smoking 50/350 (14%)
Use of folic acid 198/347 (57%)
Male sex 159/363 (44%)
D a ta  o f m atern a l a n d  u m b ilica l cord  b lo o d  s a m p le s  a re  p re s e n te d  a s  m ed ian  a n d  in te rq u artile  
ran g e . *  =  p va lu e  <  0.01 c o m p a rin g  m atern a l a n d  u m b ilica l d a ta  using tw o -s a m p le  W ilcoxo n  
ran k-su m  test.
tH c y = to ta l h o m o c yste in e . M M A =  m e th y lm a lo n ic  ac id . C b l= c o b a la m in
(r= -0.06) or fo late (r=0.04) (Pearson corre lation coeffic ients, all p robab ility  
values>0.15). Maternal tH cy showed a s ligh t negative association w ith BW 
(r=-0.12, p = 0.03).
Table II shows associations between several possib le determ inants and BW. 
Univariate analysis revealed sm oking to be the strongest pred ic to r of BW; 
babies of sm oking m others had b irth  w eights approxim ately 300 gram s lower 
than those of non-sm oking mothers. GA and newborn infant sex were weaker 
determ inants of BW. An increase in maternal tH cy of 1sd (2.3jumol/L) resulted 
in a decrease in BW of 65 grams. W ith the use of SBW, sm oking and sex 
rem ained the strongest determ inants in univariate and m ultip le linear
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regression analysis. The re lationship between tH cy and SBW disappeared 
after the in troduction  of sm oking into the model. There was no d ifference in 
results between w om en w ith or w ithout fo lic  acid use, considering the relation 
between maternal hom ocyste ine and BW (data not shown). Maternal folate, 
Cbl and M M Aw ere not associated s ign ifican tly  w ith LBW. Analysis of um bilical 
cord blood analytes and BW did not reveal a clear relation in univariate or 
m ultip le regression analysis (data not shown).
We also analyzed w hether high maternal concentra tions of tHcy, MMA and 
creatin ine or low concentra tions of Cbl or fo late were pred ictors of LBW. 
However, we did not find  s ign ifican t odds ratios (Table III).
Figure 1 Curves representing the association of maternal concentrations of 
total homocysteine, methylmalonic acid, cobalamin and folate and 
birth weight
a
m aternal homocysteine (umol/L)
S o lid  lines re p re s e n t m ean  va lu es , th in  lines re p re s e n t 9 5 %  c o n fid e n c e  in te rva ls . C u rv e s  w ere  
f itte d  by G au ss ian  g e n e ra liz e d  ad d itiv e  reg ress io n  m o d els .
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Figure 1 Continued
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S o lid  lines re p re s e n t m ean  va lu es , th in  lines re p re s e n t 9 5 %  c o n fid e n c e  in te rva ls . C u rv es  w ere  
f itte d  by G au ss ian  g e n e ra liz e d  ad d itiv e  reg ress io n  m o d els .
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Figure 1 Continued
d
m aternal folate (nmol/L)
S o lid  lines re p re s e n t m e a n  va lu es , th in  lines re p re s e n t 9 5 %  c o n fid e n c e  in te rva ls . C u rv e s  w e re  
fitte d  by G a u s s ia n  g e n e ra lize d  a d d itive  reg ress io n  m odels .
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Table II Different analyses to study determinants of birth weight in our 
population
Possible determinants Model 1
ß [95% Cl]
Model 2
ß [95% Cl]
Model 3
ß [95% Cl]
Gestational age (weeks) 150 [118; 182] - -
Age at delivery (years) -3.5 [-17; 10] -3.6 [-16;8.7] -8.3 [-22;5.2]
Parity (0-7) 56 [-8; 121] 60 [1.9; 119] 104 [37; 171 ]
Smoking (no/yes) -286 [-450;-122] -261 [-410;-112] -313 [-479;-149]
Use of folic acid (no/yes) 11 [-107; 129] 13.6 [-94; 121] -64 [-186;56]
Female gender (no/yes) -150 [-263;-36] -149 [-252;-46] -146 [-256;-35]
Homocysteine ,
1 sd = 2.3 pmol/L
- 65 [-122;-7.4] -56 [-108;-4.5] -12 [-82;58]
Cobalamin, 1 sd = 69 pmol/L - 33 [-90;24] - 29 [-81 ;23] -37 [-100;29]
Methylmalonic acid, 
1 sd = 0.09 pmol/L
9.5 [-54;73] 12 [-45;69] 9.2 [-51 ;70]
Folate, 1 sd = 13 nmol/L 45 [-12; 102] 55 [3.5;107] 28 [-78; 133]
Creatinine, 1 sd = 7.5 pmol/L - 55 [-112;2.9] - 45 [-98;7.1] - 44 [-104; 17]
The coeffic ients presented, give the increase/decrease in birth weight (grams) for the several 
variables. Coeffic ients presented for maternal concentrations (total homocysteine, cobalamin, 
methylmalonic acid and folate) are calculated using calculated z scores of these metabolites. 
They now represent the increase or decrease in birth weight (grams) fo llow ing 1 standard 
deviation increase in maternal analytes. |3=(3coefficient. The different analyses are:
Model 1 =univariate analysis of possible determ inants on birth weight
Model 2=univariate analysis of possible determ inants on standardized birth weights
Model 3=m ultivariate analysis of possible determ inants on standardized birth weights
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Table III Odds ratios for low birth weight according to maternal plasma 
indices
Cutoff point OR [95% Cl]
tHcy > 6.71 /jmol/l 1.17 [0.70;1.95]
Cbl < 134 pmol/l 0.70 [0.44; 1.11]
MMA > 0.22 /jmol/l 0.93 [0.48;1.79]
Folate < 6.11 nmol/l 1.35 [0.93; 1.96]
Creatinine > 49.7 /jmol/l 1.34 [0.89;2.01]
The risk of birth weight being in the lowest quartile determ ined in our study (<3075 grams) was 
determ ined for maternal concentrations of tHcy, MMA and creatinine being in the highest 
quartile and folate and Cbl being in the lowest quartile com pared to the other three quartiles 
together. tH cy= to ta l homocysteine (/jmol/L). C bl=cobalam in (pmol/L). M M A=m ethylmalonic 
acid (/jmol/L).
Discussion
We prospective ly studied the potentia l re lationship between maternal tHcy, 
related B vitam ins and risk of LBW in a large Dutch study population of 
pregnant w om en. We focused on maternal concentra tions because our aim  
was to explore possible treatable risk factors fo r LBW. Maternal tHcy, folate, 
Cbl and MMA concentra tions were not associated s ign ifican tly  w ith BW. GA, 
sm oking and sex were all strong determ inants of BW, as previously observed  
by others (31-35).
Study population and design
There are lim itations of the present study. First, we collected sam ples from  
one hospital. A lthough it is a large regional hospital in the N etherlands, one 
cannot extrapolate these results d irectly fo r all pregnant wom en. Furtherm ore, 
data on length, w eight and blood pressure of the m other or other vascular 
com plica tions before or during pregnancy were not known. These tra its may 
be related to tH cy and B vitam ins and hence be potentia l confounders. Despite 
this, our s tudy population seems to be com parable to  study populations of 
others, w ith respect to  GA, maternal age and BW (24, 36). LBW is often defined  
as BW <2500 g. Because BW and GA are corre lated strongly, we used birth
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w eights that were standardized fo r gestational age in our analyses. To study  
maternal Cbl status more accurately, we also determ ined MMA concentrations, 
w hich reflect in tracellu lar Cbl status. We have studied maternal variables in 
blood drawn between 30-34 weeks of gestation, w hich can be considered a 
narrow w indow . Milman et al describe concentra tions of tHcy, Cbl, MMA and 
fo late in 434 Danish w om en at 32 weeks of gestation. They measured  
concentra tions that are com parable to  our data (Table I) (BW was not studied) 
(37). Several other authors have addressed maternal tH cy th roughout 
pregnancy. They observed that maternal concentra tions are correlated  
th roughou t pregnancy, may decrease at first, seem to plateau between 20 and 
32 weeks of gestation, and may increase at labor (17, 38-40). This suggests  
that taking maternal sam ples between 30 and 34 weeks of gestation should be 
a period w ith stable hom ocyste ine concentrations.
Determinants of birth weight
Univariate analysis showed that gestational age, sm oking and sex were the  
strongest determ inants of BW. In norm al pregnancy, there is a strong positive  
corre la tion between BW and gestational age (31). Boys norm ally have a s lightly  
higher BW than girls (31, 35). Sm oking is a w ell-know n strong and 
dose-dependent risk factor fo r LBW, as confirm ed in our s tudy (33, 34, 41). 
Parity, w hich has been shown to be related to BW (32, 35), was also found by 
us to be a determ inant next to  sm oking and sex. The risk of LBW increases  
again w ith the fourth  and subsequent children (35, 35, 42).
O bservational studies have dem onstrated a positive corre lation between  
maternal serum or red blood cell folate and infant BW or higher BW in fo lic  ac- 
id-supplem ented m others (24, 43-46). Others, however, have described no 
differences in BW between infants born to m others who receive fo lic  acid  
supplem ents, com pared w ith nonsupplem ented m others (18, 46). In line w ith  
these results, neither the use of fo lic  acid in early pregnancy nor maternal 
fo late concentra tions in fluenced BW in our study.
Univariate analyses show  an inverse association between maternal tH cy and 
BW, w hich d isappeared after adjustm ent fo r sm oking and in m ultivariate  
analysis. Sm oking is associated w ith lower BW and w ith higher tH cy  
concentra tions and is a possible confounder, w hich is a good explanation for 
the loss of association described earlier (33, 34, 41, 47, 48)
In this w ell-nourished and partly supplem ented Dutch population, maternal 
tH cy and related B vitam ins are not associated w ith BW. The question remains 
w hether BW is influenced by these analytes in other populations w ith no 
w idespread use of fo lic  acid supplem ent during pregancy.
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Analyte concentrations
We observed higher concentra tions of tHcy, Cbl, MMA and folate in um bilical 
cord blood, com pared w ith maternal b lood sam ples. Some studies reported  
lower or sim ilar tH cy concentra tions in um bilical cord sam ples than in maternal 
sam ples (3, 14, 16, 23, 49). In m ost studies, maternal b lood was drawn at or 
im m ediately after delivery; in our study, maternal sam ples were drawn between  
30 and 34 weeks of gestation. M urphy et al showed lower maternal tH cy  
concentra tions at 32 weeks, com pared w ith maternal tH cy at delivery and in 
fetal cord sam ples (17). D ifferences in study design and tim e of sam pling may 
be responsib le fo r d ifferences in results. The higher um bilica l cord blood  
concentra tions of folate and Cbl could result from  active placental transport 
and the ab ility  to concentra te  vitam ins in the fetus (50, 51). Um bilical MMA 
concentra tions are also higher than maternal concentra tions, w hich confirm s  
the results from  Obeid and Hermann (52).
In conclusion, our relatively large study dem onstrated that maternal tH cy and 
related B vitam ins have a weak or even no association w ith birth  w eight.
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Abstract
Background Low birth w eight (LBW), as a proxy fo r fetal grow th, is associated  
w ith increased neonatal m orb id ity  and m orta lity  but also w ith life-long  
consequences such as poor cognitive  function  and card iovascular diseases. 
Maternal to ta l hom ocyste ine concentra tions (tHcy) have been linked to a w ide  
range of adverse pregnancy outcom es and could possib ly influence birth  
w eight. We perform ed a system atic review and m eta-analysis on the association  
of maternal tH cy and birth w eight.
Design An e lectron ic  literature search of English, German and French 
publications using Pubmed database (January 1966- July 2010) revealed 78 
abstracts. Search term s were: “ hom ocyste ine AND (birth w eight OR sm all for 
gestational age OR intrauterine grow th re tardation)” . S tudies were e lig ible if 
in form ation on maternal tHcy, b irth w eight and the possib le association  
between maternal tH cy and birth w eight was available. Effect estim ates were  
converted to odds ratios w ith a cu t-o ff level of birth w eight <10th percentile for 
gestational age (SGA) and maternal tH cy > 9 0 th percentile.
Results Full text reading of 35 studies retrieved after se lection based on 
abstract reading yie lded 19 studies fo r analysis, consisting of 21,326 
individuals. Pooled analysis resulted in a crude OR of 1.31 [1.15;1.51 ] as an 
estim ate of relative risk to  get an infant born SGA when maternal tH cy is> 9 0 th 
percentile. If this estim ate is expressed as a linear effect, it corresponds to  
-38[-20;-58] g fo r 1 sd increase in maternal tHcy. Adjustm ent fo r known 
confounders was not possib le but a tendency to decreased strength of 
association was observed in studies after adjustm ent fo r strong  
determ inants.
Conclusion Higher maternal tH cy concentra tions are associated w ith an 
increased risk fo r being SGA. Adjustm ent fo r possible confounders was 
perform ed in som e but not all studies. The small estim ated birth w eight 
difference m ight be of little  c lin ica l relevance fo r the individual newborn, 
however, it could be of greater im portance on population level.
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Introduction
LBW is a global m ajor public health problem  w ith an estim ated prevalence of 
15%. It poses the newborn at increased risk fo r m orb id ity  and m orta lity  in the  
neonatal phase (1). G rowth retardation is one of the 4 leading causes of 
perinatal death in the N etherlands (2). C onsequences of LBW can be life-long: 
LBW is associated w ith increased risk of reduced stature, poor cognitive  
function, coronary heart disease, stroke, hypertension and type  2 diabetes  
(3-5). The fetal orig ins of chron ic  disease m odel suggests that nutrition during  
fetal life changes gene expression and hereby responses to later environm ent 
in such a way that pace and pathway of early grow th appear to be a risk factor 
fo r chron ic disease in adulthood (6). A lthough BW is the end result of many 
different paths of fetal grow th and its num ber does not necessarily reflect or 
exclude grow th retardation, it nevertheless provides a basis fo r estim ating  
risks of developm ent of disease later in life.
Maternal to ta l hom ocyste ine concentra tions (tHcy) have been linked to  neural 
tube defects, congenita l heart defects and a w ide range of adverse pregnancy  
outcom es including recurrent early pregnancy loss, abruptio  placentae, 
pre-eclam psia and fetal loss (7-9). These adverse pregnancy outcom es are all 
related to maternal vascular com prom ise. If maternal tH cy w ould be causally  
related to  vascular com prom ise, it may be anticipated that it could also 
influence birth w eight (BW). Studies regarding the possib le association  
between maternal tH cy and (low) BW perform ed until now have yie lded  
conflic ting  conclusions. Sample size, defin ition of low birth w eight (LBW), 
confounders and tim ing of maternal b lood sam pling may contribute  to these  
inconsistent outcom es (8-42).
Because of the increased short- and long-term  risks of LBW, revealing possib ly  
treatable risk factors fo r LBW is of utm ost im portance. If maternal tH cy w ould  
be negatively associated w ith BW, fo lic  acid intervention tra ils lowering tH cy  
concentra tions could be the next step. Our aim was to perform  a system atic  
review and m eta-analysis focusing on the question w hether maternal tH cy are 
related to the ir o ffsp rin g ’s BW. Population (P) was defined as w om en who have 
given birth or were pregnant at or after the tim e of inclusion. Intervention (I) 
was not relevant. C om parison (C) could exist of com paring maternal tH cy  
between appropria te  fo r gestational age and small fo r gestational age (SGA) 
or LBW newborns, corre lation between maternal tH cy and BW or determ ining  
the risk fo r SGA or LBW above a cu t-o ff point fo r maternal tH cy or regression  
analysis w ith maternal tH cy as possible determ inant and BW as dependent 
factor. O utcom e (O) was defined as being LBW or SGA.
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Methods
Search strategy and selection criteria
Eligible studies were identified by searching e lectron ic  literature (PubMed 
database) fo r relevant publications between January 1966 and July 2010 using 
search term s “ hom ocyste ine AND (birth w eight OR small fo r gestational age 
OR intrauterine grow th re tardation)” . We perform ed hand searching of 
b ib liographies of all relevant studies on th is top ic  (by MH, MdH).
Study eligibility criteria
Studies were e lig ible fo r th is m eta-analysis if: (1) the study conta ined data on 
w om en who have been or were pregnant at the tim e of inclusion or were 
included preconceptiona lly  (P); (2) inform ation on BW could be extracted, 
w hether as continuous variable or d ichotom ized (O); (3) in form ation on 
maternal tH cy was available, w hether as continuous variable or d ichotom ized; 
(4) an analysis regarding the possible association between maternal tH cy and 
BW was perform ed (C). E lig ib ility  assessm ent of 78 abstracts was perform ed  
in an unblinded m anner by tw o investigators independently (MH, MdH), 
judg ing  on title  and abstract content. There were no d isagreem ents between  
both reviewers (figure 1).
Report eligibility criteria
The search was restricted to  human studies and English, French or German 
language published between January 1966 and July 2010.
Data collection
A standard data extraction form  was developed and used on the possible  
relevant articles. All data from  eligible articles were abstracted by one review 
author (MH) using the data extraction form  and extracted data were checked by 
a second review author (MdH). Inform ation was sought in each individual study  
on: (1) general study inform ation including title, first author, journal, year of 
publication, (2) characteristics of partic ipants (including num ber of participants, 
maternal age, parity, use of vitam in supplem ents, sm oking, maternal tHcy, 
threshold of maternal tHcy, tim ing of maternal sample), (3) outcom e measures 
(BW, newborn sex, GA), (4) statistical analyses and defin itions including  
definition of LBW and SGA, type  of analyses, results, adjustm ents. A fter birth, 
LBW is defined as birth w eight <2500 g and SGA is defined as BW <10th 
percentile for GA of that specific country, most of the times gender-specific. In 
utero, intrauterine growth retardation (IUGR) is most com m only defined as 
expected fetal w eight below the 10th percentile for GA and fetal sex.
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Summary measures
The prim ary outcom e measure was the odds ratio fo r BW <1 Oth percentile  for 
gestational age w ith maternal tH cy > 90th percentile.
Statistical analysis
The 19 studies that conta ined effect size estim ates d iffered in the kind of effect 
size estim ates. Some studies showed mean differences in tH cy between  
m others of children w ith norm al BW and m others w ith children born SGA (10, 
12, 13, 18, 20-23). O ther studies provided odds ra tio ’s as estim ates of relative  
risk fo r having a child born SGA (8, 13, 15-17, 19, 24, 27), while a th ird  group of 
papers showed regression coeffic ien ts or corre la tion coeffic ien ts (11, 14, 16, 
19, 20, 25-27).
Under the assum ption of a linear re lationship between tH cy and BW we 
sim ulated a dataset of 1,000,000 observations w ith a norm al d istribution and 
a corre lation coeffic ien t between -0.99 and 0.99 fo r each possible value at two  
decim als of precision. From these sim ulated datasets we calculated  
standardized mean differences at a certa in cu t-o ff level fo r BW (most studies  
used the 10th percentile, but other studies to o k  the 5th or the 33th percentile to 
define SGA or LBW). Furtherm ore we calculated odds ratios fo r these cut-o ff 
levels of BW and d ifferent cu t-o ff levels of tH cy (67th, 75th, 90th percentile). 
Because som e odds ra tio ’s in published papers were given fo r a top  versus 
bottom  quartile, we calculated these top  versus bottom  quartile  odds ra tio ’s as 
well. So, fo r each possible corre lation coeffic ien t we calculated standardized  
mean differences (also known as C ohen’s D) and odds ra tio ’s at certa in cut-o ff 
levels. The results of these calculations are shown in the supplem enta l tables  
(online supplem ental tables S1-S5). From these tables one can easily convert 
an effect size that is expressed as standardized mean d ifference or odds ratio 
into a corre lation coeffic ien t and vice versa.
Studies presenting mean tH cy in cases and contro ls did not always provide  
estim ates of standard deviation; however, they did provide p-values fo r t-tests. 
In that case the standardized mean d ifference was calculated from  the  
t-s ta tis tic  and the num ber of cases and contro ls  (43). The same princip le was 
applied to the studies that provided regression coeffic ien ts w ithout standard  
deviation, but w ith a p-value. In that case we calculated the corre lation  
coeffic ien t from  the p-value and the num ber of subjects. If a p-value was 
express as p<0.01 or p<0.001 we took it as p=0.01 or p = 0.001 respectively. 
The m ethod described above allowed us to provide reliable effect size 
estim ates of odds ra tio ’s fo r maternal tH cy > 9 0 th percentile and being SGA. 
From these odds ra tio ’s and the num ber of cases and contro ls we could easily 
calculate the 2x2 tab le  that underlies the odds ra tio ’s and subsequently
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calculate the standard errors and 95% confidence intervals using the W oo lf’s 
m ethod.
Using these odds ra tio ’s we perform ed a pooled analysis w ith the inverse of 
the standard error as w eight and using a fixed e ffect model. The METAN 
routine of STATA sta tistica l softw are (version 11.0; Stata C orporation, College  
Station, TX) was used fo r analysis.
Results
PubMed search yie lded 78 titles after applying the lim its of human studies and 
English, French or German language. The 33 studies retrieved full text for 
detailed assessm ent after reading all abstracts revealed tw o fu rther studies  
th rough hand searching b ib liographies (14, 15). From these 35 studies, 16 
studies were excluded (figure 1). Six studies were excluded because they  
were perform ed in a popula tion of w om en w ith pre-eclam psia only (28-30, 32, 
33, 39), tw o because they stud ied association between polym orphism s and 
pregnancy outcom e (31, 35), tw o because no maternal tH cy were described  
(34, 40) and one because no inform ation on BW could be retrieved (37). One 
study turned out to be a review (36), one study did not describe a contro l 
group (9), and three studies did not describe a relationship between maternal 
tH cy and BW (38, 41, 42).
Our final analysis included 19 studies, consisting of 21,326 individuals (8, 
10-27). These studies analyzed the association between maternal tH cy and 
BW through com paring means between cases and contro ls  (n=7) (10, 12, 13, 
18, 20-23), ca lcu la ting odds ra tio ’s or relative risks fo r having LBW or SGA 
babies if maternal tH cy was high (n = 8) (8, 13, 15-17, 19, 24, 27), using linear 
regression analysis to s tudy maternal tH cy as determ inant fo r BW (n = 8) (11,
14, 16, 19, 20, 25-27) or a com bination. Extensive descrip tion of the character­
istics of all included studies is described in table I. Pooled analysis revealed  
an overall odds ratio of 1.31 [1.15; 1.51 ] fo r being SGA when maternal tH cy  
>90th  percentile (figure 2).
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Figure 1 Overview of the selection process in our systematic review
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Table I Study characteristics of 19 studies regarding the association
between maternal homocysteine concentrations and birth weight
Compare means
author year N* tHcy* N# tHcy* P value
Hogg 2000 22 5.7±1.91 402 5.3±1.81 0.35
D’Anna 2004 36 5.85±1.081 36 5.6±1.111 0.20
Yajnik 2005 30 7.2(5.4;9.9)9 50 5.5(4.4;6.7)9 <0.01
Lindblad 2005 46 12(4;23)3 82 9.6(5;23)3 0.02
Onalan 2006 41 6(2.3; 16)8 324 5(1.8;25.3)8 <0.001
Martin 2007 30 9.7±0.67 52 9.1±0.47 0.4
Ronnenberg 2002 65 8.2[7.6;8.8]5 358 8.1 [7.8;8.5]5 nm
Burke 1992 37 7.7±2.31 35 7.9±2.31 nm
Odds Ratios
author year N* tHcy* N# tHcy* OR[95%CI]
Ronnenberg 2002 65 8.2[7.6;8.8]5 358 8.1 [7.8;8.5]5 1.0[0.4;2.2]
Murphy 2004 9114 1.20[0.9;3.72]
Hogeveen 2010 36614 1.17[0.70;1.95]
Vollset 2000 1727 12688 1.21 [1.02; 1.43]
Steegers 2004 144 176 1.90[1.00;3.60]
Dodds 2007 129 1990 1.60[1.00;2.60]
Infante 2003 483 5.11[4.9;5.3]2 468 5.59[5.4;5.8]2 0.55[0.39;0.81]
Murakami 2001 35 714 0.78[0.10;5.91]
Regression analysis
author year N* tHcy* N# tHcy* Effect size
Malinow 1998 3514 5.43±1.401 r=-0.36 p=0.036
Infante 2003 483 5.11[4.9;5.3]2 468 5.59[5.4;5.8]2 ß=127.5 [39.8;215.5]
Hogeveen 2010 36614 5.5(4.5;6.7)4’14 ß=-56 [-108;-4.5]
Takimoto 2007 CD no 5.9±1.41 ß=-151 p<0.01
Yajnik 2005 8014 ß=-280.3 p=0.027
Murphy 2004 9114 ß=-26.6 (93.1)6
Watanabe 2008 18714
CDCOÖIIQ.
COÖIICO
.
Pagan 2002 28514 5.1±2.21’14 ß=-7.2 p=0.679
Table 1 represents data from the individual studies included in our review and meta-analysis. 
tH cy= to ta l homocysteine (/jmol/L). N = number. BW =birth weight. pn=nth  percentile. GA= 
gestational age. EFBW=estimated fetal birth weight. ad=after delivery. Precon=preconceptional. 
BMI = body mass index. Yrs=years. Y=year. ‘ cases #con tro ls  ►cut-off 
tim ing=  tim ing maternal blood sample
1 m ean±sd 2 mean [95%CI] 3 median(range) 4 median (interquartile range) 5 geom etric mean 
[95%CI] e beta-coeffic ient (se) 7 mean±sem 8 median (range) 5 geom etric mean (interquartile 
range) 10 gender-specific percentile for GA 11 percentile for GA 12 5 /jm o l/L  13 1 sd 14 overall 
population 15 90th percentile
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► BW timing adjustments
p1010 37 wks GA GA, sex
p1010 16 wks GA GA, sex
p1010 At delivery GA, sex
<11%ÎEFBW11 At delivery GA
p511 15-19 wks GA GA
p2.510 4 days ad GA, sex
p1011 precon GA
p1010 48-72 h ad GA, sex
► tHcy ► BW timing adjustments
>12.415 <p1011 preconc GA, batch
>p67 <p33 32 wks GA GA, sex, BMI, smoking, mat age
>p75 <p25 30-34 wks GA -
>p75 vs <p25 <p1010 Yrs ad GA, sex, parity, y of birth, mat age, smoking
>1515 <p1010 >6 wks ad GA, sex
>p9011 <p1010 <20 wks G A GA, sex
Hcyt12 <p1010 <48 h ad GA, sex, race, time interval
>p97.5 <p1011 6-12 wks GA GA
► tHcy timing adjustments
labor -
Hcyt 5 /jm ol/L <48 h ad GA, sex, race, time interval
Hcyt 1 sd 30-34 wks GA GA
34-36 wks GA Mat age, BMI, parity
At delivery Mat height, weight, GA, sex
32 wks GA GA, sex, BMI, smoking, mat age
32 wks GA Mat age, sex, parity
30 wks GA GA, sex, BMI, smoking, race
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Figure 2 Effect sizes of individual studies after conversion into Odds ratios
Study Odds %
ID ratio (95% Cl) Weight
Burke --------------------------- ♦-
i
—i------------ 0.83 (0.05, 12.98) 0.25
Malinow ------------- i •i ------  3.53(0.26,47.70) 0.28
Hogg ------ 1.44 (0.57, 3.67) 2.15
Vollset 1.24 (1.05,1.47) 66.26
Murakami ----- i-*------- 1.24 (0.59,2.59) 3.44
Pagan ----------- _ i • i 1.11 (0.32,3.85) 1.21
Ronnenberg ---------- H-------- 1.00 (0.35,2.88) 1.67
Infante ------- • - 0.72(0.33,1.61) 2.95
D’Anna --------------- i ti 1.77 (0.21,14.92) 0.41
Steegers ♦-------- 1.90 (0.71,5.12) 1.91
Murphy --------------------- •-i------------ 1.11 (0.12,10.02) 0.39
Lindblad ------ _l__ »l 2.26 (0.51,10.10) 0.84
Yajnik --------- I • 2.41 (0.37,15.55) 0.54
Onalan i ♦---- 2.69 (1.15,6.30) 2.59
Martin —1«-----------l 1.44 (0.17, 12.06) 0.42
Dodds — •— 1.60 (1.07,2.40) 11.46
Takimoto ------- i • 2.69 (0.45,16.20) 0.58
Watanabe --------------- —i------ 1.03 (0.21,4.98) 0.76
Hogeveen ----- 1“ 1.49 (0.55,4.03) 1.89
Overall (l-squared = 0.0%, p = 0.945)
?
1.31 (1.15,1.51) 100.00
I I 
.1 .5
‘ 1 
2
1
10
Discussion 
Summary of key findings
Our m eta-analysis of 19 e lig ible studies regarding maternal tH cy in relation to  
BW revealed a 30% increased risk on having BW < 10th percentile  fo r GA when  
maternal tH cy > 9 0 th percentile. To express th is e ffect size estim ate as a linear 
effect, th is OR of 1.31 [1.15;1.51] can be converted to a regression coeffic ient 
(supplem ental tab le  S3) w hich im plies that fo r 1 sd increase in maternal tHcy, 
BW will decrease -0.075[-0.04;-0.114] sd. Using a standard deviation fo r BW of 
505 g (based on the data in literature stud ied fo r th is review) and fo r maternal 
tH cy of 1.9 jumol/l, th is means that 1.9 jumol/L increase in maternal tH cy w ould  
result in a decrease in BW of -38[-20;-58] g. We assum e that th is is of relatively  
little  influence fo r the individual newborn. However, if maternal tH cy is causally
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related to lower birth w eight and could be m odified in aw ay that less newborns 
w ould be SGA, e.g. by the use of fo lic  acid, th is could be of im portance on 
popula tion level, because being SGA is one of the 4 main causes of perinatal 
death in the N etherlands.
Novelty of findings
Discovering possible treatable determ inants of BW is c lin ica lly  relevant not 
only fo r the newborn but also fo r the risk on com m on diseases occurring  later 
in life. Results of studies regarding the association between maternal tH cy and 
BW perform ed so far have yie lded d ifferent conclusions. W ith the use of an 
innovative sta tistica l techn ique we were able to  convert all the d ifferent effect 
sizes into odds ratios, w hich allowed us to com pare and pool the results.
Interpretation, strength and limitations in the context of the totality of 
evidence
As anticipated, the included studies used d ifferent m ethods fo r e ffect size 
estim ation such as mean d ifferences, calculation of OR’s or regression  
analysis. Furtherm ore they used d ifferent defin itions fo r hyperhom ocyste ine- 
mia and LBW. A fter conversion of all e ffect sizes to OR’s fo r maternal tH cy  
concentra tions exceeding the 90th percentile  and being small fo r gestational 
age defined as birth w eight below  the 10th percentile  fo r GA we were able to  
perform  a pooled analysis.
Adjustm ents fo r known and strong confounders such as GA (8, 12-24, 27), 
newborn sex (8, 12, 14, 16-21, 23, 24, 26), parity (8, 25) and sm oking (8, 14, 19) 
were perform ed in som e but not all s tudies (table II). In studies describ ing  
both adjusted and unadjusted e ffect size estim ates, strength of association  
decreased or disappeared after adjustm ents in three studies (17, 20, 27). The 
association rem ained the same in the study by R onnenberg et al and increased  
in the study perform ed by Infante et al (13, 16). Some of the w ell-known  
determ inants of BW, like sm oking and GA, have an association w ith tHcy. In 
our previous s tudy the association between maternal tH cy and BW disappeared  
after in troducing sm oking into the sta tistica l model (27). We are not able to 
adjust all data fo r the same possible confounders but observed a tendency to 
decreased strength of association after adjustm ent fo r the stronger 
determ inants (table 2).
THcy concentra tions are in fluenced by B vitam in status, especia lly by folate  
and hence by fo lic  acid supplem entation or fo rtifica tion. In only one of the  
countries where the studies were perform ed fo lic  acid fo rtifica tion  had been 
in troduced very recently at that tim e (1998 in Canada) (16). In eight studies
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Table II Unadjusted and adjusted effect size estimates for the association  
between maternal homocysteine and birth weight
Effect size
Ronnenberg OR for BW<p10 when maternal tHcy > 12.4 /jmol/L
Infante RR for BW<p10 when maternal tHcy T 5 /jmol/L
Yajnik Linear regression using BW as dependent factor
Steegers OR for BW>p10 when maternal tHcy > p90
Hogeveen P for difference in sd of BW following 1 sd increase in maternal tHcy
Hogeveen P for difference in sd of BW following 1 sd increase in maternal tHcy
a: OR[95%CI],
b: regression coeffic ient [95%CI] 
c: regression coeffic ient [95%CI]
Hb=hem oglobin.GA=gestational age. PE=pre-eclampsia. IUGR=intrauterine growth retardation
in form ation on supplem entation was described, varying from  using a non-folate  
defic ient study population based on serum fo late concentra tions (20, 25), a 
percentage w om en w ith low folate at certa in GA (14), to describ ing % wom en  
taking fo lic  acid supplem entation (8, 11, 24, 26, 27). Folate status can possibly  
influence the association between maternal tH cy and BW: a possible  
association could be stronger in low fo late status or an observed association  
between tH cy and birth w eight could be a reflection of an association between  
fo late and BW. Positive associa tions between fo lic  acid intake, birth w eight 
and reduced risk on being SGA or LBW have been observed by several authors  
as sum m arized by Tim m erm ans et al, a lthough no inform ation on tH cy is 
available (44). Recent observational studies showed 37-68 g higher BW in 
w om en using periconceptiona l fo lic  acid supplem entation (44, 45). This BW 
difference is com parable  to the BW difference in our m eta-analysis. Precon- 
ceptional fo lic  acid supplem entation was also associated w ith reduced risk on 
LBW and being SGA (57% and 60% respectively, adjusted fo r maternal age, 
height and w eight, GA, parity, newborn sex, ethnicity, educational level and 
sm oking) (44). These effects were m odified by parity. Furtherm ore, fo lic  acid  
started preconceptiona lly  resulted in a decreased risk on being SGA (OR 
0.40[0.22;0.72]) and LBW (OR 0.43[0.28;0.69], analyses adjusted fo r maternal 
age, height and w eight, GA, parity, newborn sex, ethnicity, educational level
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unadjusted adjusted adjustments
1.0[0.4;22.2]a 1.0[0.4;2.3]a GA, maternal age, BMI, Hb, batch
0.55[0.39;0.81]a 0.42[0.27;0.84]a GA, sex, race, BMI, smoking, PE, primiparity, 
time interval, previous IUGR
-431.7, p0.001b -280.3, p0.027b maternal height and weight, GA, sex
1.9[1.0;3.6]a 1.4[0.7;3.1]a GA, maternal age, creatinine, time interval
-65[-122;-7.4]c -56[-108;-4.5]c GA
-65[-122;-7.4]c -12[-82;58]c GA, maternal age, sex, smoking, parity, use folic acid
and sm oking) (44). Evaluation of rate of LBW before and after folate food  
fo rtifica tion  showed a small reduction in prevalence of LBW (46). Several 
random ized contro lled tria ls and observational studies observed sim ilar 
associations between fo lic  acid supplem entation or maternal fo late status and 
BW or SGA rate (47-51). In contrast, other studies could not observe such an 
association (27, 45, 52, 53). To sum m arize, studies regarding the e ffect of fo lic  
acid or maternal fo late status in relation to the ir o ffsp rin g ’s BW yie lded d ifferent 
conclusions.
Tim ing of maternal b lood sam pling varied from  preconceptional (13), during  
pregnancy (12, 14, 15, 18, 19, 22, 24-27), peripartum  (11, 16, 18, 20, 23) to 
different tim e intervals after delivery (8, 17). Tim ing of maternal sam ples can 
influence observed maternal tHcy. Maternal tH cy in pregnancy tend to 
decrease at first, reach a through between 20 and 32 weeks and increase  
again at or shortly  after delivery to  p reconceptional concentra tions (19, 54-56). 
In th is s tudy we could not observe an association between effect size and 
tim ing of maternal sam pling (data not shown). Vollset et al describe the largest 
study population in th is m eta-analysis. B lood was sam pled years after delivery  
(8). They assume that any association w ould be w eakened by a longer tim e  
interval between delivery and blood sam pling, supported  by the ir observation  
that stronger associa tions between BW and maternal tH cy exist in those
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pregnancies closest to the tim e of sam pling. Furtherm ore, excluding the  
results from  Vollset from  the analysis w ill increase overall crude OR.
Conclusion:
Based on this review and m eta-analysis of 19 elig ib le  studies we conclude that 
there is a small but s ign ifican tly  increased risk on being SGA w ith increased  
maternal tH cy concentra tions. One may debate w hether such small increase  
in risk w ill be of clin ical relevance fo r the individual newborn. However, at the  
popula tion level, if it w ould be possib le to decrease the tota l num ber of SGA 
new borns th rough lowering maternal tHcy, th is could result in decreased  
perinatal death rate and im proved general population health.
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Online Supplemental Material
Supplementary table 1
Correlation coefficients and their corresponding standardized mean difference 
and odds ratio’s using a cut-off levels of birth weight at the 10th percentile and 
for maternal tHcy using top versus bottom quartiles
rho odds ratio st. mean diff
-0.50 18.09 -0.97
-0.49 16.73 -0.95
-0.48 15.45 -0.93
-0.47 14.35 -0.91
-0.46 13.35 -0.89
-0.45 12.39 -0.87
-0.44 11.49 -0.85
-0.43 10.69 -0.83
-0.42 10.00 -0.81
-0.41 9.34 -0.79
-0.40 8.74 -0.78
-0.39 8.21 -0.76
-0.38 7.71 -0.74
-0.37 7.24 -0.72
-0.36 6.82 -0.70
-0.35 6.40 -0.68
-0.34 6.02 -0.66
-0.33 5.66 -0.64
-0.32 5.35 -0.62
-0.31 5.04 -0.60
-0.30 4.76 -0.58
-0.29 4.48 -0.56
-0.28 4.24 -0.54
-0.27 4.01 -0.52
-0.26 3.79 -0.50
-0.25 3.59 -0.48
-0.24 3.40 -0.46
rho odds ratio st. mean diff
-0.23 3.21 -0.44
-0.22 3.05 -0.42
-0.21 2.89 -0.40
-0.20 2.74 -0.38
-0.19 2.59 -0.37
-0.18 2.46 -0.35
-0.17 2.34 -0.33
-0.16 2.22 -0.31
-0.15 2.11 -0.29
-0.14 2.00 -0.27
-0.13 1.90 -0.25
-0.12 1.81 -0.23
-0.11 1.72 -0.21
-0.10 1.63 -0.19
-0.09 1.55 -0.17
-0.08 1.47 -0.15
-0.07 1.40 -0.13
-0.06 1.33 -0.11
-0.05 1.27 -0.09
-0.04 1.20 -0.07
-0.03 1.15 -0.05
-0.02 1.09 -0.03
-0.01 1.04 -0.01
0.00 1.00 0.00
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Supplementary table 2
Correlation coefficients and their corresponding standardized mean difference 
and odds ratio’s using a cut-off levels of birth weight at the 10th percentile and 
for maternal tHcy at the 75th percentile
rho odds ratio st. mean diff rho odds ratio st. mean diff
-0.50 5.30 -0.97 -0.20 1.89 -0.38
-0.49 5.09 -0.95 -0.19 1.83 -0.37
-0.48 4.90 -0.93 -0.18 1.78 -0.35
-0.47 4.72 -0.91 -0.17 1.73 -0.33
-0.46 4.55 -0.89 -0.16 1.67 -0.31
-0.45 4.39 -0.87 -0.15 1.62 -0.29
-0.44 4.23 -0.85 -0.14 1.56 -0.27
-0.43 4.08 -0.83 -0.13 1.51 -0.25
-0.42 3.94 -0.81 -0.12 1.47 -0.23
-0.41 3.80 -0.79 -0.11 1.42 -0.21
-0.40 3.66 -0.78 -0.10 1.37 -0.19
-0.39 3.54 -0.76 -0.09 1.33 -0.17
-0.38 3.43 -0.74 -0.08 1.29 -0.15
-0.37 3.31 -0.72 -0.07 1.25 -0.13
-0.36 3.19 -0.70 -0.06 1.20 -0.11
-0.35 3.09 -0.68 -0.05 1.17 -0.09
-0.34 2.99 -0.66 -0.04 1.13 -0.07
-0.33 2.89 -0.64 -0.03 1.09 -0.05
-0.32 2.79 -0.62 -0.02 1.06 -0.03
-0.31 2.70 -0.60 -0.01 1.02 -0.01
-0.30 2.61 -0.58 0.00 0.99 0.01
-0.29 2.53 -0.56
-0.28 2.45 -0.54
-0.27 2.37 -0.52
-0.26 2.30 -0.50
-0.25 2.22 -0.48
-0.24 2.15 -0.46
-0.23 2.09 -0.44
-0.22 2.02 -0.42
-0.21 1.96 -0.40
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Supplementary table 3
Correlation coefficients and their corresponding standardized mean difference 
and odds ratio’s using a cut-off levels of birth weight at the 10th percentile and 
for maternal tHcy at the 90th percentile
rho odds ratio st. mean diff
-0.50 5.85 -0.97
-0.49 5.62 -0.95
-0.48 5.42 -0.93
-0.47 5.22 -0.91
-0.46 5.02 -0.89
-0.45 4.84 -0.87
-0.44 4.66 -0.85
-0.43 4.50 -0.83
-0.42 4.34 -0.81
-0.41 4.19 -0.79
-0.40 4.04 -0.78
-0.39 3.91 -0.76
-0.38 3.78 -0.74
-0.37 3.65 -0.72
-0.36 3.53 -0.70
-0.35 3.41 -0.68
-0.34 3.30 -0.66
-0.33 3.18 -0.64
-0.32 3.08 -0.62
-0.31 2.98 -0.60
-0.30 2.89 -0.58
-0.29 2.79 -0.56
-0.28 2.69 -0.54
-0.27 2.60 -0.52
-0.26 2.50 -0.50
-0.25 2.41 -0.48
-0.24 2.33 -0.46
-0.23 2.26 -0.44
-0.22 2.18 -0.42
- 0.21 2.11 - 0.40
rho odds ratio st. mean diff
-0.20 2.03 -0.38
-0.19 1.96 -0.37
-0.18 1.90 -0.35
-0.17 1.83 -0.33
-0.16 1.77 -0.31
-0.15 1.71 -0.29
-0.14 1.65 -0.27
-0.13 1.60 -0.25
-0.12 1.54 -0.23
-0.11 1.49 -0.21
-0.10 1.44 -0.19
-0.09 1.38 -0.17
-0.08 1.33 -0.15
-0.07 1.29 -0.13
-0.06 1.24 -0.11
-0.05 1.20 -0.09
-0.04 1.15 -0.07
-0.03 1.11 -0.05
-0.02 1.07 -0.03
-0.01 1.03 -0.01
0.00 0.99 0.01
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Supplementary table 4
Correlation coefficients and their corresponding standardized mean difference 
and odds ratio’s using a cut-off levels of birth weight at the 5th percentile and 
for maternal tHcy at the 95th percentile
rho odds ratio st. mean diff
-0.50 7.71 -1.08
-0.49 7.43 -1.06
-0.48 7.14 -1.04
-0.47 6.87 -1.02
-0.46 6.59 -1.00
-0.45 6.35 -0.97
-0.44 6.11 -0.95
-0.43 5.86 -0.93
-0.42 5.62 -0.91
-0.41 5.41 -0.89
-0.40 5.21 -0.87
-0.39 4.97 -0.84
-0.38 4.80 -0.82
-0.37 4.61 -0.80
-0.36 4.43 -0.78
-0.35 4.26 -0.76
-0.34 4.11 -0.73
-0.33 3.96 -0.71
-0.32 3.79 -0.69
-0.31 3.64 -0.67
-0.30 3.50 -0.65
-0.29 3.37 -0.63
-0.28 3.23 -0.60
-0.27 3.10 -0.58
-0.26 2.97 -0.56
-0.25 2.87 -0.54
-0.24 2.76 -0.52
-0.23 2.65 -0.50
-0.22 2.54 -0.47
-0.21 2.45 -0.45
rho odds ratio st. mean diff
-0.20 2.35 -0.43
-0.19 2.26 -0.41
-0.18 2.17 -0.39
-0.17 2.08 -0.37
-0.16 1.99 -0.34
-0.15 1.91 -0.32
-0.14 1.83 -0.30
-0.13 1.76 -0.28
-0.12 1.69 -0.26
-0.11 1.63 -0.24
-0.10 1.57 -0.21
-0.09 1.51 -0.19
-0.08 1.45 -0.17
-0.07 1.39 -0.15
-0.06 1.33 -0.13
-0.05 1.27 -0.10
-0.04 1.22 -0.08
-0.03 1.17 -0.06
-0.02 1.12 -0.04
-0.01 1.07 -0.02
0.00 1.02 0.00
129
CHAPTER 6
Supplementary table 5
Correlation coefficients and their corresponding standardized mean difference 
and odds ratio’s using a cut-off levels of birth weight at the 33th percentile and 
for maternal tHcy at the 67th percentile
rho odds ratio st. mean diff
-0.50 4.17 -0.82
-0.49 4.04 -0.80
-0.48 3.91 -0.79
-0.47 3.78 -0.77
-0.46 3.66 -0.75
-0.45 3.55 -0.74
-0.44 3.43 -0.72
-0.43 3.32 -0.70
-0.42 3.21 -0.69
-0.41 3.11 -0.67
-0.40 3.02 -0.66
-0.39 2.93 -0.64
-0.38 2.84 -0.62
-0.37 2.76 -0.61
-0.36 2.68 -0.59
-0.35 2.60 -0.57
-0.34 2.53 -0.56
-0.33 2.45 -0.54
-0.32 2.38 -0.52
-0.31 2.32 -0.51
-0.30 2.26 -0.49
-0.29 2.19 -0.48
-0.28 2.13 -0.46
-0.27 2.07 -0.44
-0.26 2.01 -0.43
-0.25 1.96 -0.41
-0.24 1.90 -0.39
-0.23 1.85 -0.38
-0.22 1.80 -0.36
-0.21 1.75 -0.34
rho odds ratio st. mean diff
-0.20 1.71 -0.33
-0.19 1.66 -0.31
-0.18 1.62 -0.30
-0.17 1.57 -0.28
-0.16 1.53 -0.26
-0.15 1.49 -0.25
-0.14 1.45 -0.23
-0.13 1.41 -0.21
-0.12 1.37 -0.20
-0.11 1.34 -0.18
-0.10 1.30 -0.16
-0.09 1.27 -0.15
-0.08 1.24 -0.13
-0.07 1.20 -0.12
-0.06 1.17 -0.10
-0.05 1.14 -0.08
-0.04 1.11 -0.07
-0.03 1.08 -0.05
-0.02 1.05 -0.03
-0.01 1.02 -0.02
0.00 1.00 0.00
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Abstract
Background Cobalam in (Cbl) de fic iency is a com m on clin ical phenom enon, 
in particu lar am ong the elderly and possib ly also am ong infants. M ethylm alonic  
acid (MMA) is the most sensitive and specific  marker of in tracellu lar Cbl status, 
but its application is hindered by lim ited m ethods available fo r accurate and 
high th roughput MMA determ ination.
Method We developed a non-laborious m ethod fo r determ ination of MMA 
w ithou t the need fo r prior derivatization using HPLC com bined w ith liquid  
chrom atography electro spray ionization tandem  mass spectrom etry  
(LC-ESI-MS/MS). S table isotope-labeled m ethyl-d3-m alon ic acid (M MA-d3) 
was added to 100 jal of plasm a as an internal standard. A fter deprote in ization  
by ultra filtra tion, an acid ified aliquot of the eluate was in jected into the HPLC 
system  and analyzed by LC-ESI-MS/MS m onitoring of the carbonyl loss of 
MMA and M M A-d3.
Results C alibrations between 0.1 jumol and 1.0 jumol exhibited consistent 
linearity and reproducib ility . The lower lim it of detection fo r plasm a MMA was 
0.1 |amol (signal to noise ratio > 10). The intra- and inter-assay CVs of ten 
determ inations of a plasm a sam ple were 1.5% and 6.7%, respectively, at a 
mean concentra tion of 0.29 |amol/L. Inter- assay CVs of 25 determ inations of 
low, medium  and high concentra tions (0.22, 0.45 and 0.94 jumol/L MMA 
respectively) were 8.3%, 5.9% and 4.6%, respectively. The mean recovery of 
MMA added to plasm a was 100%.
Conclusion By avoiding derivatization, we developed a new, non-laborious, 
sim ple and reliable h igh-th roughput m ethod fo r th e  determ ination of M M Athat 
is su itab le  fo r autom ation.
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Introduction
Cobalam in (Cbl) is utilized as co factor in tw o reactions: as m ethylcobalam in in 
the hom ocyste ine rem ethylation to m ethionine by m ethionine synthase (ho- 
m ocyste ine-m ethylte trahydrofo la te  m ethyltransferase) and as adenosylcoba- 
lamin in the conversion of L-m ethylm alonylCoA to succinylC oA  by m ethylm al- 
onylC oA mutase (1). As a consequence, im paired Cbl status results in elevated  
plasm a tota l hom ocyste ine (tHcy) and m ethylm alonic acid (MMA) 
concentra tions, w hich make them  sensitive markers of in tracellu lar Cbl status  
(2-6). THcy is not a spec ific  marker fo r Cbl de fic iency since it is utilized in 
different m etabolic pathways and is influenced by a variety of environm ental 
factors such as Cbl, vitam in B6 or folate status, renal failure, age, sex, lifestyle, 
drugs and by genetic factors. Plasma MMA is influenced by renal failure or 
thyro id  disease only (7-9).
There are a num ber of advantages of determ ining MMA instead of plasm a Cbl. 
First, despite evidence of functiona l Cbl deficiency, plasm a Cbl concentra tions  
can be norm al. This is explained at least partly by the fact that approxim ately  
80% of to ta l plasm a Cbl is bound to haptocorrin, w hich is not taken up by the  
cells. The rem aining 20% of to ta l plasm a Cbl is bound to transcobalam in and 
th is com plex is responsib le fo r transport and cellu lar uptake of Cbl. Plasma  
Cbl m easurem ent shows the sum of both bound form s of Cbl and thus does 
not necessarily reflect in tracellu lar Cbl status (10). Therefore, the determ ination  
of holo transcobalam in rather than Cbl may be well more favorable. Second, 
Cbl is less stable, e.g., it is sensitive to  light, whereas MMA is very stable (11). 
Furtherm ore, plasm a MMA levels are several orders of m agnitude higher than  
Cbl concentra tions (jamol/l versus pm ol/l) and elevated concentra tions of MMA 
are easier to  detect than decreased Cbl concentra tions. A fourth argum ent 
favoring MMA determ ination is that plasm a MMA concentra tions can be used 
in fo llow -up m onitoring of in tracellu lar Cbl status during Cbl adm inistration  
w hich results in high plasm a Cbl.
Cbl de fic iency is a com m on clin ica l problem  in the elderly (12, 13). Recent 
studies suggest that Cbl defic iency is more com m on am ong neonates and 
infants than previously recognized w ith incidences as high as 15% (14-17).
As MMA appears to  be the most sensitive and spec ific  m arkerfo r Cbl defic iency  
and because determ ination of MMA is likely to  be requested in large 
populations, the aim of th is s tudy was to develop an easy, accurate and high- 
th roughpu t m ethod fo r plasm a MMA m easurement.
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Materials and Methods
Materials
M M A and m ethyl-tri-deuterated MMA (M M A-d3; purity  >95%) were purchased  
from  Fluka (Zw ijndrecht, the Netherlands) and C am bridge Isotope Laboratories  
(Apeldoorn, the Netherlands), respectively. Human ED TA-plasm afor recovery, 
precision and stab ility  studies was obta ined from  the blood bank of our 
institu tion. Plasma deprote in ization was perform ed by ultra filtra tion using 
M icrocon centrifuga l filte r tubes w ith a m olecular mass cuto ff value of 30 kD 
purchased from  M illipore (Amsterdam, the Netherlands). The HPLC colum n  
(2.1mm x 100mm 3.5 pm  Sym m etry C18 colum n) was purchased from  Waters 
(Etten-Leur, the Netherlands). Methanol and fo rm ic  acid were purchased from  
M erck (Amsterdam, the Netherlands).
Preparation of Standards
Standards of MMA and M M A-d3 were prepared in deionized w ater and kept at 
-2 0  °C. MMA in plasm a is stable at room tem perature fo r at least tw o days. 
MMA in deionized w ater can be kept at room tem perature fo r more than two  
weeks before any sign ifican t change becom es apparent (data not shown). It 
can be kept at minus 20° C fo r more than 10 years, based on the com parison  
of plasm a MMA determ ined w ith our new m ethod w ith results from  gas chro- 
m atography-m ass spectrom etry (GC-MS) analysis (see also the Results 
section).
Sample preparation
An aliquot of 100 jal of plasm a was p ipetted onto the M icrocon ultra filte r 
fo llow ed by 100 jal of 0.8 |amol/L M M A-d3 internal s tandard solution. A fter 
vortexing, the tube was centrifuged fo r 30 min at 14000 x g. Then 100 p i of the  
resulting ultra filtra te was acid ified w ith 10 jul of 4% fo rm ic  acid and 10 pi of the  
resulting sam ple was in jected into the liquid chrom atography electro spray  
ionization tandem  mass spectrom etry (LC-ESI-MS/MS) system.
Preparation of Calibrators
A liquots of 100 |il of MMA standards (0, 0.1, 0.2, 0.4, 0.6, and 1.0 pm ol/L) were 
p ipetted into E ppendorf cups (Eppendorf, Ham burg, Germany) fo llow ed by 
100 pi of 0.8 |amol/L M M A-d3 internal standard solution. A fter vortexing, a 100 
pi a liquot was acid ified w ith 10 jul of 4% fo rm ic  acid. A fter vortexing again, 10 
pi was injected into the LC-ESI- MS/MS system . The use of M icrocon centrifuge  
filte rs had no e ffect on MMA detector response, show ing no b inding of MMA 
by these filters.
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LC-ESI-MS/MS system
The LC-ESI-MS/MS system consisted of a M icrom ass Quattro LC (Waters) 
connected to  an Agilent HP1100 HPLC (Amsterdam, the Netherlands) and a 
Gilson 232 XL auto sam pler (Den Haag, the Netherlands). Using the auto 
sam pler 10 p i a liquots of prepared sam ples were in jected onto the colum n. 
The m obile phase consisted of 15% methanol / 0.4% form ic acid and elution  
was isocratic at a flow  rate of 200 p l/m in. The effluent was split, d irecting only  
40 p i into the tandem  MS. For routine d iagnostics and research, the HPLC 
colum n (Waters) lasted at least 800 injections.
A M icrom ass Q uattro LC (Waters) trip le -quadrupo le  tandem  mass spectrom eter 
was fitted  w ith an electro spray ionization probe operated in negative mode  
(figure 1). The capilla ry voltage was set to 3 kV and the cone voltage to 15V. 
N itrogen was used as the drying gas at a flow  rate of 250 L/h w ith ion b lock  
and source tem peratures of 80 °C and 150 °C, respectively. The co llis ion cell 
was operated at 9 eV at a pressure of 0.18 Pa Argon. The mass resolution of 
Q1 and Q3 quadrupoles is 1 Dalton. The tandem  MS was set to m onitor the  
carbonyl loss of MMA and M M A-d3 by recording the transition  of m/z 117 ->73 
and m/z 120->76, respectively. M asslynx 3.2 (M icrom ass; Manchester, UK) 
was used fo r HPLC and auto sam pler contro l, data acquisition and data  
processing. Q uantification was based on peak areas. Total in jection-to- 
in jection tim e was 5 m inutes.
Figure 1 Overview LC Tandem mass spectrom eter
Prefilter Postfilter Dynode
Z-spray 
Ion source
Hexapole Quadrupole Hexapole 
ion bridge MS1 collision
Quadrupole
MS2
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Normal values
We determ ined plasm a MMA concentra tions in 100 healthy individuals from  a 
general p ractitioners practice  (18). We used SPSS softw are (version 12.2; 
Gorinchem , the Netherlands) fo r sta tistica l analysis and M icrosoft Excel for 
constructing  graphs.
Results
The chromatographic profile
Figure 2 shows a typ ica l chrom atogram  for a contro l and a patient w ith Cbl 
deficiency. The deuterated and the naturally occurring  MMA co-elute from  the  
c o lu m n a t2 .5 m in  w ith a peak w id th  of <0 .20  min. In the ESI source, conditions  
fo r MMA and its deuterated analogue w ill therefore be sim ilar w ith in  one 
sam ple, w hich is im portant in term s of possib le ion suppression. Under the  
MS/MS cond itions used, the physio log ica lly  abundant isom er succ in ic  acid 
w ill also be detected. However, its retention tim e is 1.9 m inutes and therefore  
it is e ffic iently separated from  MMA. We have not observed any interference  
effect by succ in ic  acid on the MMA results in more than 4000 samples.
Calibration, Linearity, Recovery, Intra- and Inter-assay CV 
and Detection Limit
To evaluate the linearity and recovery of MMA, standards of 0, 5, 10, 20, 50, 
100 and 200 pm ol/L  were dilu ted 100-fold w ith deionized w ater or human  
plasm a by adding 4 0 pi of s tandard to 4 ml of deionized w ater or 10pl standard  
to  1 ml of plasm a. There was excellent linearity up to  at least 2 pm ol/L  MMA 
both in w ater and in plasm a (coeffic ient of corre lation >0.999 in linear 
regression analysis). The slopes of the calibration lines in the tw o m atrices  
were equal (water: 1.006 + 0.004; plasma: 1.039 + 0.009). Analysis of 25 
ca libra tor curves in a 12-month period resulted in mean + SD slope and 
in tercept of 0.993 + 0.031 and 0.001 + 0.009, respectively. The recovery of 
MMA added to plasm a sam ples am ounted to 98-101% in the concentra tion  
range up to 2 pm ol/L . Adequate recovery is also confirm ed by the sim ilar 
slopes of the corre la tion lines in water and plasm a matrices.
A plasm a pool w ith a mean MMA content of about 0.29 pm ol/L  was processed  
resulting in a 1-day mean (n=10) of 0.292 and a overall (4-m onth period) mean 
(n = 10) of 0.278 pm ol/L  w ith intra- and inter-assay CVs of 1.5 and 6.7%, 
respectively. Inter-assay CVs were fu rther evaluated by 25 determ inations over 
25 different days of three d ifferent plasm a sam ples conta in ing low, medium  or 
high plasm a MMA concentra tion of 0.22, 0.45 and 0.94 pm ol/L  MMA,
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Figure 2 LC-MS/MS Chromatograms using MRM ES 116.8>72.9 for MMA 
and MRM ES: 119.8>75.9 for MMA-d3
Time (min)
Time (min)
A. control subject (plasma MMA = 0.18 /jm o l/l)
B. patient w ith a cobalam in deficiency (plasma MMA = 0.54 /jm o l/l)
C. MMA-d, standard.
The retention time of MMA and MMA-d, is 2.5 min and that of the isomer succinic acid is 1.9 min
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respectively. This resulted in inter-assay CVs of 8.3%, 5.9% and 4.6%, 
respectively. The lower lim it of detection fo r plasm a MMA was 0.1 |amol/L 
(signal to noise ratio > 10).
Ion suppression was also investigated by continuous infusion of eluent 
conta in ing 14 pm ol/L  MMA, w hich was possib le because MMA and M M A-d3 
have the same retention time. In jection of processed plasm a or w ater sam ples  
showed no ion suppression in the testing phase. When large series of plasm a  
sam ples (>500) were analyzed using the same HPLC colum n, we observed  
fluctua tions of the internal standard M M A-d3 in general between 75% and 
125%, but in som e series even more, but never <50% . This indicates likely ion 
suppression of substances slow ly eluting from  the colum n. Our standard  
curves were not in fluenced by th is probable ion suppression (data not shown), 
dem onstra ting the same effect of proposed ion suppression on MMA as well 
as M M A-d3.
Comparison with GC-MS method
Until the developm ent of the m ethod described here, a GC-MS m ethod (13, 19) 
was em ployed fo r the determ ination of MMA in plasm a in our laboratory. To 
verify if our new LC-ESI-MS/MS m ethod shows good corre lation w ith this  
existing GC-MS m ethod, the GC-MS quality  contro l, a plasm a pool w ith a 
mean MMA content of 0.29 |amol/L and w e ll-estab lished upper and lower lim its 
of 0.33 and 0.25 |amol/L, respectively, was tested using the LC-ESI-MS/MS  
m ethod. Results show  a 1-day mean (n=10) of 0.292 pm ol/L  and an overall (2 
years, n=25) mean of 0.275 |amol/L, w ith intra- and inter-assay CVs of 1.5 and 
5.3%, respectively. In addition, we used the LC-ESI-MS/MS m ethod to test 
plasm a sam ples from  29 ind iv idua ls fo r w hom  the plasm a MMA concentra tions  
had already been determ ined by GC-MS. C om parison of the results by means 
of a Bland Altm an plot showed a mean d ifference of 0.012 pm ol/L  (figure 3).
Normal values
A tota l of 100 subjects (42 male, 58 female) were random ly selected from  a 
large study group (18). Median age was 53.7 years (range 21.8-78.4 years). 
Since the d istribution of MMA concentra tions was skewed, we calculated the  
logarithm ica lly  transform ed MMA concentra tions (InMMA) and geom etric  
means where appropriate. The geom etric mean (GM) fo r MMA was 0.185 
nm ol/l (range 0.09-0.76 jamol/l) w ith 10th and 90th percentile of 0.12 and 0.29 
jamol/l, respectively. We observed a s ign ifican t corre la tion fo r InMMA versus  
InCbl only (rho = -0.244, p =  0.014). Neither age nor creatin ine was sign ifican tly  
corre lated w ith plasm a MMA concentra tions. The GM for MMA was 0.18 jamol/l 
fo r males and 0.19 jamol/l fo r fem ales (not s ign ifican tly  different).
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Figure 3 Correlation of LC-Tandem Mass MS with GC-MS
0 . 1 0 0 1
0.080 ■
0.060 •
0.040 •
’ 0.020  ■
0.000 ■
- 0.020  ■
-0.040 ■
-0.060 ■
-0.080 ■
0.
+2SD = 0.063
MEAN = 0.012
♦  -2SD = -0.040
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
Average MMA (|iM )
The correlation of LC-MS/MS and GC-MS (n = 29) is depicted in a Bland Altman plot showing a 
mean difference of 0.012 /jm ol/L.
Discussion
We consider plasm a MMA to be the m ost spec ific  and sensitive marker of Cbl 
defic iency and therefore developed a new, non-laborious and effective  
M ethod fo r MMA determ ination. To achieve a suitab le  m ethod, MMA had to be 
separated by HPLC from  its isom er succ in ic  acid before MS/MS detection. 
The feasib ility  and characteristics of d icarboxy lic  acid determ ination using 
MS-MS has been described previously (20). D ifferent analytica l techniques  
includ ing HPLC, MS-MS, stable isotope d ilu tion gas chrom atography mass 
spectrom etry  and capilla ry e lectrophoresis have been developed fo r the  
determ ination of plasm a MMA in the norm al range (19, 21-25). Most, if not all, 
HPLC m ethods include extraction into o rgan icso lven tfo llow ed  by derivatization  
prior to HPLC in jection (22). Mills et al describe an HPLC-MS m ethod suitable  
only fo r detection of very high concentra tions of accum ulated MMA due to a
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classical inborn error of Cbl m etabolism  (21). Analysis of GC-MS has probably  
been applied m ost often but, a lthough considered a reliable m ethod, some  
authors report a large in ter-laboratory difference. Furtherm ore, a relatively low  
th rough-pu t (3-6 sam ples per hour) is reached (24).
Magera et al described a LC-MS/MS m ethod fo r the determ ination of MMA as 
the n-butyl ester derivative in plasm a and urine (26). A lthough the analysis  
tim e was faster than conventional GC-MS m ethods, tim e- consum ing and 
laborious sam ple preparation is still involved. Kushnir et al developed an 
LC-MS/MS m ethod w ith high se lectiv ity  fo r d icarboxy lic  acids and the ab ility  to 
differentia te  MMA from  its isom er succ in ic  acid (23). Again, derivatization was 
applied. Very recently, Schm edes et al developed a LC-MS/MS m ethod that 
also requires derivatization and a overnight incubation (27). The h igh-through- 
put cap illa ry e lectrophoresis m ethod described by Schneede et al also 
requires derivatization (25). Our new m ethod does not require derivatization  
owing to  the optim al use of the sensitiv ity  and spec ific ity  of LC-MS/MS and 
because succinate can be e ffic ien tly  separated from  MMA on the C18 colum n  
. Sample preparation is extrem ely sim ple and is lim ited to addition of the  
internal s tandard fo llow ed by centrifugation and in jection, allow ing autom ation  
of th is method.
A possib le pitfa ll in determ ining MMA by MS/MS m ethods is the presence of 
its isom er succin ic  acid in a concentra tion higher than that fo r MMA. Like MMA 
succ in ic  acid looses a carbonyl m oiety in the co llis ion cell underthe  conditions  
used, resulting in a fragm ent w ith the same m/z as MMA. We applied HPLC on 
a C18 colum n to separate MMA from  succin ic  acid w ith a m obile phase of 15% 
m ethanol/0.4%  form ic acid, resulting in a reliable d ifference in retention time  
of 0.7 min.
A technica l consideration is the potentia l occurrence of ion suppression (28). 
As MMA and its deuterated analogue co-elute in th is m ethod, cond itions in the  
ESI system are the same w ith in the same sam ple. Any ion suppression that 
occurs is therefore likely to affect both com pounds equally, and the deuterated  
MMA internal s tandard thus autom atically  com pensates fo r this effect. Ion 
suppression, w hich was indeed observed, may vary between sam ples due to 
matrix effects. If we assume the area fo r the internal s tandard in water to be 
100%, this area varied considerab ly in a series of 29 plasm a sam ples (range 
53%-189%). In th is same series of sam ples the corre lation between the current 
m ethod and the independent GC-MS m ethod was excellent. Thus, our data  
show  that the deuterated internal standard is suitable fo r correction of the  
resulting MMA concentra tion fo r this effect of variable ion suppression. In a 
larger series of over 4000 plasm a sam ples measured w ith this new method, 
the area under the curve fo r the deuterated standard never was lower than
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50%. In cases fo r w hich th is area > 50% because of the specific  sam ple matrix, 
the MMA concentra tion cannot be determ ined reliably using th is m ethod to  
our opinion.
In sum m ary, we have validated the m ethod by confirm ing its linearity and by 
obta in ing acceptable  intra- and inter-assay CVs and full recovery of MMA 
spikes. The m ethod showed excellent corre lation w ith an independent GC-MS  
method and the reference values obta ined fo r plasm a are in line w ith literature  
data (13, 29).
Conclusions
We developed a new, non-laborious and reliable m ethod fo r determ ination of 
MMA that does not require any derivatization. C entrifugation after addition of 
the internal s tandard is the only step required prior to  LC-MS/MS injection, 
resulting in reliable and qu ickly available results suited fo r autom ation and 
h igh-throughput.
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Abstract
Background: Plasma m ethylm alonic acid (MMA) is a spec ific  marker for 
functiona l cobalam in deficiency. This de fic iency can give rise to  non-specific  
but serious sym ptom s in ch ildhood such as developm ental delay, convulsions  
and failure to thrive and may even lead to irreversible neurological damage. 
Our aim was to analyze plasm a MMA concentra tions in Dutch children and to  
evaluate possible factors in fluencing its concentration.
Methods: A num ber of 186 Dutch children aged 0-19 years were analyzed  
cross-sectionally. B lood was co llected to measure MMA, tota l hom ocyste ine  
(tHcy), cobalam in (Cbl) and serum creatin ine concentra tions. In addition, 
inform ation about m edical history, age and sex was recorded.
Results: Median age was 11.3 years. The geom etric mean (GM) plasm a MMA 
concentra tion was 0.17pm ol/l [95% Cl 0.07;0.42] and the GM tH cy w as6 .6 p m o l/l 
[95% Cl 3.1;13.9], There is a s light positive corre la tion between plasm a MMA 
and age in children > 1 year (r= 0.21, P<0.05). Plasma MMA concentra tions  
were s ign ifican tly  higher in children w ith low Cbl concentra tions. No s ign ificant 
difference in MMA, Cbl, tH cy or creatin ine concentra tions between sexes 
could be observed. Regression analysis showed that Cbl was the strongest 
determ inant of plasm a MMA (regression coeffic ien t -0.41, P<0.05). The 
association between MMA and Cbl is stronger at increasing age (P fo r trend  
0.045).
Conclusions: Plasma Cbl is the main determ inant of MMA in th is group of 
Dutch children. The strength of the association increased with increasing age.
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Introduction
In mam m alians, cobalam in (Cbl) is a co factor fo r only tw o known enzymes: i.e. 
fo r m ethionine synthase in the rem ethylation of hom ocysteine to m ethionine as 
m ethylcobalam in (meCbl) and fo r m ethylm alonylC oA m utase in the form ation  
of succinylC oA  from  L-m ethylm alonylCoA as adenosylcobalam in (adoCbl) 
(1). Consequently, an in tracellu lar Cbl defic iency may cause increased  
concentra tions of to ta l plasm a hom ocyste ine (tHcy) and m ethylm alonic acid 
(MMA), w hich make them  m etabolic m arkers of Cbl deficiency. Cbl values in 
serum  or plasm a can be norm al despite evidence fo r functiona l defic iency (2- 
4). This is at least partly explained by the fact that about 80% of to ta l plasm a Cbl 
is bound to haptocorrin , w hich is not taken up by the cells. The rem aining 20% 
of tota l plasm a Cbl is bound to transcobalam in and th is com plex is involved 
in transport and u ltim ately cellu lar uptake of Cbl. P lasma Cbl measurem ent 
shows the sum of both form s of Cbl and does not necessarily reflect the  
availability fo r cellu lar processes (4).
THcy is in fluenced by many environ mental factors such as fo late and cobalam in  
status, renal or thyro id  function, age, sex, lifestyle factors such as sm oking, 
coffee intake and several drugs as well as genetic factors including the MTHFR 
c.677 C>T po lym orphism  (5-9). P lasma MMA is in addition to  Cbl status only  
m odulated by severe renal fa ilure and is therefore a more spec ific  marker of 
Cbl de fic iency (10-12).
In recent studies evidence was obta ined that Cbl defic iency is a relatively  
com m on find ing in infants and children (13-15). Cbl de fic iency in ch ildhood  
is not characterized by the classical sym ptom s of m egalob lastic anem ia and 
neurological dysfunction as observed in adults, but can give rise to  non­
spec ific  sym ptom s such as developm ental delay, feeding problem s and 
fa ilure to thrive (13, 16-19). There is increasing evidence that Cbl de fic iency in 
childhood may cause im pairm ent of grow th and developm ent and may even 
lead to irreversible neurological dam age (20-22).
Data on plasm a MMA concentra tions and its determ inants in children aged 
0-19 years are scarce. In a study perform ed by Bjorke Monsen et al infants 
aged 6 weeks to 6 m onths had concentra tions of MMA and tH cy that were  
higher and serum  Cbl concentra tions that were lower than in o lder ch ild ren (13). 
In children above 12 m onths of age, median plasm a MMA rem ained low and 
stable, also during puberty. Sex d ifferences could not be observed. A strong  
corre lation between Cbl and MMA and tH cy and MMA was found in both age 
groups (16). Specker et al reported m arkedly higher urinary MMA excretion  
in 62 infants com pared to adults w ith the highest MMA excretion in breastfed  
infants of vegetarian m others (15).
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Because data on plasm a MMA concentra tions and pred ictors are scarce and 
in the light of the suggested high prevalence of Cbl de fic iency in children, 
we analyzed plasm a MMA concentra tions in a group of Dutch children and 
evaluated possible determ inants. These data are relevant to explore the  
prevalence of Cbl de fic iency am ong infants and children and to evaluate long­
term  effects of Cbl deficiency.
Subjects and methods
MMA was m easured in 186 healthy Dutch children. B lood sam ples were  
co llected in 1997 as described before (23). In short, o lder children (11-19years) 
were recruited as healthy volunteers, whereas younger children (< 11 years) 
were recruited in a hospital setting. When blood was drawn fo r d iagnostic  
or fo llow -up reasons, children and/or the ir parents were asked to donate  
som e blood in the same venipuncture  session. Exclusion criteria  were closure  
defects, overt renal, thyro id  and/or liver dysfunction, use of fo late antagonists, 
m alignancies, horm onal therapy and ob jective ly defined occlusive vascular 
disease. Inform ation about m edical history, sm oking behavior and puberty  
features was obta ined from  m edical records or by questionnaire. The study  
was approved by the local m edical ethics com m ittee and inform ed consent 
was obtained from  parents and/or children depending on the ir age.
Blood sam ples were drawn by venipuncture. Three ml EDTA vacutainers  
were used fo r the co llection of plasm a fo r tH cy and MMA measurem ent. In 
new borns and infants, 1 ml EDTA m icrota iners obta ined from  capillary blood  
sam ples were used. The EDTA sam ples were im m ediately placed on ice and 
centrifuged at 2000xg fo r 10 m inutes w ithin 4 h. The plasm a was separated  
and stored at -2 0  °C until analysis. If possible, b lood was drawn into 5 ml 
heparin conta in ing vacuta iners fo r analysis of cobalam in and creatinine.
THcy concentra tions were determ ined in EDTA plasm a by an autom ated high- 
perform ance liquid chrom atography m ethod w ith reverse-phase separation  
and fluorescent detection (Gilson 232-401 sam ple processor, S pectra Physics 
8800 solvent delivery system and Spectra Physics LC 304 fluorom eter) as 
described by Fiskerstrand et al (24) w ith som e m odifications (25). Plasma 
MMA was determ ined by a new LC/MS-MS m ethod as described by us (26). 
After deprote in ization by ultra filtra tion, an acid ified aliquot of the eluate was 
in jected into the HPLC system  and analyzed by LC-ESI-MS/MS m onitoring of 
the carbonyl loss of MMA and M M A-d3. C alibrations between 0.1 pm ol and 
1.0 jumol exhibited consistent linearity and reproducib ility . The lower lim it of 
detection fo r plasm a MMA was 0.1 |amol (signal to noise ratio >10). The intra-
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and interassay CVs of ten determ inations of a plasm a sam ple were 1.5% and 
6.7%, respectively, at a mean concentra tion of 0.29 |amol/L. Inter-assay CVs of 
25 determ inations of low, medium  and high concentra tions (0.22, 0.45 and 0.94  
pm ol/L  MMA respectively) were 8.3%, 5.9% and 4.6%, respectively. The mean 
recovery of MMA added to plasm a was 100%. Plasma Cbl was determ ined  
by using D ualcount Solid Phase Boil Radioasssay (D iagnostic Products, Los 
Angeles, CA, USA).
S tatistica l analysis was perform ed using SPSS-software package (version 
12.0.1). The d is tribu tions of MMA and Cbl were skewed, so logarithm ic  
transform ations were applied to  norm alize these d istributions. Inverse 
transform ations were com puted to describe geom etric means and 95%  
confidence intervals. D ifferences between tw o groups were tested by t test 
analyses where appropriate. We used a m ultivariate linear regression m odel to 
study the sim ultaneous influence of variables on plasm a MMA concentra tion  
and to observe possib le in teractions between individual determ inants. 
Plasma MMA was the dependent variable, and age, creatin ine and Cbl were  
the independent variables. The beta-coeffic ien t expresses the change in 
logarithm ica lly  transform ed plasm a MMA that is related to a one unit change  
in logarithm ica lly  transform ed plasm a Cbl or creatin ine (a 1% change in the x 
variable correlates w ith a beta% change in the y variable). Possible interaction  
between the variables was stud ied by adding interaction term s into the model. 
All sta tistica l analyses were perform ed in children >1 year.
Results
Study population
A total num ber of 186 children were evaluated in th is s tudy (92 boys, 94 girls). 
The median age of th is group was 11.3years (range 0.01-19.3). The d istribution  
of plasm a MMA was skewed to the right in th is population of healthy Dutch 
children. The concentra tions of the variables measured (MMA, tHcy, Cbl, 
creatinine) are sum m arized in table I. None of the children used m edication  
possib ly in terfering w ith the studied variables. Pubertal features (m enstruation  
and/or axillary hair growth) were present in 54 children aged 10-19 years. No 
sign ifican t d ifference in MMA, Cbl, tH cy or creatin ine concentra tions was 
found between children w ith or w ithou t these features. Six children sm oked. 
This subgroup was too  small to  study d ifferences between sm oking and non­
sm oking children. In the w hole s tudy population, no sign ifican t differences  
in MMA, Cbl, tH cy or creatin ine concentra tions between sexes could be 
observed.
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In an attem pt to delineate possib le age dependency of the b iochem ical variables  
we calculated geom etric means of MMA, Cbl, tH cy and creatin ine in d ifferent 
age categories (figure 1 a-d). In children >1 year, GM Cbl concentra tions  
decreased w hereas tH cy and creatin ine concentra tions increased w ith  
increasing age. There were positive corre la tions between logarithm ica lly  
transform ed MMA, tH cy and creatin ine and age (r=0.21, r=0.63, r=0.68, 
p<0.05  respectively). Cbl corre lated negatively w ith age (r= -0.53, p<0.05). 
Associa tions between MMA and Cbl and between tH cy and Cbl are nearly the  
same (r=-0.35, p<0.001 and r=-0.41, p<0.001, respectively). No corre lation  
between MMA and creatin ine was found (r= 0.07, p=0.377).
C hildren w ith plasm a Cbl concentra tions below 250 pm ol/l (25th percentile) 
showed s ign ifican tly  higher mean plasm a MMA concentra tion com pared to  
those w ith higher plasm a Cbl concentra tions (GM plasm a MMA 0.18 pm ol/L  
versus 0.25 pm ol/L , respectively, p=0.001). Children w ith Cbl concentra tions  
below  and above 200 pm ol/L (10th percentile) also showed sign ifican t different 
GM MMA of 0.25 and 0.17 pm ol/L , respectively (p = 0.003).
Table I Concentrations of MMA, tHcy, Cbl and creatinine in 186 Dutch children
number GM 95%CI 10th 25th 50th 75th 90th
MMA 186 0.17 0.07-0.42 0.11 0.13 0.17 0.23 0.30
tHcy 184 6.6 3.1-13.9 3.8 5.6 6.9 8.3 10.0
Cbl 161 339 139-824 200 250 330 455 592
creat 151 65 39-111 46 59 67 78 87
G M =geom etric mean. 95%CI = 95% confidence intervals. MMA = methylmalonic acid (/jmol/L). 
tHcy = total homocysteine (/jmol/L). Cbl = cobalamin (pmol/L). Creat = creatinine (/jmol/L).
Multiple linear regression
M ultip le linear regression analysis was perform ed to elucidate the main 
predictors of plasm a MMA. In this analysis, Cbl was found to be the strongest 
determ inant of plasm a MMA; a 1% decrease in logarithm ica lly  transform ed  
plasm a Cbl resulted in a 0.41% increase in logarithm ica lly  transform ed plasm a  
MMA. The regression coeffic ien t fo r the association between Cbl and MMA  
corrected fo r age and creatin ine was -0 .4 3  (pcO.OOOl). Cbl alone explained  
12% of the variance in plasm a MMA concentra tions. When Cbl, age, sex and
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creatin ine were added to the model, Cbl explained 19 %, whereas the other 
factors each explained less than 0.1%.
Interaction between age and Cbl was stud ied by adding an interaction term  
age x Cbl to a linear regression model describ ing the continuous relationship  
between plasm a MMA and Cbl w ith increasing age (p=0.032). Because we 
observed a s ign ifican t in teraction between Cbl and age we calculated beta- 
coeffic ien ts fo r the re lationship between MMA and Cbl stratified to age (Table
II). We observed negative relationships between plasm a MMA and Cbl fo r all 
age groups who becom e stronger w ith increasing age (p fo r trend 0.045 in 
children > 1 year of age).
Figure 1 Geometric mean concentrations of plasma MMA (a), serum Cbl 
(b), plasma tHcy (c) and creatinine (d) amongst different age 
groups
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Characters indicate s ignificant differences between age categories (P < 0.05). Character a 
symbolizes a significant d ifference with geom etric mean of children aged 1-5 years; character b 
with children aged 5-10 years; character c symbolizes a signifcant different geom etric mean 
from age category 10-15 years; and character d from children above 15 years of age.
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Figure 1 Continued 
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Characters indicate significant differences between age categories (P < 0.05). Character a 
symbolizes a s ignificant difference with geom etric mean of children aged 1 -5 years; character b 
with children aged 5-10 years; character c symbolizes a s ignifcant different geom etric mean 
from age category 10-15 years; and character d from children above 15 years of age.
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Figure 1 Continued
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Characters indicate significant differences between age categories (P < 0.05). Character a 
symbolizes a s ignificant difference w ith geom etric mean of children aged 1-5 years; character b 
with children aged 5-10 years; character c symbolizes a signifcant different geom etric mean 
from age category 10-15 years; and character d from children above 15 years of age.
Table II Linear regression model for plasma MMA stratified for age
1-5 y 5-10 y 10-15 y >15 y
Cbl -0.04 [-0.5;0.4] -0.35[-0.7;-0.03]* -0.34[-0.6;-0.06]* -0.64[-0.99;-0.3]
Cbl, creat O o IV) -0.7;0.8] -0.33[-0.7;0.006]* -0.35[-0.6;-0.07]* -0.64[-0.99;-0.3]
Number 21 37 54 44
Linear regression model for plasma MMA versus plasma Cbl stratified for different age 
groups. Data for MMA and Cbl were log transformed because of skewed distribution. Results 
are expressed as p-coeffic ients with 95% confidence intervals in parenthesis ([95%CI]). The 
P-coefficient represents the percentage of change in logarithm ically transform ed plasma MMA 
fo llow ing a one-unit change in logarithm ically transformed Cbl. M M A=m ethylm alonic acid. Cbl 
= cobalamin. creat=creatinine. y=  year. * = P value < 0.05.
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Discussion
Both MMA and tH cy are m etabolic markers of an in trace llu lar Cbl deficiency. 
Because tH cy is in fluenced by many factors, especially fo late status and 
kidney function, MMA is considered to be more sensitive and specific  (10,
12). In view of the high prevalence of Cbl de fic iency among the elderly and 
the m ounting evidence of a high prevalence of Cbl defic iency in infants and 
children, extensive know ledge on plasm a MMA concentra tions in the normal 
popula tion and factors that influence this concentra tion is warranted (2, 14,
15, 27).
We evaluated plasm a MMA concentra tions in a cohort of Dutch children and 
stud ied possib le determ inants of p lasm a MMA. Regression analysis showed 
that Cbl was the main determ inant of p lasm a MMA concentra tions. The strength 
of the negative association between plasm a MMA and Cbl becom es stronger 
w ith increasing age. Plasma MMA levels were s ign ifican tly  d ifferent between 
children w ith normal and low Cbl concentra tions. No gender d ifference was 
found fo r MMA, Cbl, tH cy or creatin ine fo r the w hole group. There were 
positive associations between plasm a MMA, tH cy and creatin ine w ith age in 
the children older than one year.
We observed a skewed MMA d istribu tion  in our population of Dutch children. 
GM MMA concentra tions were highest in infancy. This is in line w ith the results 
from  Bjorke Monsen et al who observed the highest MMA concentra tions in 
children aged 6 weeks to 6 m onths in 173 newborns (13). In the ir study, MMA 
concentra tions strong ly corre lated w ith Cbl, show ing low median Cbl and high 
median MMA in infants during the firs t six months (13). This contrasts w ith 
our data that show the highest MMA concentra tions, but also the h ighest Cbl 
concentra tions in the youngest children. Since we only have a very lim ited 
num ber of ch ildren in th is age category w ith both variables known (n=5), these 
data should be interpreted cautiously. The higher plasm a MMA concentra tions 
in infancy could also be caused by im m aturity of liver and kidney function, 
prop ionate production by gut bacteria or other, yet unknown factors (28-30). 
C lassic cobalam in de fic iency is a disease most often observed in the elderly and 
w hich usually presents w ith m egalob lastic  anem ia and/or neuropathy. There 
is no defin ite  cu t-o ff value defined fo r low Cbl levels but in general, patients 
w ith Cbl concentra tions less than 120-200 pm ol/L are considered deficient. 
Several authors have em phasized the im portance of markers of Cbl status 
like plasm a MMA since a functiona l Cbl de fic iency (= decreased intracellu lar 
availability) can exist in spite of normal or low-norm al Cbl concentra tions (1-4). 
The im portance of an adequate Cbl status in infancy and ch ildhood is more 
and more recognized (10-13, 15, 17, 19, 20, 22, 31) as well as the possib le
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clin ica l sequelae of functiona l Cbl de fic iency that may have a m ajor im pact on 
ch ild ren ’s health in the general population.
Im paired Cbl status in infancy and ch ildhood can cause a variety of com m on 
and non-specific  sym ptom s such as fa ilure to thrive, developm ental delay or 
arrest, convuls ions and may even lead to irreversible neuro log ica l sequelae 
(13, 16, 18, 20-22, 27). No hem atological sym ptom s need to be present. Ten to 
15% of apparently healthy infants from  om nivorous mothers, showed increased 
plasm a and/or urinary MMA concentra tions in studies perform ed by Bjorke 
Monsen, Minet and Specker [(13-15). In most infants th is increased plasma 
MMA concentra tion is accom panied by an increase in tH cy concentra tions and/ 
or decrease in Cbl concentra tions reflecting most p robably not an immature 
system but a true functiona l Cbl defic iency. Our observation that ch ildren w ith 
elevated MMA also have decreased Cbl supports  th is theory.
This high proportion  of suspected Cbl de fic iency in infants is an alarm ing 
observation considering the role of Cbl in the developm ent of the central 
nervous system. Irreversible neuro log ica l sequelae have been described (18, 
22). Causes of functiona l Cbl defic iency in infants and children are, am ongst 
others, decreased intrauterine storage (placental d isorders, low Cbl status 
of the pregnant woman), postnatal decreased d ie tary intake (vegetarian or 
m acrob io tic  diet, breastfed infants of Cbl defic ient women) and absorption 
problem s (3, 13, 32, 33).
We observed a s ign ifican t d ifference in GM MMA between the 1-5 years old 
and the children above 15 years as well as a slight positive corre la tion between 
MMA and age, w hich contrast w ith the observations of Bjorke Monsen et al who 
found no effect of age on median plasm a MMA values in children above 1 year 
of age (16, 27), a lthough a decline in Cbl levels was found. The relationship 
between Cbl w ith age in children has been described before (16, 23, 34).
As expected, plasm a MMA and Cbl were strong ly inversely correlated, 
confirm ing data from  literature (16, 27). The strength of the negative association 
increased w ith increasing age. As antic ipated, it appeared that the association 
between MMA and Cbl is the strongest in the lowest Cbl concentrations.
To summ arize, we studied plasm a MMA concentra tions in a cohort of Dutch 
children. In the youngest age group (<1 year), p lasm a MMA values show the 
greatest variation and highest values. Plasma Cbl is the main determ inant of 
MMA in th is Dutch study group, especia lly in those indiv iduals > 1 year of age. 
The strongest corre lation exists in the e ldest age group (> 15 years of age). 
There is a s ligh t increase w ith age in the children o lder than one year of age. 
We suggest th ink ing  of functiona l Cbl de fic iency at a w ide range of clin ica l 
sym ptom s in infants and children. Plasma MMA should be the main marker for 
fu rthe r evaluation.
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Abstract
Background Fetal nutrient deprivation and low birth w eight are associated 
w ith increased m orb id ity  and m orta lity  fo r the newborn but also w ith increased 
risk on chron ic diseases in adulthood. Choline has an essential role in the 
in tegrity  of cell mem branes, in m ethylation reactions and in m em ory 
developm ent. We exam ined w hether um bilica l or maternal choline and related 
m ethylam ines betaine and d im ethylg lycine concentra tions were associated 
w ith infant birth w eight in Dutch women.
Methods Blood was sam pled from  um bilica l cords at delivery (n = 1126). From 
the m others v is iting the hospita l during pregnancy, blood was sam pled at 
30-34 weeks of gestational age (n=366). We calculated birth weights 
standardized (SBW) fo r gestational age and defined low birth w eight as SBW 
< 2500 grams.
Results Maternal p lasm a concentra tions of all analytes were lower com pared 
to um bilica l cord plasm a concentra tions. Plasma betaine, d im ethylg lyc ine and 
creatin ine concentra tions between m others and newborns were strong ly 
corre lated. Maternal analytes were no determ inant of b irth w eight. Linear 
regression analyses showed that higher um bilica l cord plasm a choline and 
betaine concentra tions were associated w ith lower birth  w eight ((3= -60[-89;-31] 
and (3= -65[-94;-36] respectively). Furthermore, the O dds ratio fo r having a 
low birth w eight baby was 4.12 [1.15; 14.78] and 5.68 [1.24;25.91] fo r the highest 
plasm a um bilica l choline and betaine quartile  respective ly com pared to the 
lowest quartiles.
Conclusion We observed an increased risk of lower birth w eight w ith increased 
um bilica l p lasm a choline and betaine concentra tions in venous um bilica l cord 
blood. These results m ight reflect a change in choline consum ption or 
m etabolism  in fetal as well as placental tissue or a d isturbed placental 
function.
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Introduction
Low birth  w eight poses the newborn at increased risk fo r m orb id ity  and 
m orta lity  (1, 2). Low birth w eight also relates to increased risk fo r chronic 
disease in adu lthood like hypertension, coronary heart disease, stroke and 
diabetes (3) underlin ing the im portance of revealing possib le and especially 
treatable risk factors fo r low birth weight.
Choline is an essential nutrient and is involved in several m etabolic processes 
includ ing lip id m etabolism , m ethylation reactions and synthesis of ace tylcho line 
and plays a role in structura l in tegrity  and signa ling functions of cell mem branes, 
brain developm ent and neurotransm ission (Figure 1) (4-9).
Choline is c ritica l fo r the rapid ly grow ing fetus (8, 10, 11). In utero, the fetus 
lives in a high choline environm ent due to a system active ly transporting  
choline against a concentra tion gradient across the placenta to the fetus 
(12-16). Variation in maternal choline status could possib ly influence fetal 
outcom e through d isturbances in cell mem brane synthesis, increase in 
hom ocyste ine concentra tions and/or perturbation of m ethylation reactions 
and changes in acetylcho line production. Choline also influences stem cell 
pro liferation, apoptosis in the brain and the developing h ippocam pus (memory 
center) in rodents (17). Maternal choline supp lem entation in rats during critica l 
periods in pregnancy causes life long changes in brain s tructure (18). Also, 
perinatal choline supp lem entation attenuates behavioral a lterations associated 
w ith fetal or neonatal a lcohol exposure in rats (19, 20). Human m ilk conta ins 
high am ounts of choline, and lactation is thus fu rther increasing maternal 
choline dem and (11, 21).
C linically, low maternal choline concentra tions or intake relate to neural tube 
defects (22, 23). Accum ulation of choline in the fetal c ircu la tion has been 
observed by several authors (14, 24-26). The placenta itself is a major site for 
choline consum ption and m etabolism  (12, 13, 27). Given these facts, fetal 
choline concentra tions could be a better reflection of fetal and placental 
choline d is tribu tion  and m etabolism  than maternal choline concentrations. 
Since choline is essential fo r the developing and rapid ly grow ing fetus, we 
investigated the relation between umbilical and maternal choline concentrations, 
betaine and d im ethylg lyc ine and birth weight.
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Figure 1 Choline metabolism
glycine
Î
sarcosine
Acetylcholine
Oxidation: Choline is oxidized to betaine aldehyde which is then converted to betaine in two 
steps catalyzed by choline dehydrogenase (ChD) and betaine aldehyde dehydrogenase (BAD) 
respectively. Betaine can be used as m ethyldonor in a remethylation reaction from homocysteine 
to methionine catalyzed by betaine homocysteine methyltransferase (BHMT). This reaction 
generated dim ethylglycine (DMG). Methionine is the precursor of S -adenosylm ethionine (SAM), 
which serves a methyldonor for numerous physio logical reactions resulting in the formation of 
S -adenosylhomocysteine (SAH).
Phosphorylation: Choline can also be phosphorylated: choline kinase (ChK) catalyses the 
reaction in which choline is phosphorylated to phosphocholine with adenosine triphosphate as 
phosphate donor. The next step is the formation o f cytid ine d iphosphate-choline (CDP-choline) 
from phosphocholine and cytid ine triphosphate (CTP), catalyzed by CTP-phosphocholine 
cytidyl transferase (PhChCT). CDP-choline is subsequently com bined with d iacylg lycerol to 
form phosphatidylcholine in a reaction catalyzed by phosphatidylcho line glyceride transferase 
(PhChGT).
Acétylation: A small fraction of choline is acetylated: choline and acetyl coenzyme A form 
acetylcholine in a reaction catalyzed by choline acetyltransferase (ChAT).
De novo synthesis of choline: Sequential méthylation of phosphatidylethanolam ine, catalyzed 
by phosphatidylethanolam ine-N-m ethyltransferase (PEMT) produces new choline molecules in 
the form of phosphatidylcho line (lecithin).
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Subjects and Methods
Participants
Patients were recruited as described before (28). In summ ary, patients were 
included in our study when v is iting the outpatient c lin ic and/or the delivery 
ward of the departm ent of O bstetrics and G ynecology at the Canisius 
W ilhelm ina Hospital in N ijmegen, the Netherlands. All pregnant women 
attend ing the departm ent were potentia lly  e lig ib le. W omen attend ing the 
outpatient c lin ic  or the delivery ward were asked to partic ipate  when time 
schedule of the clin ician, the nurses and/or the adm inistrative w orker allowed 
this. All wom en gave inform ed consent.
From the partic ipants v is iting the outpatient c lin ic  departm ent of the hospita l 
a lready during pregnancy, 366 maternal b lood sam ples were co llected 
between 30 and 34 weeks of gestational age during routine blood sam pling. 
B lood sam ples were co llected from  the ir 366 um bilica l cords at delivery. From 
the partic ipants vis iting the delivery ward only, 760 um bilica l cord blood 
sam ples were collected.
A pproxim ate ly 20% of all wom en delivering in this hospita l during the study 
period (2002-2004) were included. To check w hether the included women 
were representative fo r the entire popula tion vis iting  th is hospita l we random ly 
selected 500 additiona l wom en from  the same period from  the delivery ward 
records and found com parable  results fo r maternal age, gestational age, birth 
w eight and newborn sex (data not presented). We have excluded tw in 
pregnancies. All m others were asked to fill out a questionnaire. The study 
protocol was approved by the local m edical ethics com m ittee.
Data collection
Birth w eight and gestational age were obta ined form  the delivery charts. 
In form ation on parity, m edical history, education, sm oking during pregnancy 
and use of fo lic  acid was co llected through questionnaires and, if necessary, 
review of patient charts.
Blood sampling
Im m ediately after b irth, the um bilica l cord was clam ped and venous cord 
blood was co llected into a 3.5 ml EDTA conta in ing vacuum  tube and 
im m ediate ly p laced on ice. Maternal venous blood was drawn between 30 and 
34 weeks of gestational age and co llected in 3.5 ml EDTA conta in ing tubes 
and im m ediately placed on ice. A fter centrifugation (w ithin 2 hours after 
sam pling), plasm a was separated and EDTA plasm a and blood cells were 
stored at -2 0 ° C until analysis.
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Biochemical analyses
All analytes were determ ined in both maternal and um bilica l cord EDTA plasma 
prepared from  venous blood. Plasma choline, betaine, d im ethylg lyc ine (DMG) 
and creatin ine were determ ined as described before (29).
Statistical analyses
Results are presented as median values w ith the interquartile range. Variables 
were log-transform ed before further analysis. Maternal and umbilical samples 
were com pared using paired samples t test. Correlations between variables 
were estimated as Pearson correlations on the transform ed data. Z scores were 
calculated. Linear regression analysis was used to determ ine the predictors of 
birth weight. Since birth weight and gestational age were strongly related we 
calculated birth weights standardized for gestational age using linear regression 
on birth weight and gestational age. Again, Z scores were calculated and linear 
regression analyses were perform ed using the standardized birth weights 
as dependent variable. To show nonlinear relations, dose-response curves 
were constructed to describe corre la tions between um bilica l and maternal 
concentrations and birth weight, using Gaussian generalized additive regression 
models (GAM). Logistic regression analysis was used to determ ine odds ratio’s 
fo r umbilical and maternal analytes in relation to birth weight. Low birth weight 
was defined as standardized birth weight < 2500 grams. STATA for W indows 
version 11.0 was used for all statistical analyses.
Results
Study population
Population characteristics are presented in table I. Most babies were born at 
or near term (range 33+4 to 43+2 weeks) w ith 4.9% of the babies born before 37 
gestational weeks and 6.6% after 42 gestational weeks. Birth w eights ranged 
from  1400 to 5300 grams; 4.3% from  this study group was born w ith birth 
w eight < 2500 g. Four out of each ten wom en gave birth fo r the first time. Male 
to fem ale ratio of newborns was 55:45. Approxim ate ly 50% used fo lic  acid 
during pregnancy.
Blood indices and correlations
C oncentra tions of um bilica l and maternal choline, betaine and DMG are shown 
in table II. Median concentra tion of choline was 4-tim es whereas betaine was
2 tim es higher in cord blood com pared to maternal b lood. The feta l-m aternal 
gradient was less pronounced fo r DMG and relatively small fo r creatinine.
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Table I Population characteristics
n=1126
Age at delivery (years) 31.9 (22.9;41.0)
Gestational age (weeks) 40.0 (38.7;41.1)
Birth weight (grams) 3470 (3130;3835)
Primiparity, n/N (%) 457/1105 (41%)
Smoking n/N (%) 167/1093 (15%)
Use of folic acid n/N(%) 529/1088 (49%)
Male sex n/N(%) 501/1122 (45%)
Results are expressed as median and interquartile range unless reported otherwise.
Table II Umbilical and maternal concentrations of choline, betaine and 
dimethylglycine
Umbilical cord plasma 
n=1126
Maternal plasma 
n=366
Choline 28.0 (24.3;33.8)* 7.0 (6.1;8.3)
Betaine 24.6 (20.8;29.5)* 11.0 (9.2;12.9)
DMG 3.8 (3.1;4.6)* 2.1 (1.7;2.5)
Creatinine 54.5 (48.6;61.4)* 45.0 (40.4;49.7)
Concentrations are expressed as median and interquartile range. DM G=dim ethylglycine. 
C reat=creatinine All concentrations are expressed as /jm o l/L . * All um bilical analytes are higher 
com pared to maternal analytes (paired samples t test; p values < 0.001).
C orre lations between um bilica l and maternal analyte concentra tions are 
presented in table III. As expected, strong corre la tions between choline and 
betaine in both maternal and um bilica l cord plasm a sam ples were found. W ith 
the exception of choline, all maternal and um bilica l cord plasm a concentra tions 
were s trong ly related. Um bilical cord plasm a creatin ine was positive ly 
corre lated to um bilica l p lasm a choline. Maternal choline was positive ly 
corre lated to um bilica l cord plasm a betaine.
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Umbilical and maternal concentrations and birth weight
Dose-response curves obta ined by GAM show relations between um bilical 
concentra tions of choline, betaine, DMG and birth w eight (figure 2). GAM 
curves concern ing maternal concentra tions did not reveal any relation w ith 
birth w eight (data not shown). A ssocia tions between possib le determ inants 
and birth w eight are shown in table IV. Sm oking, gender and parity were the 
strongest determ inants of b irth w eight next to gestational age in all analyses. 
H igher um bilica l choline and betaine concentra tions were associated w ith 
lower birth  w eight whereas higher um bilica l DMG proved to be a determ inant 
fo r h igher birth w eight. Maternal analytes were no determ inants of 
(standardized) birth w eight in these analyses.
Figure 2 Gaussian generalized additive regression model curves showing 
non-linear relations between umbilical metabolites and birth 
weight
a venous umbilical cord blood choline concentrations and birth 
weight
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Figure 2 Continued
b venous umbilical cord blood betaine concentrations and birth 
weight
n ----------------------------------- 1-------------------- 1-------------- 1-----------1---------1------- 1------ 1----- 1----- r ~
10 20 30 40 50 60 70 80 90100
umbilical betaine (umol/L)
venous umbilical cord blood dimethylglycine (DMG) 
concentrations and birth weight
1 2 3 4 5 6 7 8 91 0
umbilical dimethylglycine (umol/L)
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Table IV Predictors of birth weight by linear regression
Model 1
P [95% Cl]
Model 2
P [95% Cl]
Model 3
P [95% Cl]
Gestational age (weeks) 163 [147; 180] -
Age at delivery (years) 2.9 [-4.2;9.9] 3.5 [-2.7;9.6] -8.2 [-16.3;-0.2]
Parity 52 [16;88] 69 [38; 100] 95.8 [54.5;137]
Smoking (no/yes) -276 [-365;-187] -234 [-312;-157] -251 [-348;-153]
Use folic acid (no/yes) 15 [-51 ;80] 35 [-22;92] 38.2 [-29.4; 106]
Female gender -135 [-199;-71] -147 [-202;-92] -156[-261;-51]
Umbilical cord plasma, n=1126
UC Choline -94[-128;-61] -55[-84;-26] -60 [-89;-31]
UC Betaine -101 [-133;-69] -57[-84;-29] -65[-94;-36]
UC DMG 52[20;85] 38[9.6;66] 35[6.1;63]
UC Creatinine 23[-13;58] -5.2 [-36;25] -3.2 [-35;28]
Maternal plasma, n=366
Mat Choline 41[-17;99] 33[-19;85] 27[-25;80]
Mat Betaine 12[-45;69] -9.9[-61;41] -16[-69;38]
Mat DMG -3.6[-63;55] -4.4[-58;49] -7.9[-62;46]
Mat creatinine -55[-112;3.0] -44[-97;8.1] -54[-108;-0.8]
The coeffic ients presented, give the change in birth weight (grams) for the several variables. 
Coefficients presented for um bilical cord plasma (UC) or maternal (Mat) concentrations (choline, 
betaine, dim ethylgycine (DMG) and creatinine) are calculated using z scores of these 
metabolites. The coeffic ients represent the increase/decrease in birth weight (grams) follow ing 
1 standard deviation increase in um bilical or maternal metabolites. All analyses are performed 
after logarithm ic transformation. p= regression coefficient.
Model 1 = univariate analysis of possible determ inants on birth weight
Model 2=univariate analysis of possible determ inants on standardized birth weights
Model 3=m ultivariate analysis of possible determ inants on standardized birth weights.
Model includes the specific metabolite and gestational age, age at delivery, parity, smoking, 
use of fo lic  acid and gender.
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Predictors of low birth weight
O dds ra tio ’s fo r having a low birth w eight baby related to um bilica l choline, 
betaine, DMG and creatin ine are given in Table V. C oncentrations of um bilical 
choline and betaine in the h ighest quartile  were associated w ith increased risk 
fo r having a low birth w eight baby, whereas maternal concentra tions were not 
(data not shown).
Table V Odds ratio's for having a baby with birth weight <2500 g standardized 
for gestational age when umbilical metabolite concentrations are in 
the highest quartile compared to the lowest quartile
n=1126 Choline Betaine DMG Creatinine
OR[95%CI] 4.12[1.15;14.78] 5.68[1.24;25.91] 0.48[0.09;2.65] 2.26[0.69;7.42]
AOR[95%CI] 3.70[1.01; 13.53] 4.93[1.04;23.24] 0.39[0.07;2.22] 2.50[0.71;8.86]
O R =odds ratio. AOR = OR adjusted for age at delivery, parity, smoking, use of fo lic  acid and 
newborn sex. Results are expressed as OR [95% Cl].
Discussion
We observed that um bilica l choline and betaine were inversely and DMG was 
positive ly associated w ith b irth w eight. To our best know ledge, th is is the 
largest research pro ject until now studying  the possib le re la tionsh ip  between 
birth w eight and um bilica l and maternal choline and related methylam ines, 
w hich makes the results unique and robust. Venous um bilica l cord blood has 
been drawn for practica l reasons, but the corre la tion between concentra tion 
of m etabolites in venous and arterial um bilica l b lood is high (30). We have 
analyzed not only choline but also betaine and d im ethylg lycine, im portant 
m etabolites of choline oxidation pathway. This s tudy is perform ed in babies 
born at or near term  and in an assum ingly healthy pregnant population, which 
makes it possib le to extrapolate these results to the general population. Adding 
m other-baby pairs makes it possib le to describe m aternal-um bilica l corre lations 
fo r d ifferent m etabolites and to s tudy the e ffect of maternal analytes on birth 
w eight as well. Unfortunately, other possib le determ inants of b irth w eight like 
maternal w eight gain and BMI are not known. Choline and betaine have been 
shown to have divergent associa tions w ith BMI in adults; in contrast, they have 
a sim ilar d irection of association in our study.
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Maternal choline concentra tions during pregnancy varying between 7.3 and 
16.5 jumol/L have been reported by several authors (14, 24, 25, 30-33). The 
size of study populations d iffered from  11 to 201 subjects. T im ing of maternal 
sam ples d iffered from  16 weeks of gestational age to delivery. One longitudinal 
study perform ed by Velzing-Aarts et al describes a s ligh t gradual increase in 
maternal choline concentra tions from  9 to 36 weeks of gestational age, w ith a 
decrease after delivery. Maternal choline, betaine and DMG concentra tions 
described in literature are com parable  to our results (30-34).
Several studies concern ing um bilica l choline concentra tions have been 
perform ed (14, 25, 30, 32, 33, 35).They are either small (14, 30, 33, 35), did not 
involve maternal and um bilica l data (14), or did not evaluate the possib le 
association between birth w eight and choline concentra tions (14, 25, 32, 33, 
35). Um bilical cord plasm a choline concentra tions have been described 
between approxim ately 25 and 40 jumol/L (14, 24, 25, 30, 33, 35) which seems 
in line w ith our results. G estational age at sam pling varied from  25 to 43 weeks 
of gestational age. In tw o studies, venous um bilica l choline concentra tions 
were s ligh tly  h igher than arteria l choline concentra tions but w ith a strong 
corre lation (25, 30). Betaine concentra tions in um bilica l cord blood vary from  
21 to 29 jUmol/L and DMG concentra tions between 2 and 4 jumol/L (30, 32-34), 
w hich is in line w ith our results.
The reported correlation coeffic ients for the relation between maternal and 
venous umbilical cord m etabolites vary from  0.06 to 0.26 for choline, 0.11 to 0.46 
fo r betaine, and 0.58 to 0.73 for DMG (25, 30, 32-34). Furthermore, there are 
consistent reports on choline concentrations in cord plasma that are several 
fo ld higher than in maternal plasma, both in humans (14, 24, 25, 30, 32, 33, 35) 
and animals (26). S im ilar results are obtained in the present study. The much 
higher choline concentrations in cord plasma com pared to maternal plasma 
and lack of or low um bilical-m aternal correlation may reflect an active maternal- 
placental transport mechanism of choline against a concentration gradient. In 
vitro studies have characterized such a transporter (12, 13, 15, 16, 36) which 
may exist to meet the rapidly grow ing fe tus’ high choline requirements 
We found the well known pred ictors fo r b irth w eight confirm ed in our study: 
gestational age, newborn sex, sm oking and parity (37-42). In th is population of 
w e ll-nourished healthy mothers, b irth w eight showed a strong inverse 
re la tionship  to um bilica l choline and betaine, but not to maternal metabolites. 
Likewise, a previous study has dem onstrated higher um bilica l vein choline in 
28 SGA com pared to 15 non-SGA babies born to m others w ith preeclam psia
(30). Venous um bilica l cord blood is a reflection of maternal concentrations, 
m aternal-p lacenta l transfer and placental m etabolism  and reflects supp ly to 
the fetus. A rteria l um bilica l concentra tions reflect fetal metabolism . Correlation
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between concentra tions of m etabolites in venous and arterial um bilica l blood 
is high (30) and higher venous com pared to arterial concentra tions have been 
described suggesting uptake by the fetus (25, 30). High choline content in 
um bilica l cord blood from  small babies may reflect low choline consum ption 
in fetal as well as placental tissue, since the latter expresses enzymes involved 
in choline m etabolism . If fetal consum ption and m etabolism  are low, one would 
expect higher arterial concentra tions and decreased venous-arteria l 
d ifferences in sm aller babies com pared to larger babies. This explanation 
could be supported  by the observed positive relation between b irth  weight 
and um bilica l DMG, w hich indicates that flux through the BHMT pathway 
increases w ith increasing fetal size. DMG form ation is p robably confined to 
fetal tissues, because beta ine-hom ocyste ine m ethyltransferase is not 
expressed in human placental tissue (43, 44). However, it cannot be ruled out 
that increased placental transport of choline triggered by slow  fetal grow th 
represents an alternative or com plem entary mechanism.
C onsidering the positive e ffects of choline on the developing fetus in relation 
to brain developm ent and memory, we certa in ly  do not believe that a d irect 
(toxic) e ffect of choline delivered to the fetus is likely to  be the cause of the 
inverse re la tionsh ip  between um bilica l cord plasm a choline and birth w eight in 
our study. This phenom enon m ight thus be a reflection of d isturbances in 
placental choline m etabolism . Decreased acetyla tion of choline could lead to 
higher free choline concentra tions. The function of the high acetylcho line 
concentra tions in the placenta are not known (45). Also, decreased choline 
kinase and/or C TP-phosphocholine cytidy l transferase activ ity  could lead to 
lower phosphatidy lcho line  concentra tions, the predom inant phospho lip id  in 
most mam malian m em branes and im portant fo r the synthesis of lung 
surfactant, bile lip ids and plasm a lipoprote ins. Unfortunately, we were not able 
to measure acety lcho line  or phosphatidy lcho line  in our samples. The placenta 
is a major site fo r choline utilization; hence, h igher venous um bilica l cord 
p lasm a choline concentra tions could reflect a d isturbed p lacental function, 
eventually leading to d isturbed fetal grow th and lower birth w eight. Cellular 
degradation due to placental dam age e.g. due to hypoxia, leads to release of 
choline from  mem brane phosphatidy lcho line  or ace tylcho line into um bilical 
c ircu la tion and w ill increase um bilica l venous choline concentra tions. The fact 
that h igher choline and betaine but lower DMG concentra tions are associated 
w ith lower birth w eight could also indicate decreased flux through the choline 
oxidation pathway. DMG plays an im portant role in generating glycine, an 
am ino acid involved in synthesis of purines, creatine, co llagen, elastin and 
g lu ta th ione (46). G lutath ione is involved in the protection against oxidative 
stress and regulation of protein and DNA synthesis.
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In our s tudy existing of 1126 cord blood sam ples, b irth w eight showed a strong 
inverse re lationship to um bilica l choline and betaine. These results m ight 
reflect a d isturbed placental function  where choline serves as a marker. Further 
research is needed to c larify these find ings and to study if we can influence 
these pathways in such a way that the risk on low birth w eight w ill decrease. 
Determ ination of total choline and the d ifferent form s of choline in maternal 
and both arteria l and venous um bilica l cord blood in normal pregnancies and 
pregnancies com plicated by intra uterine grow th retardation, placental 
dysfunction  or low b irth  w eight should be involved in such research.
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Summary and general discussion

SUMMARY AND GENERAL DISCUSSION
Summary
In th is thesis we have stud ied the associations between cerebrovascular 
accident (CVA) in newborn infants, low birth w eight and hom ocyste ine (Hey), 
cobalam in (Cbl) and choline
Chapter 1 provides a brief sum m ary regarding cerebrovascu lar accidents 
(CVA) in newborns to em phasize the im portance of looking fo r possib le and 
treatable causes. Furthermore, it describes the relevance of b irth w eight (BW) 
in relation to im m ediate neonatal m orb id ity  and m orta lity as well as in relation 
to risk fo r vascular diseases later in life and to known determ inants. One 
carbon m etabolism  is in troduced and tHcy, Cbl and choline are described in 
detail considering m etabolism , inborn errors of m etabolism , concentrations, 
determ inants and treatm ent m odalities. Furthermore, know ledge on the 
association between tHcy, Cbl, choline and disease is presented, w ith a focus 
on adverse pregnancy outcom e and vascular diseases. In chapter 2 the 
outline of th is thesis is presented.
Homocysteine
Part I focuses on tH cy in relation to CVA and BW in newborn infants. Chapter
3 describes a retrospective study w hich enro lled 24 newborns > 34 weeks of 
gestation w ith CVA. Their tH cy concentra tions were com pared w ith those of 
94 healthy newborns. CVA was diagnosed via ultrasound and com puted 
tom ograph ic  and/or m agnetic resonance scanning. Eleven patients were 
d iagnosed w ith ischem ic CVA, th irteen w ith hem orrhagic CVA. THcy 
concentra tions between these two groups were com parable. OR for neonatal 
CVA when tH cy exceeded the 80th percentile  of contro l concentra tions was 
3.95 [1.53;10.16]. In conclusion, hyperhom ocyste inem ia in newborns was 
associated w ith increased risk fo r CVA in th is study. The retrospective design 
did not allow  us to draw a conclus ion as to w hether elevated tH cy concentra tions 
could be causally related or perhaps a biom arker of underlying pathology. 
Elevated tH cy concentra tions can be easily, safely, and e ffic ien tly  lowered 
w ith fo lic  acid supp lem entation in adults and older children. Results from 
intervention tria ls regarding a possib le preventive e ffect of tH cy lowering 
therapy on vascular disease were not available at the tim e we developed our 
study, w hich is presented in chapter 4. A prospective random ized intervention 
study w ith fo lin ic  acid supp lem entation was perform ed in 37 newborns at the 
NICU in our hospita l. We supplem ented the newborns in the in tervention group 
(n=19) w ith 70 jugram /kg/day fo lin ic  acid in travenously or orally and com pared 
tH cy and fo late concentra tions at baseline, and again after one and tw o weeks
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with concentra tions of newborns in the contro l group. Intervention and contro l 
g roup did not d iffer in gesta tiona l age, b irth w eight, sex, days on ventilator, 
incidence of sepsis and baseline tH cy and fo late concentra tions. In the 
in tervention group, p lasm a fo late concentra tions were higher at day 15 
com pared to baseline, whereas fo late concentra tions rem ained stable in the 
contro l group, suggesting adequate uptake of the supplem ent. Despite th is 
increase in plasm a folate concentra tions, tH cy concentra tions did not change 
in the in tervention group. Since sim ilar fo late supplem entation cond itions in 
adults substantia lly  lower tH cy concentra tions, our find ings suggest that one 
carbon m etabolism  in newborns d iffers from  that in adults and older children. 
Chapter 5 focuses on BW in relation to tH cy and related B vitam ins, such as 
Cbl and folate. D ivergent associations between maternal tH cy concentra tions 
and BW have been described. LBW has been identified as a risk factor fo r both 
neonatal and adult m orbidity. Therefore, we designed a prospective study to 
explore the possib le relation between maternal tH cy concentra tions and BW. 
We co llected data and blood sam ples from  366 m other-baby pairs in the 
Canisius W ilhelm ina Hospita l in N ijmegen, in the Netherlands. Plasma 
concentra tions of tHcy, Cbl, MMA, fo late and creatin ine were determ ined in all 
sam ples. Um bilical cord blood concentra tions of all analytes were higher than 
maternal concentra tions. Maternal tH cy concentra tions showed a slight 
negative association w ith BW. Linear regression analysis revealed only known 
determ inants of b irth w eight (gestational age, newborn sex, sm oking and 
parity). No increased risk fo r LBW accord ing to maternal p lasm a concentra tions 
could be observed. In our w e ll-nourished and partly supplem ented Dutch 
popula tion of pregnant wom en, maternal tH cy and related B vitam ins were not 
associated w ith BW.
Since data on the association between maternal tH cy and BW were conflic ting, 
we reviewed the literature and perform ed a m eta-analysis on studies regarding 
th is top ic  described in chapter 6. Search term s used were: hom ocyste ine AND 
(birth w eight OR small fo r gestational age OR intra uterine grow th retardation). 
S tudies were e lig ib le  if data on maternal tH cy and birth w eight could be 
abstracted and a relation between those param eters was described. A fter 
reading of 78 abstracts, full text m anuscripts from  35 studies were retrieved for 
detailed assessm ent. A fter exclusion of 16 studies fo r several reasons 19 
studies were e lig ib le  fo r m eta-analysis, includ ing 21,326 individuals. D ifferent 
studies used d ifferent e ffect size estimates. A fter conversion of all e ffect size 
estim ates into Odds ratios, pooled analysis revealed an overall crude OR of 
1.31 [1.15; 1.51 ] fo r being small fo r gestational age (SGA) when maternal tH cy 
exceeded the 90th percentile. Because adjustm ent fo r known confounders was 
not possib le but a tendency to decreased strength of association was observed
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in studies after adjustm ent fo r strong determ inants, th is e ffect size could be an 
overestim ate. In conclusion, h igher maternal tH cy is associated w ith an 
increased risk fo r being SGA. The small estim ated birth w eight d ifference 
(-38[-20;-58] fo r 1 sd increase in maternal tHcy) m ight be of little clin ical 
relevance fo r the individual newborn, however, it could be of greater im portance 
on popula tion level.
Cobalamin
Part II focuses on Cbl and its m etabolic marker fo r in trace llu lar defic iency 
m ethylm alonic acid (MMA). S ince Cbl concentra tions are a poor ind icator of 
Cbl deficiency, we have developed a m ethod to determ ine the sensitive 
m etabolic marker MMA described in chapter 7. Existing m ethods were tim e 
consum ing and laborious. Our method uses HPLC com bined w ith ESI-MS/MS 
w ithout prior derivatization. S table isotope-labe led m ethyl-tri-deuterated-M M A 
(M MA-d3) was added to 100 jul of p lasm a as an internal standard. A fter depro- 
te in ization by ultra filtra tion  an acid ified a liquot of the eluate was in jected into 
the HPLC system and analyzed by LC-ESI-MS/MS m onitoring the carbonyl 
loss of MMA and by record ing the transition of m/z 117 to m/z 73 and m/z 120 
to m/z 76 respectively. Retention tim e of MMA is 2.5 minutes. No interference 
w ith the physio log ica lly  abundant isom er succ in ic  acid was observed due to 
its retention tim e of 1.9 minutes.
A fter developing th is m ethod, we were able to analyze plasm a MMA 
concentra tions in 186 apparently healthy Dutch children aged 0-19 years as 
described in chapter 8. G eom etric mean plasm a MMA concentra tion was 0.17 
jUmol/L [0.07;0.42], A positive association between plasm a MMA and age in 
children > 1 year was observed. Plasma MMA concentra tions were higher in 
children w ith low Cbl concentra tions. No d ifference between sexes was 
observed. Cbl was the strongest determ inant of p lasm a MMA. The association 
between MMA and Cbl becom es stronger at increasing age. In children >1 
year the 90th percentile of plasm a MMA was 0.30 jumol/L.
Choline
Part III investigates the possib le re lationships between um bilica l and maternal 
choline concentra tions, related m ethylam ines betaine and DMG, and BW as 
described in chapter 9. Choline is an essential nutrient and involved in 
m etabolic processes including lip id m etabolism , m ethylation reactions and 
synthesis of m em brane phospho lip ids and acetylcholine. It plays and im portant 
role in ce llu lar in tegrity  and signa ling function, brain developm ent and neu­
rotransm ission. Variation in maternal choline could influence fetal outcom e 
through d isturbances in cell m em brane synthesis, increase in tH cy
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concentra tions, perturbation of m éthylation reactions or changes in 
acety lcho line  production. Several argum ents suggest that fetal choline 
concentra tions could be a better reflection of fetal (and placental) choline 
m etabolism  and d istribution. We co llected  1126 um bilica l cord blood sam ples 
in the Canisius W ilhelm ina Hospita l in N ijmegen, the Netherlands. From these 
partic ipants, 366 maternal sam ples were drawn between 30-34 weeks 
gestational age. We observed that umbilical choline and betaine were inversely 
associated w ith b irth w eight, whereas DMG was found to be positively 
associated w ith birth w eight. S trong positive corre la tions between um bilical 
and maternal concentra tions of betaine, DMG and creatin ine were found, 
whereas choline was weakly correlated. C oncentra tions of all um bilica l cord 
b lood metabolites, in particu la r choline, were higher than maternal 
concentra tions. U m bilical choline concentra tions in the h ighest quartile  were 
related to a four-fo ld increased risk of having a baby w ith birth w eight <2500 
g when standardized fo r gestational age. W hether these results reflect altered 
flux through the choline oxidation pathway, a disturbed placental function with 
choline serving as a marker or another yet unknown mechanism remains to be 
solved.
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General discussion and future perspectives
Homocysteine and CVA in infancy
The observation that c lassic hyperhom ocyste inem ia was associated w ith 
prem ature vascular disease form ed the basis fo r extended research studying 
the association between tH cy concentra tions and risk fo r card iovascular 
disease in the general popula tion. S trong ep idem io log ica l proof fo r increased 
tH cy concentra tions as an independent p red icto r of card iovascular disease in 
human adults exists. Several p lausible m echanism s includ ing endothelia l 
damage, im paired NO mediated endothelium  dependent vasodila tation, 
increased lip id peroxidation, pro liferation of vascular sm ooth muscle cells and 
altered DNA m ethylation, have been proposed and considered relevant (1). 
However, m eta-analysis on large hom ocyste ine lowering intervention tria ls  in 
adults showed no net effect on cardiovascular risk. Some possible explanations 
fo r these results were sum m arized by Sm ulders and Blom very recently (2). 
Lim itations of Mendelian random ization, power of the in tervention studies 
(study duration, severity of increased tH cy concentra tions, contrast between 
groups), and a possib le dual effect of B vitam ins increasing the risk for 
card iovascular diseases (potentia l adverse effects of fo lic  acid in general, 
adverse e ffect of fo lic  acid on atherosclerosis) could all have contribu ted  to 
the lack of net effect on clin ica l card iovascu lar diseases. Furthermore, using 
fo lic  acid alone or in com bination w ith other B vitam ins is not a selective 
intervention. Instead, supplem entation w ith fo lic  acid influences the entire B 
vitam in netw ork and as such one carbon m etabolism , but also influences cell 
replication, amino acid methylation, DNA hyperm ethylation and conversion of 
L-arginine into ADMA (3).
In conclusion, no clin ica l beneficia l e ffect on card iovascu lar risk using B 
vitam ins as tH cy lowering therapy has been found despite the observed strong 
association between tH cy and card iovascu lar risk. However, defin ite 
conclus ions to w hether increased tH cy concentra tions are causally related to 
card iovascular risk cannot be drawn.
The argum ents discussed above hold true fo r adults and intervention. But 
what about infants and children?
Perinatal CVA occurs in late pregnancy or w ith in fou r weeks after birth, and 
thus pathogenesis is unlikely to  be the same as in adults where the process of 
atherosclerosis may take 30 to 40 years. Also, pa thophysio logy fo r perinatal 
stroke is d ifferent from  perinatal intracerebral hem orrhage. Furthermore, 
underlying mechanisms differ between term and preterm newborns. Anecdotal 
reports  and re trospective  case/contro l s tud ies study ing  increased tH cy
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concentra tions and/or Mendelian random ization using the MTHFR C677T 
po lym orphism  in association w ith CVA in children have been published. Our 
s tudy (ch a p te r 3) is the firs t to  observe an increased risk fo r CVA (both stroke 
and hemorrhage) in newborn infants w ith increased tH cy concentra tions (4). 
In contrast, a recent s tudy by Sturtz et al could not reveal an association w ith 
tH cy concentra tions and occurrence of in traventricular hem orrhage in preterm 
infants (5). Van Beynum et al showed increased tH cy concentra tions as risk 
factor fo r ischem ic stroke in infants and children (6). These results are in line 
w ith other studies (7-12). In conclusion, previous published data based on 
retrospective studies, includ ing our study, suggest that increased tH cy 
concentra tions m ight be a risk fac to r fo r CVA in newborns, infants and 
children.
Focusing on newborns, th is brings to m ind the fo llow ing questions:
• Can these results be confirm ed in large prospective trials? To determ ine 
whether or not tH cy is merely a proxy fo r underlying risk factors or disease 
or a causally related factor in th is age category, a prospective study could be 
the next step. The heterogeneity in the popula tion of newborn infants w ith 
CVA and the low incidence of CVA in newborn infants com pared to adults will 
be a challenge fo r study design and power of the study.
• If p rospective studies w ould confirm  the association between tH cy and risk 
fo r CVA in newborn infants, random ized contro lled  intervention tria ls aim ing 
at reduction of tH cy concentra tions can be considered. Several s tudy designs 
are possible. For example, because of the strong relation between maternal 
and um bilica l tH cy concentra tions, fo lic  acid and/or Cbl supplem entation 
during pregnancy could be considered. It is also possib le to supply newborns 
w ith B vitam ins. In contrast to  adults fo lic  acid did not decrease tH cy 
concentra tions in our fo lin ic  acid in tervention study (chapter 4) (13). Based 
on the results of Bjorke Monsen et al and our s tudy Cbl supplem entation 
seems more rationale than fo lic  acid in th is age category (13-15).
• What can be the underly ing m echanism  by w hich tH cy concentra tions could 
be causally related to the d ifferent types of CVA in th is age category? Basal 
research using animal m odels m ight be a suitable way to s tudy this topic.
Homocysteine, related B vitamins and birth weight
Studies considering the possib le re lationship between maternal tH cy 
concentra tions and (low) BW yie lded conflic ting  conclusions. Our study did 
also evaluate the poss ib ility  of tH cy being merely a marker of Cbl defic iency 
but we could not observe an association between maternal tHcy, Cbl, MMA or 
fo late and birth w eight in 366 w e ll-nourished and partly fo lic  acid supplem ented 
m other-baby pairs (chap te r 5) (16). Review and m eta-analysis of 19 elig ib le
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studies includ ing 21,326 indiv iduals revealed a 31% increased risk fo r BW 
being <10th percentile  fo r GA when maternal tH cy concentra tions exceeded 
the 90th percentile  (ch a p te r  6) (17). This m ight be a small d ifference fo r the 
individual newborn infant (-38[-20;-58] g fo r 1 sd increase in maternal tHcy). 
but could be of greater im portance on population level. Because not all studies 
were adjusted fo r strong determ inants of BW such as sm oking, newborn sex 
and parity, we assume that th is effect could be an overestim ate. Individual 
data analysis m ight be able to study the influence of known determ inants on 
the observed effect size in our meta-analysis.
If maternal tH cy concentra tions w ould be causally related to birth weight, 
lowering tH cy should result in increased BW. O bservational studies from  
Tim m erm ans et al and Czeizel et al showed higher BW (37-68 g) in fo lic  acid 
supplem ented wom en (18, 19). This BW difference is com parable to the BW 
difference in our meta-analysis. Furthermore, fo lic  acid started preconcep- 
tiona lly  resulted in a decreased risk on being SGA (OR 0.40[0.22;0.72]) and 
LBW (OR 0.43[0.28;0.69], analyses adjusted fo r maternal age, height and 
w eight, GA, parity, newborn sex, ethnicity, educational level and sm oking) 
(18). Evaluation of rate of LBW before and after fo late food fo rtifica tion  showed 
a small reduction in prevalence of LBW (20). Several random ized contro lled 
tria ls and observational studies observed sim ilar associa tions between fo lic  
acid supp lem entation or maternal fo late status and BW or SGA rate (21-25). In 
contrast, other studies could not observe such an association (16, 19, 26, 27). 
To summ arize, studies regarding the effect of fo lic  acid or maternal fo late 
status in relation to the ir o ffsp ring ’s BW yie lded d ifferent conclusions. 
System atic review and m eta-analysis of relevant literature regarding fo lic  acid 
supp lem entation during pregnancy and its influence on BW could provide 
insight into the factors in fluencing these d ifferent results and conclusions. 
Also, a prospective European m ulticenter study includ ing the co llection  of 
in form ation on known confounders of BW and inform ation on B vitam in sup ­
plem entation and status could provide more answers.
Being SGA is one of the four leading causes of perinatal death in the 
Netherlands (28). If adequate fo lic  acid and/or Cbl supp lem entation during 
pregnancy leading to decreased tH cy concentra tions w ould result in less 
infants being born SGA, th is could potentia lly  contribute  to im proved survival 
and decreased m orbidity. However, given the small d ifference in BW, it m ight 
be better to focus on other potentia lly  treatable factors leading to being SGA.
Cobalamin deficiency in infancy and childhood
There is an increasing am ount of studies suggesting that Cbl defic iency is a 
frequently  occurring problem , especially in infancy (14, 15, 29, 30). N utritional
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Cbl de fic iency is one of few treatable causes of developm ental delay or 
regression. Main factors in fluencing the severity of Cbl de fic iency in infants 
are the severity of maternal Cbl deficiency, Cbl concentra tions in breast m ilk 
and duration of defic iency. Due to a low index of susp ic ion and the variety of 
presenting sym ptom s, marked d iagnostic  delay is present alm ost w ithout 
exception.
Is increased MMA concentration in in fancy a reflection o f tru ly im pa ired  Cbl 
status o r m erely o f a transient phys io log ica l process?
W ith our new MMA m ethod, investigations regarding incidence and fo llow -up 
of functiona l Cbl de fic iency in infants and children are feasible (ch a p te r 7)
(31). Our upper reference range of p lasm a MMA in children >1 year is 0.30 
jumol/L (90th percentile) (ch a p te r  8) (32). In younger children however, there is 
more variation and there is a lim ited num ber of patients aged <1 year in our 
study. Refsum et al described an upper reference lim it (90th percentile) of 
plasm a MMA in —5000 newborn screening sam ples of 0.44jum ol/L (33). Bjorke 
Monsen et al describe median(IQR) plasm a MMA at birth in 173 newborn 
infants of 0.29(0.24;0.38) jumol/L, sharp ly increasing to median MMA 
concentra tion of 0.81 jumol/L at 6 weeks (15). MMA concentra tions remain high 
until 6 m onths and decrease in the second half of the firs t year to values 
rem aining relatively constant afterw ards (figure 1). The increase in MMA in the 
firs t year co inc ides w ith an increase in tH cy and a decrease in Cbl 
concentra tions.
Suggestive fo r the existence of a tru ly  im paired Cbl status in a high percentage 
of infants is:
•  Increased MMA concentra tions co inc ide  w ith increased tH cy and fo late, and 
decreased Cbl concentra tions (34).
•  S trong pred ictors of MMA, Cbl and tH cy concentra tions in infants at 6 weeks 
of age are maternal concentra tions of these analytes (15).
•  Infant nutrition and factors known to influence maternal Cbl status e.g. parity, 
influence infant Cbl status as well.
•  Cbl supp lem entation to infants at 6 weeks of age resulted in decrease of 
elevated MMA and tH cy concentra tions and an increase in Cbl concentra tions 
(14).
•  Folate concentra tions are higher in infants w ith higher MMA and tH cy and 
lower Cbl concentra tions and decrease after Cbl supplem entation. This is 
suggestive fo r am elioration of a m ethylfo late trap.
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Does Cbl therapy have a bene fic ia l c lin ica l e ffect on infants w ith im pa ired  Cbl 
status?
As m entioned above, a s ingle Cbl in jection resulted in change in m etabolic 
profile toward Cbl su ffic ien t status in infants (14). Besides this b iochem ical 
im provem ent, no inform ation regarding the clin ica l effect of Cbl supp lem enta­
tion in infants w ith im paired Cbl status but often w ithout overt sym ptom s is 
available. To fu rther e lucidate this subject, prospective random ized Cbl 
in tervention tria ls w ith am ongst others neuropsycholog ica l, m otor and 
cognitive developm ent as outcom e measures could provide strong evidence 
fo r the “ im paired Cbl s ta tus” hypothesis.
A pproxim ate ly one th ird  of investigated infants at 6 weeks showed increased 
MMA concentra tions (15). The true incidence of Cbl de fic iency in infants and 
children in the Netherlands has not been investigated, nor have the reference 
lim its of Cbl and MMA concentra tions in newborns and young infants. There 
are several ways to explore Cbl status and defic iency in infancy in the 
Netherlands:
Preconception
Prenatal counseling regarding health and disease in pregnancy could offer a 
way to screen and if necessary treat wom en fo r Cbl defic iency before they get 
pregnant. D ietary advice or Cbl supplem entation orally or in tram uscularly 
could be considered.
Pregnancy
During pregnancy routine laboratory investigations are perform ed at 12 weeks 
of GA (Hb,Ht, b lood type, irregular antibodies, serology) and between 30 and 
34 weeks of GA (Hb, Ht and irregular antibodies). To our opin ion, routine blood 
sam pling at 12 weeks of GA could be com bined w ith determ ination of Cbl, 
MMA and tH cy concentra tions to select Cbl defic ient m others and have the 
opportun ity  to tim ely perform  investigations and initiate appropria te  therapy if 
necessary. The offspring  of these m others should be carefu lly fo llowed. 
Neonatal period
• Newborn screening
The intention of newborn screening is to identify infants w ith serious and 
potentia lly  treatable diseases before the onset of serious sym ptom s. In the 
Netherlands, newborn screening has been expanded from 3 to 17 diseases in 
January 2007, includ ing several inborn errors of m etabolism . P ropionylcarn i- 
tine can be used as ind irect marker of Cbl defic iency in expanded newborn 
screening program s. Several cases of detection of Cbl de fic iency in newborns 
through newborn screening program s w orldw ide have been published (35-39). 
However, in 40 exclusively breast fed infants w ith b iochem ica l and clin ica l Cbl
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defic iency only 2 had positive newborn screening results (40). This questions 
the sensitiv ity  of p rop ionylcarn itine  as ind ica tor of Cbl deficiency.
On the other hand, Refsum et al investigated tHcy, Cbl and MMA in —5000 
newborn screening sam ples and revealed b iochem ical evidence of Cbl 
de fic iency in approxim ately 5% of tested newborns (based o n tH cy  > 10jumol/L 
and MMA > 0.40 jumol/L) (33). If the same results could be extrapolated to the 
Netherlands, approxim ately 9,000 newborns each year are born w ith 
b iochem ica l evidence of Cbl defic iency. These are the children who are at 
increased risk of developing clin ica l sym ptom s early in infancy, especia lly if 
exclusively breastfed.
•  Randomized contro lled  trials.
Cbl in tervention studies in newborn infants could be designed to perform  dose 
find ing  studies and evaluate several form s of supplem entation. Additional 
in form ation involving system atic docum entation of both maternal and infant 
clin ica l and laboratory data are necessary
In conclusion, we argue that early detection and intervention of Cbl deficiency is 
critical. The severity of this problem is not clear yet. If intervention trials will support 
the “ impaired Cbl status” hypothesis, adding Cbl supplem entation next to vitamin 
K and D (standard care in Dutch breast fed infants) could be an option.
Choline and birth weight
Maternal choline influences fetal outcom e through d isturbances in cell 
m em brane synthesis, increased tH cy concentra tions, changed m ethylation 
reactions or changed acety lcho line  production . Furtherm ore choline influences 
the brain developm ent. Pregnancy and lactation place a heavy burden on 
maternal choline stores due to an active transport m echanism  to the fetus and 
high am ounts of choline in breast m ilk (42, 43). S ince choline is essential for 
the developing and rapid ly grow ing fetus, we hypothesized that fetal choline 
concentra tions w ould be positive ly associated w ith birth w eight. To our 
surprise, we observed an increased risk of LBW w ith increased um bilical 
choline concentra tions (chap te r 9) (44). This could reflect d isturbed placental 
choline m etabolism  due to placental dysfunction or a decreased flux through 
the choline oxidation pathway. To unravel possib le m echanism s fo r the 
observed results and to determ ine w hether we can influence these pathways 
in such a way that the risk on LBW w ill decrease fu rther studies are required. 
We recom m end includ ing determ ination of total choline and the d ifferent form s 
of choline in maternal and both arterial and venous um bilica l cord blood in 
norm al pregnancies, but also in pregnancies com plicated by IUGR, placental 
dysfunction  and in pregnancies resulting in LBW or SGA offspring.
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Figure 1
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Aspects of one carbon metabolism and cognition in children
All analytes stud ied in th is thesis have been related to cogn ition  in adults, 
children, and animals in various studies.
Plasma tH cy concentra tions have been linked to patho log ica l changes in the 
brain as well as declines in age-sensitive cognitive  abilities, such as processing 
speed and ep isodic memory, in adults.
Folates are im portant fo r fetal developm ent and grow th in early pregnancy. 
Inborn errors of fo late m etabolism  are associated w ith mental retardation (45). 
Anim al studies suggest an effect of d ie tary fo late availab ility on mouse brain 
developm ent in late pregnancy (46). H igher maternal fo late concentrations, 
but not Cbl or tH cy concentra tions, predicted better ch ildhood cognitive 
function  assessm ent in Indian children 9-10 y of age (47). Inadequate maternal 
fo lic  acid supplem ent use in early pregnancy was associated w ith increased 
risk on behavioral problem s in 4,000 18 month old todd lers in Rotterdam (48). 
However, at this young age, reliable in form ation on cognition is not available. 
A bundant inform ation from  animal studies reveals that perinatal choline is 
im portant fo r neurodevelopm ent, such as cognitive  ab ility  and m em ory 
function . In contrast, S ignore et al recently described the only human study 
results so far. They observed no corre lation between maternal or um bilical 
choline concentra tions and ch ildhood inte lligence at five years of age (49). 
Overwhelm ing evidence corre la ting Cbl de fic iency to neuro log ica l sym ptom s 
such as developm ental delay, regression, or cognitive  decline has been 
published in several reviews (50, 51).
In summ ary, tHcy, folate, choline and Cbl have been related to cognitive 
problem s in animal and human adult studies. Data on the influence in children 
is scarce; therefore, fu rthe r research investigating the strength of the 
associa tions between these m etabolites and B vitam ins and neurocognitive 
developm ent is warranted. The strongest evidence exists fo r the association 
between developm ent and Cbl. In form ation on possib le confounders such as 
educational level, national orig in, maternal or paternal psychopathology, 
sm oking and a lcohol use should be obtained.
Summary of the general discussion
We observed an increased risk on CVA in newborns w ith tH cy concentra tions 
exceeding the 80th percentile, leaving unrevealed w hether tH cy concentra tions 
are causally related to CVA or merely a marker of underlying disease. Folinic 
acid supp lem entation did not decrease tH cy concentra tions in newborn infants 
despite an increase in fo late concentra tions suggesting a d ifferent one carbon 
m etabolism  in infants com pared to adults and older children. Prospective 
studies focusing  on CVA in newborns in relation to tH cy concentra tions and/or
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in tervention tria ls  w ith B vitam ins could be designed.
Maternal tHcy, Cbl, MMA nor fo late were associated w ith BW in our s tudy in 
366 w ell-nourished and partly supplem ented Dutch m other-baby pairs. 
M eta-analysis regarding maternal tH cy concentra tions and BW revealed an 
overall crude OR of 1.31 [1.15; 1.51 ] fo r being small fo r gestational age (SGA) 
when maternal tH cy exceeded the 90 th percentile. Individual data analysis 
could provide insight into factors in fluencing the d ifferent conclusions from  
individual studies and could make it possib le to perform  proper adjustm ents 
w hich may influence the observed effect size.
It is suggested that Cbl de fic iency in infancy is more prevalent than previously 
thought. There is a variety of presenting sym ptom s, a low index of susp ic ion 
and plasm a Cbl does not reflect in tracellu lar Cbl status, leading to marked 
d iagnostic  delay in most cases. Several argum ents and studies support the 
“ im paired Cbl status in in fancy” hypothesis. Inform ation on both b iochem ical 
and clin ica l response to Cbl therapy is warranted, necessitating prospective 
random ized Cbl in tervention tria ls. Exploration of plasm a MMA and Cbl in 
infancy in the Netherlands could provide rationale fo r in tervention w ith Cbl 
during pregnancy and/or lactation.
We observed an increased risk of LBW w ith increased um bilica l choline and 
betaine concentra tions and decreased DMG concentra tions w hich was in 
contrast to  our expectations. To fu rther e lucidate th is subject, a prospective 
s tudy includ ing determ ination of tota l choline and the d ifferent form s of choline 
in maternal and both arterial and venous um bilica l cord blood in normal 
pregnancies, but also in pregnancies com plica ted  by IUGR, placental 
dysfunction  and in pregnancies resulting in LBW or SGA o ffspring could be 
perform ed.
Based on relevant literature, we have to conclude that tHcy, fo late, choline and 
Cbl have been related to cognitive problem s in animal and human adult 
studies. However, data on the influence in children are scarce. We recom m end 
fu rthe r research investigating the strength of the associations between these 
m etabolites, B vitam ins and neurocognitive  developm ent.
In th is thesis we have investigated some aspects of one carbon m etabolism  in 
pregnancy and infancy in relation to CVA and BW. One carbon m etabolism  
seems to d iffer from  adults. Based on relevant literature and th is thesis study 
designs to fu rther e lucidate questions raised by our investigations could be 
developed and perform ed.
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SAMENVATTING (DUTCH SUMMARY)
Samenvatting van de artikelen
In dit p roe fschrift hebben we de m ogelijke relaties tussen cerebrovascula ir 
accident (CVA) bij pasgeborenen, het optreden van laag geboortegew ich t en 
hom ocyste ine (Hcy), cobalam ine (Cbl) en choline bestudeerd.
Hoofdstuk 1 geeft een korte samenvatting van risicofactoren voor het optreden 
van een CVA bij pasgeborenen. CVA kan leiden to t serieuze restverschijnselen 
en zelfs tot overlijden. Het is daarom  van groot belang om te zoeken naar 
potentieel behandelbare oorzaken. Verder beschrijft het de relatie tussen laag 
geboortegew ich t en verhoogd ris ico op ziekte en overlijden als pasgeborene. 
Laag geboortew ich t (t.o.v. zw angerschapsduur) is één van de vier meest 
voorkom ende oorzaken van perinatale sterfte  in Nederland. Tevens is het 
bekend dat laag gew icht bij de geboorte  geassocieerd is met verhoogde kans 
op hart- en vaatziekten als volwassene. Ook h iervoor geldt dat de zoektocht 
naar potentieel beïnvloedbare factoren van groot belang is. H oofdstuk 1 
beschrijft kort het one carbon m etabolism e en de associaties met diverse 
aandoeningen. Daarna gaat het u itgebreid in op drie onderdelen van het one 
carbon metabolisme, te weten Hcy, Cbl (=vitam ine B12) en choline. Hoofdstuk 2 
beschrijft de vraagste llingen van dit proefschrift.
Homocysteine
Deel I van dit p roefschrift legt de nadruk op Hcy in relatie to t CVA bij 
pasgeborenen en tot geboortegew ich t. Hoofdstuk 3 geeft de resultaten van 
een retrospectieve studie met 24 patiënten en 94 contro les weer. Patiënten 
waren pasgeborenen met een CVA, 11 met ischem isch CVA, 13 met 
hem orrhagisch CVA. Hcy concentra ties van patiënten werden vergeleken met 
die van gezonde pasgeborenen. Er bleek sprake van een bijna 4 x verhoogd 
risico op CVA bij Hcy concentra ties boven de 80e percentie l van controles. 
Ondanks het vinden van deze associatie  tussen CVA bij pasgeborenen en 
tH cy concentraties kan, mede in verband met het retrospectieve karakter van 
de studie, niet d irect worden geconcludeerd dat er een oorzake lijk  verband is. 
Het zou ook zo kunnen zijn dat verhoogde Hcy concentra ties een uiting zijn 
van een onderliggende stoorn is die het CVA heeft veroorzaakt.
Bij volwassenen is goed onderzocht dat Hcy concentra ties veilig en m akkelijk 
kunnen worden verlaagd met fo lium zuur (vitam ine B 11). In hoofdstuk 4 
onderzoeken we of het toedienen van een actieve vorm  van fo lium zuur aan 
pasgeborenen hun Hcy concentraties kan verlagen. We hebben bloed 
monsters afgenom en bij de start van het onderzoek en 1 en 2 weken nadien. 
De helft van de baby ’s kreeg folinezuur, de andere helft kreeg niets. De twee
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groepen waren vergelijkbaar met betrekking tot zwangerschapsduur, geboorte­
gewicht, geslacht, beadem ingsbehoefte en infectie. Hoewel folaat waardes in 
het bloed du ide lijk  waren gestegen in de groep die fo linezuur had gekregen, 
was er geen verschil in Hcy concentra ties tussen beide groepen. Deze 
resultaten zouden kunnen worden beïnvloed door de dosis van folinezuur, de 
duur van de toed ien ing, of door andere factoren. Op grond van beschikbare 
literatuur lijkt de dosis en de duur vo ldoende te moeten zijn om een effect te 
kunnen waarnem en. De relatief hoge fo laat concentra ties bij pasgeborenen 
zouden de associatie  tussen tH cy en fo laat bij pasgeborenen m inder sterk 
kunnen maken.
Diverse onderzoekers beschreven de relatie tussen m oederlijke Hcy 
concentra ties en geboortegew ich t van hun kinderen, echter, met w isselende 
conclusies. Laag geboortegew ich t is een ris ico factor voor ziekte als 
pasgeborene en als volwassene. We voerden een prospectief onderzoek uit in 
het Canisius W ilhelm ina Z iekenhuis te N ijmegen en verzam elden bloed 
monsters en klinische gegevens van 366 moeder- baby paren, zoals beschreven 
in hoofdstuk 5. Bij moeders werd het bloed afgenomen tussen 30 en 34 weken 
zw angerschapsduur, bij de pasgeborenen werd d irect na de geboorte  veneus 
bloed uit de navelstreng afgenom en. De concentra ties van Hcy, Cbl, MMA, 
fo laat en creatin ine waren hoger in navelstreng bloed dan in m oederlijk  bloed. 
Na correctie  voor bekende determ inanten van geboortegew ich t als roken en 
geslacht, vonden we geen relatie tussen geboortegew ich t en m oederlijke 
concentraties.
Wij voerden een system atische review uit van de verschenen m edische 
literatuur die de relatie tussen m oederlijke Hcy concentra ties en geboortege ­
w ich t beschreef. Negentien studies met in totaal 21,326 mensen konden 
worden geïncludeerd. De resultaten hiervan worden beschreven in hoofdstuk 6. 
Wij vonden 31% verhoogd ris ico op het krijgen van een kind dat te licht is voor 
zijn /haar zw angerschapsduur als m oederlijke Hcy concentraties de 90ste 
percentie l overschreden. Dit komt ongeveer overeen met 38 gram lager ge­
boortegew icht. We konden echter niet alle studies corrigeren voor bekende en 
sterke determ inanten van geboortegew ich t zoals roken, geslacht en pariteit. 
H ierdoor zou het gevonden percentage een overschatting van het werkelijke 
e ffect kunnen zijn. Hogere m oederlijke Hcy concentra ties lijken gerelateerd 
aan verhoogd ris ico op dysm aturite it. Hoewel het geschatte verschil in ge­
boortegew ich t relatief klein is en voor het individu m isschien geen grote 
klin ische betekenis heeft, zou het op bevolkingsniveau van grotere betekenis 
kunnen zijn.
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Cobalamine
In deel II ligt de focus op Cbl. Een intrace llu la ir tekort aan Cbl oftewel vitam ine 
B12 zal leiden tot verhoging van m ethylm alonzuur (MMA) en Hcy in bloed. 
Deze twee stoffen fungeren dus als markers voor Cbl defic iëntie. MMA w ordt 
als meer specifieke en sensitievere marker beschouwd. Om dat de bestaande 
m ethodes om MMA te bepalen arbeidsintensief waren en veel tijd  kostten, 
ontw ikke lden wij een nieuwe m ethode zoals beschreven in hoofdstuk 7. 
H ierbij w ordt HPLC gecom bineerd met tandem  MS zonder voorafgaande 
derivatisatering. Met deze m ethode is het m ogelijk  om op grotere schaal en 
sneller betrouwbare MMA bepalingen te doen.
Met behulp van deze m ethode bepaalden we plasm a MMA concentraties in 
189 Nederlandse kinderen. De resultaten worden gedeta illeerd beschreven in 
hoofdstuk 8. G eom etrisch gem idde lde  plasm a MMA concentra tie  was 0.17 
jUmol/L [0.07;0.42], In kinderen ouder dan 1 jaar werd een positieve relatie 
tussen plasm a MMA concentra ties en leeftijd gevonden. Cbl concentraties 
waren de voornaam ste voorspe lle r van MMA concentraties. De relatie tussen 
Cbl en MMA w ord t sterker met leeftijd. De 90ste percentie l p lasm a MMA 
concentra tie  in kinderen > 1 jaar is 0 .30pm o l/L .
Choline
In deel III onderzoeken we de m ogelijke verbanden tussen concentraties 
choline, betaine en d im ethylgycine in m oederlijk  en navelstrengbloed en ge­
boortegew icht, gezien het belang van choline voor de snel groeiende foetus, 
zoals beschreven in hoofdstuk 9. Choline is een essentië le voed ingssto f en 
is betrokken in diverse m etabole processen, oa ve t m etabolism e, de productie  
van cel mem braan bestanddelen en bij m ethyleringsreacties. Het speelt een 
belangrijke rol bij de in tegrite it van cellen, neurotransm issie en de ontw ikkeling 
van de hersenen. Diverse gegevens suggereren dat foeta le  choline 
concentraties een betere reflectie zonden kunnen zijn van foetaal en placentair 
m etabolism e dan maternale concentraties. We verzam elden 1126 navelstreng 
b loedm onsters. Van 366 hadden we ook m oederlijke b loedm onsters 
a fgenom en tussen 30 en 34 weken zw angerschapsduur. Onze resultaten 
toonden dat navelstreng choline en betaine een inverse relatie hebben met 
geboortegew ich t . We vonden een 4 maal verhoogd ris ico op het krijgen van 
een baby met een geboortegew ich t < 2500 g gestandaard iseerd voor zw an­
gerschapsduur indien navelstreng choline concentraties in het hoogste 
kwartie l waren. Of deze resultaten te verklaren zijn door een veranderde flux 
door choline oxidatie route, door een gestoorde p lacentaire functie  le idend tot 
lager geboortegew ich t w aarbij choline slechts een marker is of ander nog 
onbekend mechanisme, dient opgehelderd te worden.
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Samenvatting van de discussie
We vonden een verhoogd risico op CVA bij pasgeborene met verhoogde tH cy 
concentraties. Dit is geen bewijs voor een causaal verband. Folinezuur 
toed ien ing  gedurende 2 weken aan pasgeborenen le idde niet to t een daling 
van de tH cy concentraties ondanks een stijg ing van de fo laat concentraties. 
Dit zou kunnen betekenen dat het one carbon m etabolism e van pasgeborenen 
op dit punt versch ilt van dat van volwassenen. P rospectieve studies naar de 
relatie tussen CVA en tH cy concentra ties en interventie onderzoek met Cbl 
zouden meer inform atie geven.
In onze studie onder 366 m oeder-baby paren waren maternale concentraties 
van tHcy, Cbl, MMA noch fo laat gerelateerd aan geboortegew ich t. Meta-analyse 
toonde 31% hoger risico op dysm aturite it (geboortegew ich t t.o.v. zwanger- 
schapsduur < 10e percentie l) bij verhoogde maternale tH cy concentraties 
(90ste percent iel). Individuele data analyse zou w e llich t inzicht in de verschil lende 
conclusies van de individuele studies kunnen verschaffen. De m ogelijkhe id  tot 
correctie  voor bekende en sterke determ inanten van geboortegew ich t zou van 
invloed kunnen zijn op het nu door ons gevonden effect.
Medische literatuur toont aan dat lagere Cbl status vaker voor komt dan men 
to t nu toe aannam. Men zou zowel de b iochem ische als de klin ische reactie op 
Cbl toed ien ing w illen bestuderen, hetgeen in gerandom iseerd Cbl interventie 
onderzoek bij kinderen m ogelijk  zou zijn. Ook interventie met Cbl tijdens de 
zw angerschap en/of borstvoeding zou kunnen worden overwogen.
In tegenste lling to t wat w ij verw achtten, vonden wij een verhoogd ris ico op 
laag geboortegew ich t indien navelstreng concentra ties choline en betaine 
hoger en DMG concentra ties lager waren. Om deze bevinding verder uit te 
zoeken zou men maternaal en navelstrengbloed, zowel arterieel als veneus, 
af kunnen nemen bij ongecompliceerde zwangerschappen maar ook bij zwan­
gerschappen gecom pliceerd  door intra-uteriene groeiretardatie , placentaire 
d isfunctie , laag geboortegew ich t of dysm aturite it. Hierin zou dan totaal choline 
maar ook de versch illende vorm en van choline bepaald kunnen worden. 
Diverse studies suggereren dat tHcy, fo laat, choline and Cbl gerelateerd zijn 
aan cognitie  in zowel d ierstud ies als bij volwassenen. Er zijn echter nauwelijks 
data bekend bij kinderen. Wij zouden in ons cohort de associaties tussen deze 
metabolieten en vitaminen en neurocognitieve ontwikkeling willen onderzoeken.
In dit p roefschrift hebben we enkele aspecten van het one carbon m etabolism e 
in zw angerschap en bij het jonge kind onderzocht, met name in relatie to t CVA 
bij pasgeborenen en (risico op laag) geboortegew ich t. Het one carbon 
m etabolism e lijkt te verschillen van volwassenen en relaties met diverse 
ziektes bij k inderen zijn nog niet helder.
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Dankwoord
Het “ boekje” in handen, dus toch! Te vergelijken met een reis, een ontdek­
k ingstocht maar bovenal een leerschool met diverse meesters, juffen, 
stagia ires en klasgenoten, met nablijven, huiswerk, extra taken maken en nu
de CITO.....  Nu het m om ent daar is, is het m oeilijker om dit dankw oord te
form uleren dan ik had gedacht. Want hoe druk je uit in woorden wat een ieders 
bijdrage is geweest zonder mensen te kort te doen, te vergeten? Ik vat het dus 
maar als vo lg t samen: dit boekje had niet to t stand kunnen komen zonder de 
bijdrage van vele mensen waarvan ik h ieronder de be langrijkste zal noemen.
Lieve Henk, professor Blom, zelf u itgeroepen goeroe/coach/m entor, mijn on- 
derzoeksbegele ider en nu prom otor! Het begon bij jou op je kamer in het B 
gebouw. We werden aan elkaar voorgeste ld  door Margot van de Bor met de 
bedoeling om gezam enlijk onderzoek te gaan doen. B lijkbaar zag je toch iets 
“onderzoekerigs” in de jonge enthousiaste assistent die bij je binnen kwam 
huppelen en daar ben ik nog steeds blij om. Ik kan het natuurlijk  niet zelf 
vergelijken maar wat ik hoor van anderen bevestigt voor mij elke keer weer dat 
jij een b ijzondere prom otor bent. Je bent w ellich t niet streng genoeg (©) maar 
ik kan met alles bij je terecht. W etenschap, stoom  afblazen, frustratie, 
aankondig ing van (weer) gezinsuitbre id ing....J ij hoorde alles aan, gaf 
com m entaar of onth ie ld je er van, liet me uitrazen en bleef one ind ig  geduld ig. 
Een van de a llerbe langrijkste  dingen is dat we samen erg kunnen lachen. Mijn 
zelfspot over het boekje en gedeelde humor over allerlei andere zaken maakten 
onze b ijeenkom sten altijd to t een vro lijk  geheel. Enne....dankzij m ijn tem po 
ben ik nu -hoewel niet je beste-, wèl je eerste promovenda als promotor! Ik zal 
de m iddagen in het VUMC missen!
Beste Martin, mijn kennism aking met jou kwam pas later in het tra ject en ik 
weet zeker dat het dit boekje ten goede was gekom en als jij er eerder bij was 
betrokken. Jouw kritische blik, je grote kennis van ep idem io log ie  en sta tistiek 
maar vooral je vermogen om getallen te vertalen naar praktische consequenties, 
ze betekenis te geven die een dokter kan begrijpen, heeft mij veel geleerd. Je 
droge gevoel voor hum or was een prettige ontdekking. Jouw  bijdrage aan en 
aandeel in de sta tistische analyses voor dit boekje zijn van zeer grote waarde. 
Jij s tim uleerde me elke keer weer m ijn eigen m ening te vorm en. Dit was ook 
wel nodig want zoals je zelf zei: “ Henk en ik zijn het nooit met elkaar eens 
maar we maken er ook nooit ruzie over” . Voor de prom ovenda er tussen in 
een leerzaam traject...Ik wens je veel succes en plezier nu ook jij als professor 
den Heijer in het VUMC gaat werken!
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Ik w il de leden van de m anuscriptcom m issie, prof dr Frank Vandenbussche, dr 
ir Nel Roeleveld en prof Hans van G oudoever harte lijk  danken voor hun 
kritische beoorde ling van mijn m anuscript.
I am very honored w ith the presence of prof dr Per Magne Ueland here today. 
He is an expert in the fie ld of one carbon m etabolism  and he and his group 
have published an abundant am ount of papers on th is subject. Furthermore, it 
is fun to have dinner or a drink w ith him. I hope you like your Dutch present...
“ M ijn” m etabole c lubbie .... Lieve Jan: scherp, am bitieus, het kan altijd groter, 
focus! Lieve Eva: kleurrijk, vrouw elijk, borrelen, wandelende encyclopedie. 
Lieve Maaike: kam ergenote, gedeelde fe llow tijd , rust en nooit concurrentie. Ik 
heb heel erg veel van ju llie  geleerd en met groot plezier. Dat onze wegen zijn 
gescheiden was mijn persoonlijke  keuze en had absoluut niets met ju llie  te 
maken! Beste Leo, Wim, Ron, Dirk, Marcel: dank voor alles wat ju llie  me met 
veel geduld hebben b ijgebracht. Dank ook aan alle analisten van het LKN en 
in het b ijzonder Arno voor het opzetten van de MMA m ethode en Diny (f2011) 
voor haar persoonlijke be langste lling en aandeel in het bewaren en analyseren 
van de m onsters. D iëtisten, Marion en verpleegkundigen: ik heb prettig  met 
ju llie  sam engew erkt en gezorgd voor “onze” patiënten.
Ik ben ook dank verschu ld igd  aan de studenten die mij hebben geholpen met 
het verzam elen van monsters, invoeren van data of verrichten van analyses: 
Marjolein, Bas, Bea, Yvonne, Marloes en Lisette: dank!!
Vrienden, het is e indelijk  zover!
Duizendmaal dank voor be langste lling, tijd, adviezen, lu isterend oor, kopjes 
thee, maar vooral voor ons team gevoel! Voor ons allen geldt dat we frequent 
werken op nachtelijke uren met zeer kwetsbare en ernstig zieke kinderen, vaak 
in acute situaties met hoog risico op com plicaties. Ik zou dit nooit kunnen 
doen zonder ju llie  om me heen en achter me op de mom enten waarop dat 
nodig was.
Arno -the Big Boss: s inds Keystone weet ik dat er 1 sport is waarin ik sneller 
ben!, tijd  voor lu isterend oor en kopjes thee, u itw isselen van muziek, en 
filosoferen over de geneugten van het leven. Djien -stille kracht: onverwacht 
som s lang van stof, “ the m aster” op gebied van prikvaardigheden, grote 
kennis en sinds kort mijn buurm an. W illem -“ ik w il drum m er w orden..” : 
gezinsman, bulderende lach, plagerij, oprechte be langste lling en vertrouwen 
in goede afloop. Viola- harde werker: eerlijk, grondige kennis, protocollen 
altijd als eerste up to date! Katarina -OR is bij jou iets anders dan Odds ratio:
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bredere kijk op het werk, de pastorale. Sabine -jij tw ijfe lt niet over België: uren 
draaien, prom overen, grote betrokkenheid. René -grote mond, gouden hartje: 
sportm an, gam edrive in Zuid-Afrika, goede gesprekken tijdens de braai, 
dokter pur sang. Maresa -m oeder en dokter: praktisch, nooit om een w oordje 
verlegen, gezelligheid en schaterende lach. Robin -  m ister pharm acology: te 
kort bij ons maar w aardevolle aanvulling in die periode. Ronny -u b e rco o l is 
een understatem ent: Rotterdam boft met jou. Femke -  o o Den Haag: pollewop, 
grobbebol, Haagse bluf en b ijzondere medefellow.
Alle verp leegkundigen, nurse-practitioners, secretaresses, en arts-assisten- 
ten: dank voor de vele gedeelde (nachtelijke) uren, waarin ju llie  me bij de les 
hielden, kritische vragen stelden, persoonlijke interesse toonden etc. A ltijd  
weer bedacht ik dan dat ik een bofkont ben dat ik op deze afdeling met deze 
mensen in deze sfeer mag samenwerken: DANK!
Rinie: een speciaal plekje in mijn hart voor jou....
Lieve fam ilie  en vrienden, dank voor alle afle id ing, d inertjes, mom enten dat er
wel of ju ist niet gevraagd werd naar de vorde ringen .....Een paar mensen wil ik
met name noemen.
Blauw: sinds 1990 ken ik ju llie  a l....Ju llie  kennen mijn streken en e igenaard ig ­
heden, we hebben lol als we samen zijn, met tijd  voor een lach en een traan: 
DANK!
Lieve lieve lieve Gaby: jouw  vriendschap is me zo veel waard en zo verschrik­
kelijk d ierbaar! Ik leer van jouw  kijk op het leven, jij bleef a ltijd in contact met 
mij. Ik verheug me elke keer weer op kopjes koffie of etentjes samen!
Lex en Sharon: vrienden voor het leven! Jullie verstaan de kunst om intens te 
genieten van alle leuke en mooie dingen maar ook om te zorgen voor de 
mensen om ju llie  heen. Speciale oom en tante voor onze kids maar vooral hele 
b ijzondere mensen voor mij!
Mijn “schone” fam ilie: ju llie  kreeg ik er bij toen ik Simon leerde kennen en dus 
een fam ilie met zijn eigen gew oontes (de b ierlaars surprise!) en e igenaard ig ­
heden maar vooral met een liefdevolle benadering van mij. O ok in m oeilijker 
tijden bleef dat zo en daar ben ik ju llie  intens dankbaar voor. Lieve Eugene, 
C hristien, Meike, Erik, V incent, Jonas, Camiel, Maryse, Julie en Anna: dank!
Tim othy: hier komen de veren...en joy! Slim, w izzkid, continu in beweging (op 
gebied van sim ulator developm ent en patiëntenzorg dan!), maatje van het 
eerste uur....w ie anders kon mijn paranim f zijn? Geen s im ulatie tra in ing ging 
voorb ij zonder dat ik proefkonijn  was voor veranderingen/verbeteringen, geen 
overdracht zonder je com m entaar of kritische vragen, geen grote visite zonder
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een bondige sam envatting, geen gezam enlijke presentatie voorbereid  zonder 
mojito, geen NVK zonder borrel op donderdag...Tnx mate! Ik wens jou samen 
met C indy en Minne alle geluk toe.
Mallory: lieve Mallo, ik ken je al meer dan de helft van mijn leven....Need I say 
more? In good tim es and in bad times.. th a t’s what friends are for, m aakte jij 
voor mij waar toen ik het nodig had. We herkennen in elkaar ambitie, werklust 
en werkplezier, interne drive die ons voorts tuw t, zowel kracht als valkuil. Maar 
boven alles ben je mijn vriendin en vandaag de getu ige van mijn prom otie! 
Veel geluk voor jou, Frank en Karina.
Lieve ouders, ik heb het grote geluk gehad op te kunnen groeien onder de 
lie fhebbende vleugels van ju llie  allebei. En hoe oud ik hopelijk  ook word, zo 
lang ju llie  leven ben ik ju llie  kind en ju llie  mijn ouders, in any way. Dank voor 
ju llie  nooit aflatende vertrouwen, hulp, steun, en liefde. Dit boekje is voor jullie. 
Ik hou van jullie.
Lief zusje, lieve Anouk, lees mijn trouw speech voor ju llie  nog een keer. A lles 
uit de grond van mijn hart. Op nog vele gezam enlijke mom enten met je man 
Peter en vooral met ju llie  boeven Justin en Raoul!
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DANKW O O RD
Last but defin ite ly not least...
Samen met Siem heb ik 4 gew eldige kinderen mogen krijgen. Lieve Madelief, 
verantw oorde lijk , muzikaal, zorgzaam  en vro lijk . Lieve Imke, authentiek, 
g iechel, muzikaal, en dierenfan. Lieve Mees, voetballer, rustig, a ltijd zichzelf, 
m akkelijk en grappig . Lieve Thilo, boef, vro lijk , fan van piraten en zwaarden en 
bum ba-speen. Ik hou onge lo fe lijk  veel van ju llie . Jullie komst heeft mij 
veranderd in de vurigste  leeuwin en het g rootste  w eekdier tegelijk, een 
boeiende com binatie.
May a ll o f you r w ishes 
Come true fo r life
May a ll that yo u ’re after 
Be conquered w ith grace  
May a ll that you reach fo r  
be w orthy and true 
And guard you a lifetime
And cry  tears o f laughter
You w ill c ry  tears o f pain
B ut a ll o f that hurting  and the heartbreaking
It w ill gu ide your way
(vrij naarA II I can do, Kane)
Lieve Siem, samen, met z ’n 6en, in ons fijne thu is__ik zou graag nog heel lang
en ge lukkig  met jou genieten! De rest vertel ik je wel als we samen z ijn __
2 2 1
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